STOCK TITAN

Flyte Aviation Q3 net loss widens to $15.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Flyte Aviation, Inc. (VJET) reported $1.838 million in continuing-operations revenue for the three months ended September 30, 2026, and a consolidated net loss of $15.121 million, compared with $2.344 million a year earlier. For the nine months, revenue was $2.771 million and net loss was $20.117 million, versus no revenue and a net loss of $11.847 million in 2025.

Private aviation generated the reported continuing-operations revenue. In September, the company classified its VIVO and LockeT businesses as discontinued operations and recorded a $12.490 million noncash impairment on the disposal group. On November 1, it entered into a non-binding letter of intent to sell the group; Flyte said there can be no assurance the sale will be completed or as to the amount or timing of proceeds.

Management disclosed substantial doubt about the company’s ability to continue as a going concern within 12 months of the financial statements’ issuance. Flyte reported $2.393 million in cash as of September 30 and $10.156 million used in operating activities over the nine months, and said it needs additional capital. In October, certain existing investors agreed to purchase $2.05 million of Series C-4 convertible preferred stock.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss was $20.117 million, versus $11.847 million in 2025.
  • Major pointSubstantial doubt about continuing as a going concern within 12 months.

Filing Explained

On November 10, 2026, Flyte reported 3,397,626 common shares; the split was complete, while separate issuances can reduce existing holders’ ownership percentages.

Form 10-Q is the unaudited quarterly report; Flyte Aviation reports that its 1-for-10 reverse split took effect on October 5, 2026. Each ten pre-split common shares became one, with fractional entitlements settled from sale proceeds; the split itself does not change company value.

Common shares outstanding were 2,101,988 at September 30, 2026, compared with 173,896 at December 31, 2025; the cover reports 3,397,626 as of November 10, 2026.

The equity statement lists common-stock issuance, warrant exercises and preferred-stock conversions during the period. Issuing additional shares increases the total share count and reduces an existing holder's percentage ownership, absent offsetting changes.

Continuing-operations revenue $1.838 million Three months ended September 30, 2026; $0 in 2025.
Continuing-operations revenue $2.771 million Nine months ended September 30, 2026; $0 in 2025.
Consolidated net loss $15.121 million Three months ended September 30, 2026; $2.344 million in 2025.
Consolidated net loss $20.117 million Nine months ended September 30, 2026; $11.847 million in 2025.
Cash used in operating activities $10.156 million Nine months ended September 30, 2026; $6.784 million in 2025.
Cash and cash equivalents $2.393 million As of September 30, 2026.
Noncash impairment loss $12.490 million Disposal group classified as held for sale; three and nine months ended September 30, 2026.
Agreed preferred stock purchase $2.05 million In October 2026, certain existing investors agreed to purchase Series C-4 convertible preferred stock.
going concern financial
"prepared on a going concern basis"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
substantial doubt financial
"substantial doubt about the Company’s ability to continue"
discontinued operations financial
"classified these businesses as discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
held for sale financial
"classified the Disposal Group as held for sale"
An asset or a group of assets classified as 'held for sale' is one the company intends to sell rather than keep using, and management has committed to that plan with an active effort to find a buyer. Investors care because these items are removed from ongoing operating results and valued differently, offering a clearer view of the business’s continuing performance—think of it like marking a piece of furniture for the garage sale rather than counting it as part of your regular household setup.
performance obligation technical
"Each flight represents a performance obligation"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.
Level 3 financial
"measured at fair value on a recurring basis using significant unobservable inputs (Level 3)"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did VJET report for the third quarter of 2026?

Flyte reported $1.838 million of continuing-operations revenue for the three months ended September 30, 2026, compared with no revenue in the 2025 period. Private aviation generated the reported continuing-operations revenue; VIVO and LockeT were classified as discontinued operations.

Why did VJET disclose substantial doubt about continuing as a going concern?

Management cited recurring net losses and negative operating cash flows, including a $20.117 million net loss and $10.156 million used in operating activities for the nine months ended September 30, 2026. Flyte reported $2.393 million in cash as of September 30 and said it needs additional capital to fund operations and obligations.

What happened in VJET’s October 2026 reverse stock split?

Effective October 5, 2026, each 10 shares of common stock became one share. No fractional shares were issued; holders otherwise entitled to a fractional share were entitled to their pro rata portion of net proceeds from the exchange agent’s aggregation and sale of fractional shares, reduced by customary brokerage fees, commissions and other expenses.

How does Flyte Aviation report Hops and Luxe charter revenue?

Flyte reports Hops revenue on a gross basis because it acts as principal for those flights. It reports Luxe revenue on a net basis as the commission, brokerage fee or other amount retained after amounts payable to third-party operators. For both services, revenue is recognized upon completion of each flight segment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001716621 Flyte Aviation, Inc. false --12-31 Q3 2026 0.0001 0.0001 10,000,000 10,000,000 0.0001 0.0001 0 0 0 2,229 2,229 0.0001 0.0001 85,770 12,874 12,874 0 0 0.0001 0.0001 6,809 6,809 6,809 0 0 0.0001 0.0001 9,490 9,490 9,490 9,490 9,490 0.0001 0.0001 500,000,000 500,000,000 2,101,988 2,101,988 173,896 173,896 1 1 0 5 2 2 0 0 11,028 — 0 0 0 1 5 7 5 0 0 12.5 0 http://www.catheterprecision.com/20260930#VivoAndLocketMember 12.5 http://www.catheterprecision.com/20260930#VivoAndLocketMember http://www.catheterprecision.com/20260930#VivoAndLocketMember 0 0 0 30 4 2 1 0 0 0 160 0 0 0 2 2 1 1 7 0 0 5 0 February 4, 2029 July 22, 2027 September 3, 2029 August 29, 2029 July 13, 2030 April 25, 2030 June 6, 2030 March 30, 2032 1.4 17 5 16 5 0 0.0001 1,000 6.32 2.30 2.30 2.30 2.30 2.6 5 20 0 0 3 5 May 30, 2024 June 25, 2025 July 1, 2024 July 18, 2024 July 25, 2024 July 11, 2025 July 11, 2025 2.30 1.00 false false false false Other segment items include other income (expense), net, consulting fees, investor relations and SEC fees, insurance fees, and other selling, general, and administrative expenses. Other selling, general, and administrative expenses primarily consist of travel expenses, computer and information technology expenses, and rent expenses. 00017166212026-01-012026-09-30 xbrli:shares 00017166212026-11-10 thunderdome:item iso4217:USD 00017166212026-09-30 00017166212025-12-31 0001716621vjet:OtherNotesMemberus-gaap:NonrelatedPartyMember2026-09-30 0001716621vjet:OtherNotesMemberus-gaap:NonrelatedPartyMember2025-12-31 0001716621vjet:VariableInterestEntitiesMember2026-09-30 0001716621vjet:VariableInterestEntitiesMember2025-12-31 0001716621us-gaap:RelatedPartyMember2026-09-30 0001716621us-gaap:RelatedPartyMember2025-12-31 0001716621us-gaap:NonrelatedPartyMember2026-09-30 0001716621us-gaap:NonrelatedPartyMember2025-12-31 iso4217:USDxbrli:shares 0001716621us-gaap:SeriesBPreferredStockMember2026-09-30 0001716621us-gaap:SeriesBPreferredStockMember2025-12-31 0001716621us-gaap:SeriesCPreferredStockMember2026-09-30 0001716621us-gaap:SeriesCPreferredStockMember2025-12-31 0001716621us-gaap:SeriesDPreferredStockMember2026-09-30 0001716621us-gaap:SeriesDPreferredStockMember2025-12-31 0001716621vjet:SeriesJPreferredStockMember2026-09-30 0001716621vjet:SeriesJPreferredStockMember2025-12-31 0001716621us-gaap:ProductMember2026-07-012026-09-30 0001716621us-gaap:ProductMember2025-07-012025-09-30 0001716621us-gaap:ProductMember2026-01-012026-09-30 0001716621us-gaap:ProductMember2025-01-012025-09-30 00017166212026-07-012026-09-30 00017166212025-07-012025-09-30 00017166212025-01-012025-09-30 0001716621us-gaap:NonrelatedPartyMember2026-07-012026-09-30 0001716621us-gaap:NonrelatedPartyMember2025-07-012025-09-30 0001716621us-gaap:NonrelatedPartyMember2026-01-012026-09-30 0001716621us-gaap:NonrelatedPartyMember2025-01-012025-09-30 0001716621us-gaap:RelatedPartyMember2026-07-012026-09-30 0001716621us-gaap:RelatedPartyMember2025-07-012025-09-30 0001716621us-gaap:RelatedPartyMember2026-01-012026-09-30 0001716621us-gaap:RelatedPartyMember2025-01-012025-09-30 0001716621us-gaap:ServiceMember2026-07-012026-09-30 0001716621us-gaap:ServiceMember2025-07-012025-09-30 0001716621us-gaap:ServiceMember2026-01-012026-09-30 0001716621us-gaap:ServiceMember2025-01-012025-09-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-12-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-12-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-12-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-12-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-12-31 0001716621us-gaap:CommonStockMember2025-12-31 0001716621us-gaap:AdditionalPaidInCapitalMember2025-12-31 0001716621us-gaap:RetainedEarningsMember2025-12-31 0001716621us-gaap:ParentMember2025-12-31 0001716621us-gaap:NoncontrollingInterestMember2025-12-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-31 0001716621us-gaap:CommonStockMember2026-01-012026-03-31 0001716621us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0001716621us-gaap:RetainedEarningsMember2026-01-012026-03-31 0001716621us-gaap:ParentMember2026-01-012026-03-31 0001716621us-gaap:NoncontrollingInterestMember2026-01-012026-03-31 00017166212026-01-012026-03-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-03-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-03-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-03-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-03-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-03-31 0001716621us-gaap:CommonStockMember2026-03-31 0001716621us-gaap:AdditionalPaidInCapitalMember2026-03-31 0001716621us-gaap:RetainedEarningsMember2026-03-31 0001716621us-gaap:ParentMember2026-03-31 0001716621us-gaap:NoncontrollingInterestMember2026-03-31 00017166212026-03-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-04-012026-06-30 0001716621us-gaap:CommonStockMember2026-04-012026-06-30 0001716621us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-30 0001716621us-gaap:RetainedEarningsMember2026-04-012026-06-30 0001716621us-gaap:ParentMember2026-04-012026-06-30 0001716621us-gaap:NoncontrollingInterestMember2026-04-012026-06-30 00017166212026-04-012026-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-06-30 0001716621us-gaap:CommonStockMember2026-06-30 0001716621us-gaap:AdditionalPaidInCapitalMember2026-06-30 0001716621us-gaap:RetainedEarningsMember2026-06-30 0001716621us-gaap:ParentMember2026-06-30 0001716621us-gaap:NoncontrollingInterestMember2026-06-30 00017166212026-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-07-012026-09-30 0001716621us-gaap:CommonStockMember2026-07-012026-09-30 0001716621us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0001716621us-gaap:RetainedEarningsMember2026-07-012026-09-30 0001716621us-gaap:ParentMember2026-07-012026-09-30 0001716621us-gaap:NoncontrollingInterestMember2026-07-012026-09-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2026-09-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2026-09-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2026-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2026-09-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2026-09-30 0001716621us-gaap:CommonStockMember2026-09-30 0001716621us-gaap:AdditionalPaidInCapitalMember2026-09-30 0001716621us-gaap:RetainedEarningsMember2026-09-30 0001716621us-gaap:ParentMember2026-09-30 0001716621us-gaap:NoncontrollingInterestMember2026-09-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2024-12-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2024-12-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-12-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2024-12-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2024-12-31 0001716621us-gaap:CommonStockMember2024-12-31 0001716621us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001716621us-gaap:RetainedEarningsMember2024-12-31 0001716621us-gaap:ParentMember2024-12-31 0001716621us-gaap:NoncontrollingInterestMember2024-12-31 00017166212024-12-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-31 0001716621us-gaap:CommonStockMember2025-01-012025-03-31 0001716621us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0001716621us-gaap:RetainedEarningsMember2025-01-012025-03-31 0001716621us-gaap:ParentMember2025-01-012025-03-31 0001716621us-gaap:NoncontrollingInterestMember2025-01-012025-03-31 00017166212025-01-012025-03-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-03-31 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-03-31 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-03-31 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-03-31 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-03-31 0001716621us-gaap:CommonStockMember2025-03-31 0001716621us-gaap:AdditionalPaidInCapitalMember2025-03-31 0001716621us-gaap:RetainedEarningsMember2025-03-31 0001716621us-gaap:ParentMember2025-03-31 0001716621us-gaap:NoncontrollingInterestMember2025-03-31 00017166212025-03-31 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-04-012025-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-04-012025-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-04-012025-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-04-012025-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-04-012025-06-30 0001716621us-gaap:CommonStockMember2025-04-012025-06-30 0001716621us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-30 0001716621us-gaap:RetainedEarningsMember2025-04-012025-06-30 0001716621us-gaap:ParentMember2025-04-012025-06-30 0001716621us-gaap:NoncontrollingInterestMember2025-04-012025-06-30 00017166212025-04-012025-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:CommonStockMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:AdditionalPaidInCapitalMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:RetainedEarningsMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:ParentMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:NoncontrollingInterestMembervjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621vjet:May2025PipeFinancingMember2025-04-012025-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:CommonStockMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:AdditionalPaidInCapitalMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:RetainedEarningsMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:ParentMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:NoncontrollingInterestMembervjet:AtmOfferingMember2025-04-012025-06-30 0001716621vjet:AtmOfferingMember2025-04-012025-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-06-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-06-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-06-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-06-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-06-30 0001716621us-gaap:CommonStockMember2025-06-30 0001716621us-gaap:AdditionalPaidInCapitalMember2025-06-30 0001716621us-gaap:RetainedEarningsMember2025-06-30 0001716621us-gaap:ParentMember2025-06-30 0001716621us-gaap:NoncontrollingInterestMember2025-06-30 00017166212025-06-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-30 0001716621us-gaap:CommonStockMember2025-07-012025-09-30 0001716621us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0001716621us-gaap:RetainedEarningsMember2025-07-012025-09-30 0001716621us-gaap:ParentMember2025-07-012025-09-30 0001716621us-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:CommonStockMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:AdditionalPaidInCapitalMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:RetainedEarningsMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:ParentMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:NoncontrollingInterestMembervjet:AtmOfferingMember2025-07-012025-09-30 0001716621vjet:AtmOfferingMember2025-07-012025-09-30 0001716621us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2025-09-30 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-09-30 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2025-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:PreferredStockMember2025-09-30 0001716621vjet:SeriesXPreferredStockMemberus-gaap:PreferredStockMember2025-09-30 0001716621us-gaap:CommonStockMember2025-09-30 0001716621us-gaap:AdditionalPaidInCapitalMember2025-09-30 0001716621us-gaap:RetainedEarningsMember2025-09-30 0001716621us-gaap:ParentMember2025-09-30 0001716621us-gaap:NoncontrollingInterestMember2025-09-30 00017166212025-09-30 0001716621us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2026-01-012026-09-30 0001716621us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2025-01-012025-09-30 0001716621vjet:FlyteMember2026-01-012026-09-30 0001716621vjet:FlyteMember2025-01-012025-09-30 0001716621vjet:CommonStockAndEquityClassifiedContractsMember2026-01-012026-09-30 0001716621vjet:CommonStockAndEquityClassifiedContractsMember2025-01-012025-09-30 0001716621us-gaap:PreferredStockMember2026-01-012026-09-30 0001716621us-gaap:PreferredStockMember2025-01-012025-09-30 0001716621vjet:StockIssuedWithAssetsAcquisitionMember2026-01-012026-09-30 0001716621vjet:StockIssuedWithAssetsAcquisitionMember2025-01-012025-09-30 0001716621us-gaap:NoncontrollingInterestMember2026-01-012026-09-30 0001716621us-gaap:NoncontrollingInterestMember2025-01-012025-09-30 xbrli:pure 0001716621vjet:CardionomixIncMember2025-02-17 0001716621vjet:FlyteMember2026-02-06 0001716621vjet:FlyteMember2026-03-09 0001716621vjet:PonderosaAirMember2026-03-09 0001716621vjet:ReverseStockSplitMember2026-09-242026-09-24 00017166212025-08-15 0001716621vjet:SeriesC4ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2026-10-012026-10-31 0001716621us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-30 0001716621us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerOneMember2026-07-012026-09-30 0001716621us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-30 0001716621us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerOneMember2026-01-012026-09-30 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-30 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-31 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerOneMember2026-01-012026-09-30 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerTwoMember2026-01-012026-09-30 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerThreeMember2026-01-012026-09-30 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerOneMember2025-01-012025-12-31 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:CustomerTwoMember2025-01-012025-12-31 0001716621us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembervjet:ThreeCustomersMember2025-01-012025-12-31 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:CardiacElectrophysiologyMembervjet:LuxeMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:PrivateAviationMembervjet:LuxeMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:LuxeMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:LuxeMember2025-01-012025-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:CardiacElectrophysiologyMembervjet:HopsMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:PrivateAviationMembervjet:HopsMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:HopsMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:HopsMember2025-01-012025-09-30 0001716621us-gaap:OperatingSegmentsMembervjet:CardiacElectrophysiologyMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMembervjet:PrivateAviationMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMember2026-01-012026-09-30 0001716621us-gaap:OperatingSegmentsMember2025-01-012025-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:CardiacElectrophysiologyMembervjet:LuxeMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:PrivateAviationMembervjet:LuxeMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:LuxeMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:LuxeMember2025-07-012025-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:CardiacElectrophysiologyMembervjet:HopsMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:PrivateAviationMembervjet:HopsMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:HopsMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:HopsMember2025-07-012025-09-30 0001716621us-gaap:OperatingSegmentsMembervjet:CardiacElectrophysiologyMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMembervjet:PrivateAviationMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMember2025-07-012025-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ProductMembervjet:CardiacElectrophysiologyMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ProductMembervjet:PrivateAviationMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ProductMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ProductMember2025-07-012025-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:CardiacElectrophysiologyMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMembervjet:PrivateAviationMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2026-07-012026-09-30 0001716621us-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2025-07-012025-09-30 0001716621us-gaap:MoneyMarketFundsMember2026-09-30 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-09-30 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-09-30 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-09-30 0001716621us-gaap:FairValueInputsLevel1Member2026-09-30 0001716621us-gaap:FairValueInputsLevel2Member2026-09-30 0001716621us-gaap:FairValueInputsLevel3Member2026-09-30 0001716621us-gaap:SegmentContinuingOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel1Memberus-gaap:SegmentContinuingOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel2Memberus-gaap:SegmentContinuingOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel3Memberus-gaap:SegmentContinuingOperationsMember2026-09-30 0001716621us-gaap:SegmentDiscontinuedOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel1Memberus-gaap:SegmentDiscontinuedOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel2Memberus-gaap:SegmentDiscontinuedOperationsMember2026-09-30 0001716621us-gaap:FairValueInputsLevel3Memberus-gaap:SegmentDiscontinuedOperationsMember2026-09-30 0001716621us-gaap:MoneyMarketFundsMember2025-12-31 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-31 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-31 0001716621us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-31 0001716621us-gaap:FairValueInputsLevel1Member2025-12-31 0001716621us-gaap:FairValueInputsLevel2Member2025-12-31 0001716621us-gaap:FairValueInputsLevel3Member2025-12-31 0001716621us-gaap:SegmentContinuingOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel1Memberus-gaap:SegmentContinuingOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel2Memberus-gaap:SegmentContinuingOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel3Memberus-gaap:SegmentContinuingOperationsMember2025-12-31 0001716621us-gaap:SegmentDiscontinuedOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel1Memberus-gaap:SegmentDiscontinuedOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel2Memberus-gaap:SegmentDiscontinuedOperationsMember2025-12-31 0001716621us-gaap:FairValueInputsLevel3Memberus-gaap:SegmentDiscontinuedOperationsMember2025-12-31 0001716621vjet:BootCapitalConvertibleNotesPayableMember2026-09-30 0001716621vjet:FlyteMember2026-03-09 0001716621vjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-02-062026-03-09 0001716621vjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-04-202026-04-20 0001716621vjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-03-09 0001716621us-gaap:MeasurementInputDiscountRateMembervjet:ValuationTechniqueIfConvertedModelMember2026-03-09 0001716621vjet:SeriesC3ConvertiblePreferredStockMembervjet:SecuritiesPurchaseAgreementsMember2026-06-282026-06-28 0001716621vjet:SeriesC3ConvertiblePreferredStockMembervjet:SecuritiesPurchaseAgreementsMember2026-07-15 0001716621vjet:SeriesC3ConvertiblePreferredStockMembervjet:SecuritiesPurchaseAgreementsMember2026-06-28 0001716621us-gaap:MeasurementInputDiscountForLackOfMarketabilityMembervjet:SeriesC3ConvertiblePreferredStockMembervjet:SecuritiesPurchaseAgreementsMember2026-06-28 0001716621vjet:SecuritiesPurchaseAgreementsMember2026-06-28 0001716621vjet:SecuritiesPurchaseAgreementsMember2026-07-012026-09-30 0001716621vjet:SecuritiesPurchaseAgreementsMember2026-01-012026-09-30 0001716621vjet:SecuritiesPurchaseAgreementsMember2026-09-30 0001716621us-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2026-09-30 0001716621vjet:RoyaltiesPayableMember2025-12-31 0001716621vjet:DeferredStockIssuanceLiabilityMember2025-12-31 0001716621vjet:DeferredConsiderationMember2025-12-31 0001716621us-gaap:ConvertibleNotesPayableMember2025-12-31 0001716621vjet:RoyaltiesPayableMember2026-01-012026-03-31 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-01-012026-03-31 0001716621vjet:DeferredConsiderationMember2026-01-012026-03-31 0001716621us-gaap:ConvertibleNotesPayableMember2026-01-012026-03-31 0001716621vjet:RoyaltiesPayableMember2026-03-31 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-03-31 0001716621vjet:DeferredConsiderationMember2026-03-31 0001716621us-gaap:ConvertibleNotesPayableMember2026-03-31 0001716621vjet:RoyaltiesPayableMember2026-04-012026-06-30 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-04-012026-06-30 0001716621vjet:DeferredConsiderationMember2026-04-012026-06-30 0001716621us-gaap:ConvertibleNotesPayableMember2026-04-012026-06-30 0001716621vjet:RoyaltiesPayableMember2026-06-30 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-06-30 0001716621vjet:DeferredConsiderationMember2026-06-30 0001716621us-gaap:ConvertibleNotesPayableMember2026-06-30 0001716621vjet:RoyaltiesPayableMember2026-07-012026-09-30 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-07-012026-09-30 0001716621vjet:DeferredConsiderationMember2026-07-012026-09-30 0001716621us-gaap:ConvertibleNotesPayableMember2026-07-012026-09-30 0001716621vjet:RoyaltiesPayableMember2026-09-30 0001716621vjet:DeferredStockIssuanceLiabilityMember2026-09-30 0001716621vjet:DeferredConsiderationMember2026-09-30 0001716621us-gaap:ConvertibleNotesPayableMember2026-09-30 0001716621vjet:RoyaltiesPayableMember2024-12-31 0001716621us-gaap:TradingLiabilitiesMember2024-12-31 0001716621vjet:RoyaltiesPayableMember2025-01-012025-03-31 0001716621us-gaap:TradingLiabilitiesMember2025-01-012025-03-31 0001716621vjet:RoyaltiesPayableMember2025-03-31 0001716621us-gaap:TradingLiabilitiesMember2025-03-31 0001716621vjet:RoyaltiesPayableMember2025-04-012025-06-30 0001716621us-gaap:TradingLiabilitiesMember2025-04-012025-06-30 0001716621vjet:RoyaltiesPayableMember2025-06-30 0001716621us-gaap:TradingLiabilitiesMember2025-06-30 0001716621vjet:RoyaltiesPayableMember2025-07-012025-09-30 0001716621us-gaap:TradingLiabilitiesMember2025-07-012025-09-30 0001716621vjet:RoyaltiesPayableMember2025-09-30 0001716621us-gaap:TradingLiabilitiesMember2025-09-30 utr:Y 0001716621us-gaap:ComputerEquipmentMembersrt:MinimumMember2026-09-30 0001716621us-gaap:ComputerEquipmentMembersrt:MaximumMember2026-09-30 0001716621vjet:FurnitureFixturesAndEquipmentMember2026-09-30 0001716621us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2026-09-30 00017166212025-01-012025-12-31 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2026-07-012026-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2026-01-012026-09-30 0001716621vjet:QhslabsNotesMember2025-07-012025-09-30 0001716621vjet:QhslabsNotesMember2025-01-012025-09-30 0001716621vjet:CardionomixIncMember2026-09-30 0001716621vjet:CardionomixIncMembervjet:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2026-09-30 0001716621vjet:CardionomixIncMembervjet:CertainThirdPartiesMember2026-09-30 0001716621vjet:May2025NotesMember2026-09-30 0001716621vjet:KardionavIncMember2025-12-31 0001716621vjet:KardionavIncMembervjet:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2025-12-31 0001716621vjet:KardionavIncMembervjet:CertainThirdPartiesMember2025-12-31 0001716621vjet:KardionavIncMember2026-09-30 0001716621country:US2026-07-012026-09-30 0001716621country:US2025-07-012025-09-30 0001716621country:US2026-01-012026-09-30 0001716621country:US2025-01-012025-09-30 0001716621us-gaap:NonUsMember2026-07-012026-09-30 0001716621us-gaap:NonUsMember2025-07-012025-09-30 0001716621us-gaap:NonUsMember2026-01-012026-09-30 0001716621us-gaap:NonUsMember2025-01-012025-09-30 0001716621vjet:SeriesXPreferredStockMember2026-09-30 0001716621vjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-02-062026-02-06 0001716621vjet:FlyteMember2026-03-092026-03-09 0001716621vjet:FlyteMember2026-01-012026-03-31 0001716621vjet:FlyteMember2026-02-06 0001716621vjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-03-092026-03-09 0001716621vjet:FlyteMember2026-07-012026-09-30 0001716621vjet:FlyteMember2026-03-102026-06-30 0001716621vjet:FlyteMember2026-09-30 0001716621vjet:FlyteMemberus-gaap:NonrelatedPartyMember2026-03-09 0001716621vjet:FlyteMemberus-gaap:NonrelatedPartyMember2026-03-102026-06-30 0001716621vjet:FlyteMemberus-gaap:NonrelatedPartyMember2026-09-30 0001716621vjet:FlyteMembervjet:ApplicationsMember2026-03-092026-03-09 0001716621vjet:FlyteMembervjet:FaaPart135OperatingCertificateMember2026-03-092026-03-09 0001716621vjet:FlyteMemberus-gaap:TrademarksAndTradeNamesMember2026-03-092026-03-09 0001716621vjet:FlyteMemberus-gaap:CustomerRelatedIntangibleAssetsMember2026-03-092026-03-09 0001716621vjet:FlyteMembersrt:ScenarioPreviouslyReportedMember2026-03-09 0001716621vjet:FlyteMember2025-07-012025-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2025-01-012025-12-31 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2026-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2025-12-31 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2025-07-012025-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMember2025-01-012025-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2025-12-31 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2024-12-31 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2026-01-012026-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2025-01-012025-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2026-09-30 0001716621us-gaap:DiscontinuedOperationsHeldforsaleMembervjet:RoyaltiesPayableMember2025-09-30 0001716621vjet:VolatoGroupIncMember2026-06-07 0001716621vjet:VolatoGroupIncMember2026-06-072026-06-07 0001716621vjet:FlyexclusiveIncMember2026-06-072026-06-07 0001716621vjet:FlyexclusiveIncMember2026-06-07 0001716621vjet:VolatoSharesAndFlyxSharesMember2026-06-18 0001716621vjet:VolatoSharesAndFlyxSharesMember2026-06-182026-06-18 0001716621us-gaap:ComputerEquipmentMember2026-09-30 0001716621us-gaap:ComputerEquipmentMember2025-12-31 0001716621us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-12-31 0001716621vjet:FurnitureFixturesAndEquipmentMember2025-12-31 0001716621vjet:ApplicationsMembervjet:PrivateAviationMember2026-09-30 0001716621us-gaap:TrademarksAndTradeNamesMembervjet:PrivateAviationMember2026-09-30 0001716621us-gaap:CustomerRelatedIntangibleAssetsMembervjet:PrivateAviationMember2026-09-30 0001716621vjet:CardiacElectrophysiologyMember2026-09-30 0001716621vjet:ShorttermFinancingArrangementWithInsuranceCarrier3Member2026-01-312026-01-31 0001716621vjet:ShorttermFinancingArrangementWithInsuranceCarrier3Member2026-01-31 utr:M 0001716621vjet:ShorttermFinancingArrangementWithInsuranceCarrier3Member2026-07-012026-09-30 0001716621vjet:ShorttermFinancingArrangementWithInsuranceCarrier3Member2026-01-012026-09-30 0001716621vjet:ShorttermFinancingArrangementWithInsuranceCarrier3Member2026-09-30 0001716621vjet:ShorttermFinancingArrangementWithAviationInsuranceCarrierMember2026-05-052026-05-05 0001716621vjet:ShorttermFinancingArrangementWithAviationInsuranceCarrierMember2026-05-05 0001716621vjet:ShorttermFinancingArrangementWithAviationInsuranceCarrierMember2026-07-012026-09-30 0001716621vjet:ShorttermFinancingArrangementWithAviationInsuranceCarrierMember2026-01-012026-09-30 0001716621vjet:ShorttermFinancingArrangementWithAviationInsuranceCarrierMember2026-09-30 0001716621vjet:CardionomixPromissoryNoteMember2025-05-05 0001716621vjet:CardionomixPromissoryNoteMember2026-07-012026-09-30 0001716621vjet:CardionomixPromissoryNoteMember2026-01-012026-09-30 0001716621vjet:CardionomixPromissoryNoteMember2025-07-012025-09-30 0001716621vjet:CardionomixPromissoryNoteMember2025-01-012025-09-30 0001716621vjet:CardionomixPromissoryNoteMember2026-09-30 0001716621vjet:CardionomixPromissoryNoteMember2025-12-31 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2024-08-23 0001716621vjet:SeriesMWarrantsMembervjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2025-12-312025-12-31 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2025-12-31 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2025-12-312025-12-31 0001716621vjet:June2026NoteMemberus-gaap:RelatedPartyMember2026-06-24 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2026-07-012026-09-30 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2026-01-012026-09-30 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2025-07-012025-09-30 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2025-01-012025-09-30 0001716621vjet:RelatedPartyNotesMemberus-gaap:RelatedPartyMember2026-09-30 0001716621vjet:KardionavNotesMembervjet:KardionavIncMember2025-07-11 0001716621vjet:KardionavNotesMembervjet:KardionavIncMember2026-07-012026-09-30 0001716621vjet:KardionavNotesMembervjet:KardionavIncMember2026-01-012026-09-30 0001716621vjet:KardionavNotesMembervjet:KardionavIncMember2026-09-30 0001716621vjet:KardionavNotesMembervjet:KardionavIncMember2025-12-31 0001716621vjet:BootCapitalFirstConvertibleNotePayableMember2025-12-26 0001716621vjet:BootCapitalFirstConvertibleNotePayableMember2025-12-262025-12-26 0001716621vjet:BootCapitalSecondConvertibleNotePayableMember2025-12-26 0001716621vjet:BootCapitalSecondConvertibleNotePayableMember2025-12-262025-12-26 0001716621vjet:BootCapitalConvertibleNotesPayableMember2025-12-26 0001716621vjet:BootCapitalConvertibleNotesPayableMember2026-06-22 0001716621vjet:BootCapitalConvertibleNotesPayableMember2026-06-222026-06-22 0001716621vjet:FebruaryBridgeNoteMember2026-09-30 0001716621vjet:MarchBridgeNoteMember2026-01-31 0001716621vjet:MarchBridgeNoteMember2026-01-012026-09-30 0001716621vjet:MarchBridgeNoteMember2026-09-30 0001716621vjet:MarchBridgeNoteMember2026-07-012026-09-30 0001716621vjet:SelloukNoteMember2026-02-27 0001716621vjet:SelloukNoteMember2026-07-012026-09-30 0001716621vjet:SelloukNoteMember2026-01-012026-09-30 0001716621vjet:SelloukNoteMember2026-09-30 0001716621vjet:SelloukNoteMember2026-03-09 0001716621vjet:FlyteNotePayableMember2026-03-31 0001716621vjet:OtherAssumedNotesMember2026-03-31 0001716621vjet:OtherAssumedNotesMember2026-03-09 0001716621vjet:OtherAssumedNotesMember2026-09-30 0001716621vjet:OtherAssumedNotesMember2026-07-012026-09-30 0001716621vjet:OtherAssumedNotesMember2026-01-012026-09-30 0001716621vjet:SbaLoanMember2020-06-13 0001716621vjet:SbaLoanMember2020-06-132020-06-13 0001716621vjet:SbaLoanMember2026-07-012026-09-30 0001716621vjet:SbaLoanMember2026-01-012026-09-30 0001716621vjet:SbaLoanMember2026-09-30 0001716621vjet:FlyteNotePayableMember2026-03-09 0001716621vjet:FlyteNotePayableMemberus-gaap:MeasurementInputDiscountRateMember2026-03-09 0001716621vjet:FlyteNotePayableMember2026-07-012026-09-30 0001716621vjet:FlyteNotePayableMember2026-01-012026-09-30 0001716621vjet:FlyteNotePayableMember2026-09-30 0001716621vjet:NotePayableMember2026-09-30 0001716621vjet:AmigoSystemRoyaltyMember2006-01-012007-12-31 0001716621vjet:RoyaltyPayment1Membervjet:AmigoSystemRoyaltyMember2006-01-012007-12-31 0001716621vjet:RoyaltyPayment1Membervjet:AmigoSystemRoyaltyMember2007-12-31 0001716621vjet:RoyaltyPayment2Membervjet:AmigoSystemRoyaltyMember2006-01-012007-12-31 0001716621vjet:RoyaltyPayment2Membervjet:AmigoSystemRoyaltyMember2007-12-31 0001716621vjet:RoyaltyPayment3Membervjet:AmigoSystemRoyaltyMember2006-01-012007-12-31 0001716621vjet:AmigoSystemRoyaltyMember2026-01-012026-09-30 0001716621vjet:AmigoSystemRoyaltyMember2025-01-012025-09-30 0001716621vjet:AmigoSystemRoyaltyMember2026-07-012026-09-30 0001716621vjet:AmigoSystemRoyaltyMember2025-07-012025-09-30 0001716621vjet:AmigoSystemRoyaltyMember2026-09-30 0001716621vjet:AmigoSystemRoyaltyMember2025-12-31 0001716621vjet:AircraftLeaseMember2026-05-31 0001716621vjet:AircraftLeaseMember2026-09-30 0001716621vjet:SouthCarolinaOfficeLeaseAgreementMember2022-09-27 0001716621vjet:SouthCarolinaOfficeLeaseAgreementMember2022-09-272022-09-27 utr:D 0001716621vjet:NewJerseyOfficeLeaseAgreementMember2022-12-07 0001716621vjet:NewJerseyOfficeLeaseAgreementMember2022-12-072022-12-07 0001716621vjet:NewJerseyOfficeLeaseAgreementMember2024-03-31 0001716621vjet:NewJerseyOfficeLeaseAgreementMember2023-03-19 0001716621vjet:ParkCityOfficeLeaseAgreementMember2023-03-19 utr:sqft 0001716621vjet:OfficeSpaceInMelvilleNewYorkMember2026-07-31 0001716621vjet:OfficeSpaceInMelvilleNewYorkMember2026-09-30 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-07-012026-09-30 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-07-012026-09-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-07-012026-09-30 0001716621us-gaap:WarrantMember2026-01-012026-09-30 0001716621us-gaap:WarrantMember2025-01-012025-09-30 0001716621us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0001716621us-gaap:EmployeeStockOptionMember2025-01-012025-09-30 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesBConvertiblePreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2025-01-012025-09-30 0001716621us-gaap:SeriesDPreferredStockMember2026-01-012026-09-30 0001716621us-gaap:SeriesDPreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesJPreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesJPreferredStockMember2025-01-012025-09-30 0001716621vjet:SeriesXPreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesXPreferredStockMember2025-01-012025-09-30 0001716621us-gaap:RestrictedStockMember2026-01-012026-09-30 0001716621us-gaap:RestrictedStockMember2025-01-012025-09-30 0001716621vjet:PlacementAgentWarrantsMembervjet:May2025PipeFinancingMember2025-05-12 0001716621vjet:AtmOfferingMember2025-05-19 0001716621vjet:AtmOfferingMember2025-06-13 0001716621vjet:AtmOfferingMember2025-08-07 0001716621vjet:AtmOfferingMember2025-01-012025-12-31 0001716621vjet:February2026PrivatePlacementMember2026-02-062026-02-06 0001716621vjet:February2026PrivatePlacementMember2026-02-06 0001716621vjet:SeriesC1ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-02-062026-02-06 0001716621vjet:SeriesC2AndC3ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-02-062026-02-06 0001716621vjet:SeriesC2AndC3ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-02-06 0001716621srt:MinimumMembervjet:SeriesC2AndC3ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-03-012026-03-31 0001716621vjet:SeriesC2ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-04-212026-04-21 0001716621vjet:SeriesC2ConvertiblePreferredStockMembervjet:February2026PrivatePlacementMember2026-07-152026-07-15 0001716621vjet:SeriesLWarrantsMember2026-02-06 0001716621vjet:SeriesLWarrantsMember2026-02-062026-02-06 0001716621vjet:SeriesLWarrantsMember2026-02-05 0001716621vjet:SeriesC1ConvertiblePreferredStockMembervjet:March2026SpaMember2026-03-092026-03-09 0001716621vjet:SeriesC2AndC3ConvertiblePreferredStockMembervjet:March2026SpaMember2026-03-092026-03-09 0001716621vjet:SeriesC4ConvertiblePreferredStockMembervjet:March2026SpaMember2026-03-09 0001716621vjet:SeriesC4ConvertiblePreferredStockMembervjet:March2026SpaMember2026-04-212026-04-21 0001716621vjet:SeriesC3ConvertiblePreferredStockMembervjet:March2026SpaMember2026-07-152026-07-15 0001716621vjet:SeriesC4ConvertiblePreferredStockMembervjet:March2026SpaMember2026-07-302026-07-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMembervjet:March2026SpaMember2026-08-012026-08-31 0001716621vjet:SeriesC4ConvertiblePreferredStockMembervjet:March2026SpaMember2026-08-31 0001716621vjet:February2026SpaMember2026-01-012026-09-30 0001716621vjet:March2026SpaMember2026-01-012026-09-30 0001716621vjet:BridgeNotesAndJune2026NoteMember2026-01-012026-09-30 0001716621vjet:February2022SeriesBWarrantsMember2026-09-30 0001716621vjet:July2022SeriesCWarrantsMember2026-09-30 0001716621vjet:September2024SeriesJWarrantsMember2026-09-30 0001716621vjet:September2024RepresentativeWarrantsMember2026-09-30 0001716621vjet:October2024SeriesKWarrantsMember2026-09-30 0001716621vjet:October2024PlacementAgentWarrantsMember2026-09-30 0001716621vjet:May2025PlacementAgentWarrantsMember2026-09-30 0001716621vjet:December2025SeriesMWarrantsMember2026-09-30 0001716621srt:WeightedAverageMember2026-09-30 0001716621vjet:The2022OfferingMember2025-12-31 0001716621vjet:The2022OfferingMember2026-09-30 0001716621vjet:PlacementAgentWarrant1Member2026-09-30 0001716621vjet:PlacementAgentWarrant2Member2026-09-30 0001716621vjet:ConversionOfSeriesXConvertiblePreferredStockIntoCommonStockMember2025-12-052025-12-05 0001716621vjet:SeriesXPreferredStockMember2025-12-31 0001716621vjet:SeriesBConvertiblePreferredStockMember2025-05-12 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-02-06 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-02-05 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-01-012026-09-30 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-06-23 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-07-292026-07-29 0001716621vjet:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMembervjet:SeriesBConvertiblePreferredStockMember2025-06-112025-06-11 0001716621vjet:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMembervjet:SeriesBConvertiblePreferredStockMember2026-03-102026-03-10 0001716621vjet:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMembervjet:SeriesBConvertiblePreferredStockMember2026-06-232026-06-23 0001716621vjet:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMembervjet:SeriesBConvertiblePreferredStockMember2026-06-242026-06-24 0001716621vjet:SeriesBConvertiblePreferredStockMember2026-09-30 0001716621vjet:SeriesBConvertiblePreferredStockMember2025-12-31 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-02-012026-02-28 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-03-012026-03-31 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-09-30 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-03-092026-03-09 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-09-30 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-07-152026-07-15 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-07-302026-07-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-08-012026-08-31 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-09-30 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-09-30 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-03-31 0001716621srt:MinimumMembervjet:SeriesC1ConvertiblePreferredStockMember2026-03-31 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-04-21 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-07-15 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-07-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-08-31 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-04-15 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-07-10 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-07-10 0001716621vjet:SeriesC1ConvertiblePreferredStockMember2026-08-10 0001716621vjet:SeriesC3ConvertiblePreferredStockMember2026-08-10 0001716621vjet:SeriesC4ConvertiblePreferredStockMember2026-08-10 0001716621vjet:SeriesC2ConvertiblePreferredStockMember2026-08-10 0001716621vjet:SeriesCAndSeriesDConvertiblePreferredStockMember2026-07-012026-09-30 0001716621vjet:SeriesCAndSeriesDConvertiblePreferredStockMember2026-01-012026-09-30 0001716621us-gaap:SeriesCPreferredStockMember2026-02-012026-09-30 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-132026-07-13 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-142026-07-14 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-152026-07-15 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-162026-07-16 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-202026-07-20 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-242026-07-24 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-07-282026-07-28 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-08-062026-08-06 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-08-102026-08-10 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-08-172026-08-17 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-08-192026-08-19 0001716621vjet:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesCPreferredStockMember2026-08-202026-08-20 0001716621us-gaap:SeriesDPreferredStockMember2026-04-202026-04-20 0001716621us-gaap:SeriesDPreferredStockMember2026-04-20 0001716621vjet:SegJetsMemberus-gaap:SeriesDPreferredStockMember2026-04-202026-04-20 0001716621vjet:SegJetsMembervjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-04-20 0001716621vjet:CreatdMemberus-gaap:SeriesDPreferredStockMember2026-04-202026-04-20 0001716621vjet:CreatdMembervjet:FlyteMemberus-gaap:SeriesDPreferredStockMember2026-04-20 0001716621srt:MinimumMemberus-gaap:SeriesDPreferredStockMember2026-04-20 0001716621us-gaap:SeriesDPreferredStockMember2026-07-09 0001716621us-gaap:SeriesDPreferredStockMember2026-07-10 0001716621us-gaap:SeriesDPreferredStockMember2026-08-10 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-132026-07-13 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-142026-07-14 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-152026-07-15 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-162026-07-16 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-202026-07-20 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-212026-07-21 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-07-222026-07-22 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-08-172026-08-17 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-08-272026-08-27 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SeriesDPreferredStockMember2026-09-172026-09-17 0001716621vjet:SeriesJPreferredStockMember2025-12-312025-12-31 0001716621srt:MinimumMembervjet:SeriesJPreferredStockMember2026-09-30 0001716621vjet:SeriesJPreferredStockMemberus-gaap:SubsequentEventMember2026-10-01 0001716621vjet:SeriesJPreferredStockMemberus-gaap:SubsequentEventMember2026-10-10 0001716621us-gaap:EmployeeStockOptionMembervjet:EquityIncentivePlan2023Membervjet:EmployeesAndConsultantsMember2023-07-012023-07-31 0001716621vjet:EquityIncentivePlan2023Member2026-09-30 0001716621vjet:EquityIncentivePlan2023Member2025-12-31 0001716621vjet:EquityIncentivePlan2023Member2025-01-292025-01-29 0001716621vjet:EquityIncentivePlan2023Member2026-09-302026-09-30 0001716621vjet:EquityIncentivePlan2023Member2026-07-012026-09-30 0001716621vjet:EquityIncentivePlan2023Member2026-01-012026-09-30 0001716621vjet:ServiceBasedOptionsMembervjet:EquityIncentivePlan2023Membervjet:VestingInThreeYearsMember2026-01-012026-09-30 0001716621vjet:TimebasedOptionsMember2026-01-012026-09-30 0001716621vjet:TimebasedOptionsMember2025-01-012025-09-30 0001716621vjet:TimebasedOptionsMembersrt:MinimumMember2025-01-012025-09-30 0001716621vjet:TimebasedOptionsMembersrt:MaximumMember2025-01-012025-09-30 0001716621vjet:PerformancebasedOptionsMember2026-01-012026-03-31 0001716621vjet:PerformancebasedOptionsMember2025-01-012025-09-30 0001716621vjet:PerformancebasedOptionsMembersrt:MinimumMember2025-01-012025-09-30 0001716621vjet:PerformancebasedOptionsMembersrt:MaximumMember2025-01-012025-09-30 0001716621us-gaap:EmployeeStockOptionMember2025-12-31 0001716621us-gaap:EmployeeStockOptionMember2025-01-012025-12-31 0001716621us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0001716621us-gaap:EmployeeStockOptionMember2026-09-30 0001716621vjet:EquityIncentivePlan2023Member2025-01-012025-09-30 0001716621vjet:NonplanOptionsMembersrt:ChiefFinancialOfficerMember2025-01-062025-01-06 0001716621vjet:NonplanOptionsMembersrt:ChiefFinancialOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-01-062025-01-06 0001716621vjet:NonplanOptionsMembervjet:MarcSelloukMember2026-01-012026-09-30 0001716621vjet:NonplanOptionsMember2026-01-012026-09-30 0001716621vjet:NonplanOptionsMember2025-01-012025-09-30 0001716621vjet:NonplanOptionsMember2025-12-31 0001716621vjet:NonplanOptionsMember2025-01-012025-12-31 0001716621vjet:NonplanOptionsMember2026-09-30 0001716621vjet:NonplanOptionsMember2026-01-012026-09-30 0001716621vjet:NonplanOptionsMember2025-01-012025-09-30 0001716621vjet:PeriKardLLCMember2025-01-24 0001716621vjet:PeriKardLLCMember2025-01-242025-01-24 0001716621vjet:PeriKardLLCMember2025-01-012025-09-30 0001716621vjet:IprdAssetMember2025-01-012025-12-31 0001716621vjet:IprdAssetMember2025-12-31 0001716621vjet:IprdAssetMemberus-gaap:SecuredDebtMember2025-12-31 0001716621vjet:FLYTEEmploymentLitigationMember2026-09-30 0001716621vjet:FlyteNoteDefaultMemberus-gaap:SettledLitigationMember2026-03-092026-03-09 0001716621vjet:FlyteNoteDefaultMemberus-gaap:SettledLitigationMember2026-04-012026-06-30 0001716621vjet:FlyteNoteDefaultMemberus-gaap:SettledLitigationMember2026-09-30 0001716621vjet:InventorOfLockeTMembervjet:ConversionOfRoyaltiesPayableIntoSeriesJPreferredStockMember2025-12-312025-12-31 0001716621vjet:MrJenkinsMember2026-01-012026-09-30 0001716621vjet:MrJenkinsMember2026-09-30 0001716621vjet:NotesPayable1Membervjet:FatboyCapitalMember2026-01-012026-09-30 0001716621vjet:NotesPayable1Membervjet:FatboyCapitalMember2026-09-30 0001716621vjet:NotesPayable2Membervjet:FatboyCapitalMember2026-01-012026-09-30 0001716621vjet:NotesPayable2Membervjet:FatboyCapitalMember2026-09-30 0001716621vjet:NotesPayable3Membervjet:FatboyCapitalMember2026-01-012026-09-30 0001716621vjet:NotesPayable3Membervjet:FatboyCapitalMember2026-09-30 0001716621vjet:JenkinsFamilyCharitableInstituteMember2026-01-012026-09-30 0001716621vjet:JenkinsFamilyCharitableInstituteMember2026-09-30 0001716621vjet:DavidJenkins1Member2026-01-012026-09-30 0001716621vjet:DavidJenkins1Member2026-09-30 0001716621vjet:LifestimIncMember2026-01-012026-09-30 0001716621vjet:LifestimIncMember2026-09-30 0001716621vjet:AircraftLeaseMembersrt:MinimumMember2026-09-30 0001716621vjet:AircraftLeaseMembersrt:MaximumMember2026-09-30 0001716621vjet:SeriesC4ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2026-10-092026-10-09 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:SubsequentEventMember2026-10-08 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:SubsequentEventMember2026-10-08 0001716621us-gaap:SeriesDPreferredStockMemberus-gaap:SubsequentEventMember2026-10-09 0001716621us-gaap:SeriesCPreferredStockMemberus-gaap:SubsequentEventMember2026-10-09 0001716621vjet:SeriesJPreferredStockMemberus-gaap:SubsequentEventMember2026-10-09 0001716621vjet:ConversionOfSeriesC2ConvertiblePreferredStockIntoCommonStockMemberus-gaap:SubsequentEventMember2026-10-062026-11-04 0001716621vjet:ConversionOfSeriesC3ConvertiblePreferredStockIntoCommonStockMemberus-gaap:SubsequentEventMember2026-10-062026-11-04 0001716621vjet:ConversionOfSeriesDConvertiblePreferredStockIntoCommonStockMemberus-gaap:SubsequentEventMember2026-10-062026-11-04 0001716621vjet:ConversionOfConvertiblePreferredStockIntoCommonStockMemberus-gaap:SubsequentEventMember2026-10-062026-11-04 0001716621vjet:ReverseStockSplitMemberus-gaap:SubsequentEventMember2026-10-052026-10-05 0001716621vjet:RoyaltiesPayableMember2026-01-012026-09-30
 

Table of Contents



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Commission File No. 001-38677

 

Flyte Aviation, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

38-3661826

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

   

1670 Highway 160 West, Suite 205

Fort Mill, South Carolina

 

29708

(Address of principal executive offices)

 

(Zip Code)

 

(973) 691-2000

(Registrant’s telephone number, including area code)

 

Catheter Precision, Inc.

(Former name, former address and former fiscal year, if changed since last report)

 

Securities Registered under Section 12(b) of the Act:

 

Title of each class:

 

Trading Symbol(s)

 

Name of each exchange on

which registered:

Common stock, par value $0.0001 per share

 

VJET

 

NYSE American

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

  

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐    No ☒

 

As of the close of business on November 10, 2026, the registrant had 3,397,626 shares of common stock, par value $0.0001 per share, outstanding.

 



 

 

    

 

Flyte Aviation, Inc.

QUARTERLY REPORT ON FORM 10-Q

 

TABLE OF CONTENTS

 

   

Page(s)

     

PART I. FINANCIAL INFORMATION

 
     

ITEM 1.

FINANCIAL STATEMENTS

3

 

Condensed Consolidated Balance Sheets (Unaudited)

3

 

Condensed Consolidated Statements of Operations (Unaudited)

4

 

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

5

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

6

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

7

     

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

49

     

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

59

     

ITEM 4.

CONTROLS AND PROCEDURES

59

     

PART II. OTHER INFORMATION

 
     

ITEM 1.  

LEGAL PROCEEDINGS

60

     

ITEM 1A.

RISK FACTORS

60

     

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

73

     

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

73

     

ITEM 4.

MINE SAFETY DISCLOSURES

73

     

ITEM 5.

OTHER INFORMATION

73

     

ITEM 6.

EXHIBITS

74

     
 

SIGNATURES

76

 

 

2

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

Flyte Aviation, Inc.  

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

 

  

September 30, 2026

  

December 31, 2025

 
  (Unaudited)     

ASSETS

        

Current Assets

        

Cash and cash equivalents

 $2,393  $88 

Accounts receivable, net

  160   155 

Prepaid expenses and other current assets

  1,200   61 

Current assets held for sale from discontinued operations

  71   86 

Total current assets

  3,824   390 

Property and equipment, net

  141   — 

Operating lease right-of-use assets, net

  2,150   162 

Other non-current assets

  189   8 

Intangible assets, net

  4,038   — 

Goodwill

  12,161   — 

Non-current assets held for sale from discontinued operations

  1,727   15,300 

TOTAL ASSETS

 $24,230  $15,860 

LIABILITIES AND STOCKHOLDERS' EQUITY

        

Current Liabilities

        

Accounts payable

 $494  $1,492 

Accrued expenses

  1,966   1,697 

Deferred revenue

  230   — 

Convertible notes payable, at fair value

  —   298 

Short-term notes payable, net of discount

  2,526   — 

Short-term notes payable of variable interest entities due to related parties

  315   306 

Current portion of operating lease liabilities

  1,495   63 

Current liabilities held for sale from discontinued operations

  30   51 

Total current liabilities

  7,056   3,907 

Royalties payable

  160   160 

Operating lease liabilities

  775   101 

Notes payable of variable interest entities, net of discount

  1,433   1,330 

Notes payable due to related parties

  1,869   1,748 

Notes payable

  63   — 

Deferred tax liability

  549   1,331 

Non-current liabilities held for sale from discontinued operations

  632   632 

Total liabilities

  12,537   9,209 

Commitments and Contingencies (see Note 18)

          

Stockholders' Equity

        

Preferred Stock, $0.0001 par value, 10,000,000 shares authorized

        

Series B Convertible Preferred Stock, $0.0001 par value, 0 designated; 0 and 2,229 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

  —   — 

Series C Convertible Preferred Stock (comprising sub-series C-1, C-2, C-3 and C-4), $0.0001 par value, 85,770 shares designated; 12,874 and 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

  —   — 

Series D Convertible Preferred Stock, $0.0001 par value, 6,809 shares designated; 6,809 and 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

  —   — 

Series J Convertible Preferred Stock, $0.0001 par value, 9,490 shares designated; 9,490 shares issued and outstanding as of September 30, 2026 and December 31, 2025

  —   — 

Common stock, $0.0001 par value, 500,000,000 shares authorized; 2,101,988 and 173,896 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

  —   — 

Additional paid-in capital

  341,748   316,589 

Accumulated deficit

  (329,623)  (309,535)

Total stockholders' equity attributable to Flyte Aviation, Inc.

  12,125   7,054 

Non-controlling interest

  (432)  (403)

Total stockholders' equity

  11,693   6,651 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 $24,230  $15,860 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

 

Flyte Aviation, Inc. 

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(Unaudited)

 

  

For the Three Months Ended September 30,

  

For the Nine Months Ended September 30,

 
  

2026

  

2025

  

2026

  

2025

 

Revenues

 $1,838  $—  $2,771  $— 

Cost of revenues

  1,514   —   2,424   — 

Gross profit

  324   —   347   — 

Operating expenses

                

Selling, general and administrative

  2,780   1,191   6,939   3,522 

Research and development

  —   —   —   2 

Acquired in-process research and development

  —   —   —   1,967 

Total operating expenses

  2,780   1,191   6,939   5,491 

Operating loss

  (2,456)  (1,191)  (6,592)  (5,491)

Other income (expense), net

                

Interest income

  2   10   8   31 

Interest expense

  (121)  (35)  (358)  (61)

Interest expense due to related parties

  (44)  (48)  (130)  (138)

Change in fair value of trading debt securities

  —   107   —   117 

Change in fair value of minority equity interest

  —   —   (2,302)  — 

Change in fair value of deferred consideration

  —   —   3,195   — 

Change in fair value of deferred stock issuance liability

  206   —   160   — 

Loss on debt extinguishment

  —   —   (105)  — 

Gains on marketable securities, net

  162   —   540   — 

Other expense, net

  (65)  —   (65)  — 

Total other income (expense), net

  140   34   943   (51)

Loss from continuing operations before income tax benefit (provision)

  (2,316)  (1,157)  (5,649)  (5,542)

Income tax benefit (provision)

  463   (78)  950   1,596 

Loss from continuing operations

  (1,853)  (1,235)  (4,699)  (3,946)

Loss from discontinued operations, net of tax

  (13,268)  (1,109)  (15,418)  (7,901)

Net loss

  (15,121)  (2,344)  (20,117)  (11,847)

Net loss attributable to non-controlling interest included in continuing operations

  (9)  (93)  (29)  (442)

Net loss attributable to Flyte Aviation, Inc.

 $(15,112) $(2,251) $(20,088) $(11,405)

Deemed dividend on warrant inducement offer

  —   —   (1,360)  — 

Deemed dividend on repurchase of preferred stock

  (126)  —   (126)  — 

Deemed contribution on extinguishment of preferred stock

  2,607   —   3,347   — 

Net loss attributable to Flyte Aviation, Inc. common stockholders

 $(12,631) $(2,251) $(18,227) $(11,405)
                 

Net income (loss) per share attributable to Flyte Aviation, Inc. common stockholders, basic:

                

Continuing operations

 $0.41  $(8.65) $(4.09) $(40.02)

Discontinued operations

  (8.57)  (8.40)  (22.47)  (90.23)

Total basic net loss per share

 $(8.16) $(17.05) $(26.56) $(130.25)
                 

Net income (loss) per share attributable to Flyte Aviation, Inc. common stockholders, diluted:

                

Continuing operations

 $(0.94) $(8.65) $(4.09) $(40.02)

Discontinued operations

  (6.78)  (8.40)  (22.47)  (90.23)

Total diluted net loss per share

 $(7.72) $(17.05) $(26.56) $(130.25)
                 

Weighted-average common shares used in computing net income (loss) per share, basic

  1,548,281   132,054   686,273   87,564 

Weighted-average common shares used in computing net income (loss) per share, diluted

  1,956,534   132,054   686,273   87,564 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

Flyte Aviation, Inc.

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

(Unaudited)

 

                                           

Total

       
 

Series B Convertible Preferred Stock

 

Series C Convertible Preferred Stock

 

Series D Convertible Preferred Stock

 

Series J Convertible Preferred Stock

 

Series X Convertible Preferred Stock

 

Common Stock

 

Additional Paid-In

 

Accumulated

 

Flyte Aviation, Inc. Stockholders'

 

Non-controlling

 

Total Stockholders'

 
 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Deficit

 

Equity

 

Interest

 

Equity

 

Balance at December 31, 2025

 2,229 $—  — $—  — $—  9,490 $—  — $—  173,896 $— $316,589 $(309,535)$7,054 $(403)$6,651 

Issuance of common stock and other equity-classified contracts, net (see Note 13)

 —  —  3,470  —  —  —  —  —  —  —  39,261  —  3,731  —  3,731  —  3,731 

Issuance of common stock upon exercise of warrants (see Note 13)

 —  —  —  —  —  —  —  —  —  —  22,556  —  401  —  401  —  401 

Conversion of preferred stock (see Note 14)

 (597) —  —  —  —  —  —  —  —  —  33,535  —  —  —  —  —  — 

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  64  —  64  —  64 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (1,681) (1,681) (9) (1,690)

Balance at March 31, 2026

 1,632  —  3,470  —  —  —  9,490  —  —  —  269,248  —  320,785  (311,216) 9,569  (412) 9,157 

Issuance of preferred stock, net (see Note 13)

 —  —  3,470  —  —  —  —  —  —  —  —  —  3,188  —  3,188  —  3,188 

Issuance of preferred stock for business combination (see Note 3)

 —  —  —  —  11,028  —  —  —  —  —  —  —  7,833  —  7,833  —  7,833 

Extinguishment of preferred stock (see Note 14)

 (1,632) —  —  —  —  —  —  —  —  —  —  —  (1,733) —  (1,733) —  (1,733)

Issuance of new preferred stock upon extinguishing old preferred stock (see Note 14)

 1,632  —  —  —  —  —  —  —  —  —  —  —  993  —  993  —  993 

Deemed contribution on extinguishment of preferred stock (see Note 14)

 —  —  —  —  —  —  —  —  —  —  —  —  740  —  740  —  740 

Conversion of preferred stock (see Note 14)

 (1,311) —  —  —  —  —  —  —  —  —  91,700  —  —  —  —  —  — 

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  266  —  266  —  266 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (3,295) (3,295) (11) (3,306)

Balance at June 30, 2026

 321  —  6,940  —  11,028  —  9,490  —  —  —  360,948  —  332,072  (314,511) 17,561  (423) 17,138 

Issuance of preferred stock, net (see Note 13)

 —  —  10,791  —  —  —  —  —  —  —  —  —  9,836  —  9,836  —  9,836 

Conversion of preferred stock (see Note 14)

 —  —  (4,857) —  (4,219) —  —  —  —  —  1,741,040  —  —  —  —  —  — 

Repurchase of preferred stock (see Note 14)

 (321) —  —  —  —  —  —  —  —  —  —  —  (195) —  (195) —  (195)

Extinguishment of preferred stock (see Note 14)

 —  —  —  —  —  —  —  —  —  —  —  —  (2,607) —  (2,607) —  (2,607)

Deemed contribution on extinguishment of preferred stock (see Note 14)

 —  —  —  —  —  —  —  —  —  —  —  —  2,607  —  2,607  —  2,607 

Deemed dividend on repurchase of preferred stock (see Note 14)

 —  —  —  —  —  —  —  —  —  —  —  —  (126) —  (126) —  (126)

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  161  —  161  —  161 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (15,112) (15,112) (9) (15,121)

Balance at September 30, 2026

 — $—  12,874 $—  6,809 $—  9,490 $—  — $—  2,101,988 $— $341,748 $(329,623)$12,125 $(432)$11,693 

 

                                           

Total

       
 

Series B Convertible Preferred Stock

 

Series C Convertible Preferred Stock

 

Series D Convertible Preferred Stock

 

Series J Convertible Preferred Stock

 

Series X Convertible Preferred Stock

 

Common Stock

 

Additional Paid-In

 

Accumulated

 

Flyte Aviation, Inc. Stockholders'

 

Non-controlling

 

Total Stockholders'

 
 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Deficit

 

Equity

 

Interest

 

Equity

 

Balance at December 31, 2024

 — $—  — $—  — $—  — $—  12,656 $—  42,133 $— $304,109 $(292,352)$11,757 $— $11,757 

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  91  —  91  —  91 

Issuance of common stock for vested restricted stock awards

 —  —  —  —  —  —  —  —  —  —  263  —  —  —  —  —  — 

Issuance of common stock for asset acquisition (see Note 16)

 —  —  —  —  —  —  —  —  —  —  1,447  —  113  —  113  —  113 

Issuance of common stock upon release of Prepaid Series Warrants (see Note 13)

 —  —  —  —  —  —  —  —  —  —  4,942  —  —  —  —  —  — 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (4,045) (4,045) —  (4,045)

Balance at March 31, 2025

 —  —  —  —  —  —  —  —  12,656  —  48,785  —  304,313  (296,397) 7,916  —  7,916 

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  98  —  98  —  98 

Issuance of common stock for vested restricted stock awards

 —  —  —  —  —  —  —  —  —  —  263  —  —  —  —  —  — 

Issuance of common stock for asset acquisition (see Note 16)

 —  —  —  —  —  —  —  —  —  —  5,263  —  280  —  280  —  280 

Issuance of common stock upon release of Prepaid Series Warrants (see Note 13)

 —  —  —  —  —  —  —  —  —  —  11,351  —  —  —  —  —  — 

Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs

 3,000  —  —  —  —  —  —  —  —  —  —  —  2,034  —  2,034  —  2,034 

Issuance of common stock upon the ATM Offering, net of issuance costs

 —  —  —  —  —  —  —  —  —  —  22,019  —  1,570  —  1,570  —  1,570 

Conversion of preferred stock

 (771) —  —  —  —  —  —  —  —  —  11,591  —  —  —  —  —  — 

Issuance of VIE shares to non-controlling interest

 —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  109  109 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (5,109) (5,109) (349) (5,458)

Balance at June 30, 2025

 2,229 $—  — $—  — $—  — $—  12,656 $—  99,272 $—  308,295 $(301,506)$6,789 $(240)$6,549 

Stock-based compensation

 —  —  —  —  —  —  —  —  —  —  —  —  70  —  70  —  70 

Issuance of common stock for vested restricted stock awards

 —  —  —  —  —  —  —  —  —  —  600  —  —  —  —  —  — 

Issuance of common stock upon the ATM Offering, net of issuance costs

 —  —  —  —  —  —  —  —  —  —  64,839  —  2,174  —  2,174  —  2,174 

Net loss

 —  —  —  —  —  —  —  —  —  —  —  —  —  (2,251) (2,251) (93) (2,344)

Balance at September 30, 2025

 2,229 $—  — $—  — $—  — $—  12,656 $—  164,711 $— $310,539 $(303,757)$6,782 $(333)$6,449 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

5

 

 

Flyte Aviation, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

  

For the Nine Months Ended September 30,

 
  

2026

  

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net loss

 $(20,117) $(11,847)

Adjustments to reconcile net loss to net cash used in operating activities:

        

Loss on impairment of assets held for sale

  12,490   — 

Depreciation and amortization

  1,193   1,588 

Stock-based compensation

  491   259 

Amortization of operating right-of-use assets

  710   67 

Change in fair value of minority equity interest

  2,302   — 

Change in fair value of deferred consideration

  (3,195)  — 

Change in fair value of deferred stock issuance liability

  (160)  — 

Change in fair value of royalties payable due to related parties

  —   2,104 

Change in fair value of trading debt securities

  —   (117)

Loss on debt extinguishment

  105   — 

Gain on marketable securities, net

  (540)  — 

Deferred income tax benefit

  (950)  (1,596)

Acquired in-process research and development

  —   1,967 

Accretion of discount on note payable

  198   27 

Changes in operating assets and liabilities:

        

Accounts receivable

  (4)  (53)

Inventories

  4   (21)

Prepaid expenses and other assets

  (1,197)  62 

Operating lease liabilities

  (592)  (72)

Current portion of royalties payable due to related parties

  (21)  7 

Accounts payable

  (1,099)  664 

Accrued expenses

  (42)  15 

Deferred revenue

  59   — 

Interest payable due to related parties

  144   138 

Interest accrued on notes payable of variable interest entities

  45   24 

Interest accrued on notes payable

  20   — 

Net cash used in operating activities

  (10,156)  (6,784)
         

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchase of acquired in-process research and development

  (103)  (34)

Purchase of marketable securities

  (1,000)  — 

Purchases of property and equipment

  (26)  (17)

Capitalized internal use software

  (68)  — 

Proceeds from sales of marketable securities

  1,540   — 

Acquisition, net of cash acquired

  (1,210)  — 

Net cash used in investing activities

  (867)  (51)
         

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Proceeds from issuance of common stock and equity-classified contracts, net of issuance costs

  16,314   4,914 

Proceeds from deferred stock issuance payable

  601   — 

Proceeds from exercise of warrants (see Note 13)

  401   — 

Payments on short-term notes payable

  (6,142)  — 

Proceeds from short-term notes payable due to related parties

  400   — 

Proceeds from notes payable due to related parties

  —   300 

Payments on convertible notes payable

  (403)  — 

Payments on notes payable

  (2)  (177)

Proceeds from notes payable

  2,880   — 

Repurchase of preferred stock

  (321)  — 

Payments on short-term notes payable due to related parties

  (400)  — 

Net cash provided by financing activities

  13,328   5,037 

NET CHANGE IN CASH AND CASH EQUIVALENTS

  2,305   (1,798)

CASH AND CASH EQUIVALENTS, beginning of period.

  88   2,873 

CASH AND CASH EQUIVALENTS, end of period.

  2,393   1,075 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

        

Cash paid for interest

 $86  $6 

SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES

        

Deemed dividend on warrant inducement offer

 $1,360  $— 

Deemed contribution on extinguishment of preferred stock

 $3,347  $— 

Deemed dividend on repurchase of preferred stock

 $126  $— 

Fair value of deferred consideration payable for initial minority equity interest

 $5,250  $— 

Acquisition date fair value of previously held minority equity interest of step acquiree

 $2,948  $— 

Fair value of deferred consideration payable in connection with acquisition

 $5,778  $— 

Fair value of convertible preferred stock issued to settle deferred consideration

 $7,833  $— 

Short-term note payable issued in connection with acquisition

 $4,788  $— 

Property and equipment reclassified from inventories

 $10  $20 

Operating right-of-use asset obtained in exchange for new operating lease liabilities

 $1,750  $142 

Note payable of variable interest entities issued in connection with an asset acquisition

 $—  $1,246 

Fair value of common stock issued in connection with asset acquisitions

 $—  $393 

Consideration for asset acquisition included in accounts payable

 $—  $185 

Consideration for asset acquisition included in non-controlling interest

 $—  $109 

Fair value of trading debt securities obtained as consideration for convertible preferred stock and other equity-classified warrants

 $—  $864 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

6

 

Flyte Aviation, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

 

Note 1. Organization and Nature of Operations

 

The Company

 

Flyte Aviation, Inc. (formerly known as Catheter Precision, Inc.) (the "Company”) was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. On January 9, 2023, the Company entered into the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") with Catheter Precision, Inc. (“Old Catheter”), a privately held Delaware corporation. Under the terms of the Merger Agreement, Old Catheter became a wholly owned subsidiary of the Company, together referred to as the Company, in a stock-for-stock merger transaction (the "Merger"). The Company's operating activities primarily related to Old Catheter's historical business, which included the design, manufacture and sale of new and innovative medical technologies in the field of cardiac electrophysiology (“EP”). 

 

On February 17, 2025, the Company formed Cardionomix, Inc. ("Cardionomix"), an 82%-owned subsidiary. On May 5, 2025, Cardionomix acquired certain assets primarily related to the Cardiac Pulmonary Nerve Stimulation ("CPNS") System, a technology for the late-stage treatment of acute decompensated heart failure.

 

On February 6, 2026, the Company entered into Securities Agreement with SEG Jets LLC ("SEG Jets"), whereby the Company agreed to acquire 19.98% of the issued and outstanding shares of common stock of Fly Flyte, Inc. ("FLYTE") held by SEG Jets. On March 9, 2026, the Company entered into Stock Agreement with Creatd, Inc. ("Creatd") and acquired the remaining 80.02% of the issued and outstanding shares of common stock of FLYTE and all of FLYTE’s wholly owned consolidated subsidiaries, which included 100% equity ownership interest in Ponderosa Air, LLC. As a result of these transactions (collectively the "Acquisition"), the Company owns 100% of the issued and outstanding common stock of FLYTE and its wholly owned consolidated subsidiaries. FLYTE and all of its wholly owned consolidated subsidiaries operate as a single business.

 

Effective October 5, 2026, the Company changed its legal name from Catheter Precision, Inc. to Flyte Aviation, Inc. In connection with the name change, the ticker symbol for the Company’s common stock listed on the NYSE American changed from “VTAK” to “VJET” effective October 5, 2026.

 

After the Acquisition, the Company's operations are organized and managed under two reportable segments: (i) cardiac electrophysiology and (ii) private aviation.

 

Cardiac Electrophysiology Segment

 

Historically, the Company's cardiac electrophysiology operations included the VIVO System, a non-invasive imaging system that provides three-dimensional cardiac mapping to assist in identifying the origin of certain ventricular arrhythmias, and LockeT, a suture retention device used to facilitate vascular access site closure following certain medical procedures. The Company began commercial sales of VIVO in the United States in 2021 and LockeT in 2024. In September 2026, the Company began negotiations for the sale of its VIVO and LockeT businesses and accordingly classified these businesses as discontinued operations and the related Disposal Group (as defined below) as held for sale. Accordingly, their results of operations are excluded from continuing operations for all periods presented. The remaining cardiac electrophysiology segment includes certain legacy medical technology assets and related activities that are not included in the Disposal Group. See Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

7

 

Private Aviation Segment

 

Through its wholly owned subsidiary, the Company operates a private aviation company providing regional private jet charter services through its fleet of leased Cirrus Vision jets and charter brokerage services through third-party operators. Charter customers are sourced through a network of brokers who make a market between customers and private aviation companies, and also through its recently launched Direct to Consumer app and website. The subsidiary’s business strategy includes providing low-cost private aviation compared to traditional charter services as an alternative to driving on regional routes, generally within 400 nautical miles of its base in Farmingdale, New York. The Company’s recently launched app enables customers to quickly and easily book and pay for flights and has begun to create and increase brand awareness among the Company’s target market of customers who choose to reduce the time required to travel to and from destinations with the speed of flight. The Company has also recently launched the ability for customers to bid to fly on empty-leg segments intended to turn those segments into cost-neutral or profitable flights. The Company had begun the regulatory approval process to operate flights to and from Canada, Mexico and the Caribbean.  During the 2026 third quarter, the Company received the required approvals to operate flights in Mexico and the Caribbean.  Additionally, on October 29, 2026 the Company announced that it had received the required approvals to operate flights within Canada.

 

Reverse Stock Split

 

On April 15, 2026, at a Special Meeting of Stockholders of the Company, the stockholders approved an Amendment to the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split within specified parameters. On September 24, 2026, the Board approved the Amendment and set the ratio of the reverse stock split at 1-for-10. The Amendment was effective October 5, 2026, effecting a reverse stock split in which each ten (10) shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding immediately prior to the effective time, automatically combined into one (1) validly issued, fully paid and non-assessable share of the Company’s common stock, par value $0.0001 per share.

 

No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share were entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). All references to share and per share amounts for all periods presented in the unaudited condensed consolidated financial statements have been retrospectively restated to reflect the reverse stock split. All rights to receive shares of common stock under outstanding securities, including but not limited to, warrants, options and convertible securities, were adjusted to give effect to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise and conversion prices and the number of shares of common stock that may be purchased or issued upon exercise or conversion of outstanding warrants, stock options and convertible securities, and the number of shares of common stock reserved for future issuance under the Company’s 2023 Equity Incentive Plan.

 

Going Concern

 

The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from uncertainty related to its ability to continue as a going concern.

 

The Company has incurred recurring net losses from operations and negative cash flows from operating activities since inception. For the nine months ended September 30, 2026, the Company incurred $20.1 million in net losses and used $10.2 million in cash for operating activities. As of September 30, 2026, the Company had an accumulated deficit of $329.6 million, working capital deficit of $3.2 million, and cash and cash equivalents of $2.4 million.

 

Management expects operating losses and negative cash flows to continue for the foreseeable future. The Company needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its private aviation operations, retained medical technology activities, and other contractual and operating obligations. 

 

During the nine months ended September 30, 2026, the Company raised aggregate gross proceeds of approximately $18.7 million from the sale of common stock and Series C Convertible Preferred Stock and the exercise of warrants (see Note 13, Equity Offerings, and Note 14, Preferred Stock). In October 2026, certain existing investors agreed to purchase an additional $2.05 million of Series C-4 Convertible Preferred Stock, and on November 1, 2026, the Company entered into a non-binding letter of intent for the sale of the Disposal Group (as defined in Note 4, Discontinued Operations and Assets Held for Sale) (see Note 20, Subsequent Events). There can be no assurance that the sale of the Disposal Group will be completed or as to the amount or timing of any proceeds.

 

Based on the Company's liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and do not reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern.

 

8

 

Management plans to raise additional capital through public or private equity or debt financing, or other innovative and specialty finance strategies, in order to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the unaudited condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders.

 

Note 2. Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements of the Company include the accounts of the Company, Old Catheter, Cardionomix, KardioNav, FLYTE, and Ponderosa. All intercompany transactions have been eliminated in consolidation.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP") applicable to interim financial statements. The Financial Accounting Standards Board (“FASB”) establishes these principles to ensure financial condition, results of operations, and cash flows are consistently reported. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the FASB Accounting Standards Codification ("ASC"). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for fair presentation of the unaudited condensed consolidated financial statements of the Company. The operating results presented herein are not necessarily an indication of the results that may be expected for the year. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026.

 

Discontinued Operations and Assets Held for Sale

 

The Company determined that the VIVO and LockeT businesses met the criteria to be classified as held for sale and discontinued operations in accordance with ASC 360, Property, Plant, and Equipment, and ASC 205-20, Discontinued Operations, as of September 30, 2026. Prior to applying the held for sale measurement, the assets and liabilities within the Disposal Group are evaluated in accordance with other applicable accounting guidance. Upon classification as held for sale, the Disposal Group is measured at the lower of its carrying amount or estimated fair value less costs to sell. Any resulting loss is recognized as loss on impairment of assets held for sale within discontinued operations, with a corresponding valuation allowance presented as a reduction of assets held for sale. Depreciation and amortization cease upon classification as held for sale.

 

Accordingly, the assets and liabilities associated with the discontinued operations are presented separately in the condensed consolidated balance sheets, and the results of operations have been reclassified to discontinued operations in the condensed consolidated statements of operations for all periods presented. The results of operations have been reported within loss from discontinued operations, net of tax, in the condensed consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025. The related assets and liabilities are presented separately as assets and liabilities of discontinued operations in the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025. The Company has elected not to separately present the cash flows of discontinued operations in the condensed consolidated statements of cash flows. Supplemental cash flow information related to discontinued operations is disclosed in Note 4, Discontinued Operations and Assets Held for Sale. Unless otherwise indicated, the notes to the condensed consolidated financial statements relate solely to the Company's continuing operations. Prior period amounts have been reclassified to conform to the current period presentation. Discontinued operations include only revenues and expenses directly attributable to the Disposal Group. The results of retained medical technology activities and general corporate overhead are included in continuing operations. Refer to Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

Reclassifications

 

Certain prior period financial statement amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on our previously reported consolidated net loss or accumulated deficit. In the current period, the Company separately discloses amortization of operating right-of-use assets in the condensed consolidated statements of cash flows. For comparative purposes, amounts in the prior periods have been reclassified to conform to current period presentations. See above discussion for reclassifications due to discontinued operations. 

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the allowance for credit losses, evaluation of impairment of long-lived assets, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, evaluation of probable loss contingencies, fair value of royalties payable, fair value of contingent consideration recorded in connection with an asset acquisition, fair value of assumed liabilities, acquired assets, and consideration transferred in connection with a business combination, fair value of preferred stock issued, including valuation of the deemed dividend and contribution, fair value of warrants issued, fair value of deferred stock issuance liabilities, fair value of the Disposal Group classified as held for sale, and fair value of equity and liability classified awards granted.

 

9

 

Concentrations of Credit Risk

 

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable during the  nine months ended September 30, 2026 and 2025. The Company generally maintains cash and cash equivalent balances in various operating accounts at financial institutions with high quality credit ratings in amounts in excess of federally insured limits of $250,000. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to significant or unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other hedging arrangements.

 

The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated balance sheets. The Company does not require collateral from its customers to secure accounts receivable.

 

One customer represented 14% of total revenues for the three months ended  September 30, 2026 and one customer represented 17% of total revenues for the nine months ended September 30, 2026. The Company had no revenues for the three and nine months ended September 30, 2025. 

 

The Company had three and five customers that individually accounted for more than 10% of total accounts receivable included in the condensed consolidated balance sheets as of  September 30, 2026 and December 31, 2025, respectively. Three customers represented 10%, 14% and 18% of accounts receivable as of  September 30, 2026. Two customers represented 27% and 15%, and three customers each represented 10% of accounts receivable as of  December 31, 2025.

 

Segment Reporting

 

Following the acquisition of FLYTE, the Company determined that it operates in two reportable segments: (i) cardiac electrophysiology and (ii) private aviation. In September 2026, the Company classified its VIVO and LockeT businesses, previously included in the cardiac electrophysiology segment, as discontinued operations. Accordingly, the results of these businesses have been excluded from the segment information presented for all periods, and prior period segment information has been recast to reflect continuing operations only. The Company’s cardiac electrophysiology segment includes the remaining activities related to its legacy medical technologies that are not included in the Disposal Group, including AMIGO related assets and Cardionomix’s CPNS related assets and activities, together with corporate level activities allocated to the segment that are reviewed by the CODM as part of this segment's results. The remaining cardiac electrophysiology activities are managed by a single corporate team. The Company’s private aviation segment includes all activities related to the marketing, sales, and delivery of private aviation services to customers through FLYTE. All of its operations are centrally managed within the United States by a single corporate team. The determination of two reportable segments is consistent with the condensed consolidated financial information available and regularly reviewed by the Company’s chief operating decision maker (“CODM”). Refer to Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

The CODM is the Company’s Chief Executive Officer, who reviews and evaluates net loss from continuing operations, for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. Segment asset measures are not used as a basis for the CODM to evaluate the performance of or to allocate resources to the segments.

 

10

 

The following table summarizes the segment revenues and significant segment expenses included in the measure of segment profit or loss (segment net loss) reviewed by the CODM for the nine months ended September 30, 2026 and 2025 (in thousands):

 

 

For the Nine Months Ended September 30,

 
 

2026

 

2025

 
 

Cardiac Electrophysiology

 

Private Aviation

 

Total

 

Total

 

Revenue, net

            

Luxe

 —  84  84  — 

Hops

 —  2,687  2,687  — 

Total revenues, net

 —  2,771  2,771  — 
             

Less:

            

Cost of revenues:

 —  2,424  2,424  — 

Acquired in-process research and development expense

 —  —  —  1,967 

Depreciation and amortization expense

 —  92  92  2 

Stock-based compensation expense

 491  —  491  195 

Salaries and benefits expense

 701  610  1,311  721 

Professional fees

 2,238  323  2,561  1,523 

Research and development expense

 —  —  —  2 

Marketing expense

 —  473  473  — 

Interest income

 (8) —  (8) (31)

Interest expense

 446  42  488  199 

Change in fair value of trading debt securities

 —  —  —  (117)

Change in fair value of minority equity interest

 2,302  —  2,302  — 

Change in fair value of deferred consideration

 (3,195) —  (3,195) — 

Change in fair value of deferred stock issuance liability

 (160) —  (160) — 

Loss on debt extinguishment

 105  —  105  — 

Gains on marketable securities, net

 (540) —  (540) — 

Income tax benefit

 (950) —  (950) (1,596)

Other segment items (1)

 1,216  860  2,076  1,081 

Segment and consolidated loss from continuing operations

$(2,646)$(2,053)$(4,699)$(3,946)

 

The following table summarizes the segment revenues and significant segment expenses included in the measure of segment profit or loss (segment net loss) reviewed by the CODM for the three months ended  September 30, 2026 and 2025 (in thousands):

 

 

For the Three Months Ended September 30,

 
 

2026

 

2025

 
 

Cardiac Electrophysiology

 

Private Aviation

 

Total

 

Total

 

Revenues, net

            

Luxe

 —  15  15  — 

Hops

 —  1,823  1,823  — 

Total revenues, net

 —  1,838  1,838  — 
             

Less:

            

Cost of revenues

 —  1,514  1,514  — 

Acquired in-process research and development expense

 —  —  —  — 

Depreciation and amortization expense

 —  40  40  1 

Stock-based compensation expense

 161  —  161  52 

Salaries and benefits expense

 231  323  554  239 

Professional fees

 587  160  747  527 

Research and development expense

 —  —  —  — 

Marketing expense

 —  320  320  — 

Interest income

 (2) —  (2) (10)

Interest expense

 165  —  165  83 

Change in fair value of trading debt securities

 —  —  —  (107)

Change in fair value of minority equity interest

 —  —  —  — 

Change in fair value of deferred consideration

 —  —  —  — 

Change in fair value of deferred stock issuance liability

 (206) —  (206) — 

Loss on debt extinguishment

 —  —  —  — 

Gains on marketable securities, net

 (162) —  (162) — 

Income tax benefit

 (463) —  (463) 78 

Other segment items (1)

 608  415  1,023  372 

Segment loss from continuing operations

 (919) (934) (1,853) (1,235)

 

(1)    Other segment items include other income (expense), net, consulting fees, investor relations and SEC fees, insurance fees, and other selling, general, and administrative expenses. Other selling, general, and administrative expenses primarily consist of travel expenses, computer and information technology expenses, and rent expenses.

 

In connection with the FLYTE acquisition, including the associated tax implications of the acquisition, the Company recognized  $12.2 million in goodwill that is fully allocated to the private aviation segment during the nine months ended September 30, 2026. 

 

11

 

Cash and Cash Equivalents 

 

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents. Cash and cash equivalents primarily represent funds invested in readily available checking and money market accounts. 

 

Investments in Marketable Securities

 

The Company accounts for its investments in equity securities pursuant to ASC 321, Investments—Equity Securities ("ASC Topic 321"). Equity securities with readily determinable fair values are initially recognized and subsequently measured at fair value, with changes in fair value, including unrealized gains and losses on securities held and gains and losses recognized upon disposition, reflected in gains on marketable securities, net, in the condensed consolidated statements of operations. Upon disposition, realized gains and losses are determined based on the difference between the proceeds received and the carrying value of the securities.

 

Fair Value Measurements

 

Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows:

 

Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

 

Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

 

Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

 

Prepaid expenses, accounts receivable, accounts payable, accrued expenses, and short-term notes payable are reported on the condensed consolidated balance sheets at carrying value, which approximate fair value due to the short-term maturities of these instruments. Similarly, the carrying value of the notes payable approximate their fair value due to the associated effective interest rates of the debt instruments.

 

The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments (in thousands). The table includes royalties payable due to related parties associated with the Disposal Group, which are presented within liabilities held for sale from discontinued operations in the condensed consolidated balance sheets. Refer to Note 4, Discontinued Operations and Assets Held for Sale, for the related Level 3 fair value reconciliation:

 

    

September 30, 2026

    
 

Total

 

Level 1

 

Level 2

 

Level 3

 

Assets:

            

Cash equivalents

            

Money market funds

$342 $342 $— $— 

Total assets

$342 $342 $— $— 
             

Liabilities:

            

Royalties payable - continuing operations

$160 $— $— $160 

Royalties payable due to related parties - discontinued operations

 632  —  —  632 

Total liabilities

$792 $— $— $792 

 

 

12

 
      

December 31, 2025

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash Equivalents

                

Money market funds

 $2  $2  $—  $— 

Total assets

 $2  $2  $—  $— 
                 

Liabilities:

                

Royalties payable - continuing operations

 $160  $—  $—  $160 

Royalties payable due to related parties - discontinued operations

  632   —   —   632 

Convertible notes payable

  298   —   —   298 

Total liabilities

 $1,090  $—  $—  $1,090 

 

Royalties Payable and Royalties Payable Due to Related Parties

 

The fair value measurement of royalties payable and royalties payable due to related parties (collectively, "Royalties Payables") includes significant unobservable inputs that are not supported by any market data. Royalties Payables reflect the present value of estimated future royalty payments. The Company applies an internally developed, revenue adjusted discount rate ("RADR”) to discount back the forecasted royalty payments. The RADR is based on the Company’s weighted average cost of capital ("WACC”) adjusted for the product revenue’s risk profile. The risk-free rate used to determine the cost of equity for the RADR is adjusted to be commensurate with the term of the royalty agreements. Furthermore, the Beta and Risk Premium used to determine the cost of equity are also adjusted to reflect the product revenue's volatility. All other inputs for the RADR and the Company’s WACC are the same.

 

Royalties payable due to related parties associated with the Disposal Group continue to be measured at fair value on a recurring basis using significant unobservable inputs (Level 3). These liabilities are presented within liabilities held for sale from discontinued operations, with changes in fair value recognized within loss from discontinued operations, net of tax, in the condensed consolidated statements of operations. The related Level 3 fair value reconciliation is presented in Note 4, Discontinued Operations and Assets Held for Sale.

 

See Note 10, Royalties Payable, for additional information over royalties payable associated with continuing operations.

 

Convertible Notes Payable 
 

The Company elected the fair value option to measure the convertible notes payable. The fair value of the convertible notes payable is determined using a probability weighted expected return model ("PWER model”) that values the convertible notes payable based on the discounted cash flows of three potential settlement outcomes: (i) the convertible notes payable will be converted into and settled in shares of common stock, (ii) the convertible notes payable’s principal and accrued interest will be paid in cash, and (iii) a dissolution scenario wherein the investor receives a partial payment based on a recovery rate. The conversion outcome incorporates a Monte Carlo simulation to estimate the Company’s common stock price at the expected conversion date and the number of shares issuable based on the variable conversion price. Aside from the probability of the three potential settlement outcomes, the fair value measurement incorporates several significant unobservable inputs, including the recovery rate, implied equity volatility, expected term assumptions, simulated conversion price, and credit-risk adjusted discount rate. The convertible notes payable were settled in June 2026, such that there is no remaining balance as of September 30, 2026. See Note 9, Notes Payable for additional information.

 

Deferred Consideration

 

The deferred consideration consisted of two components. The first deferred consideration component arose from the Company's initial 19.98% minority equity interest in FLYTE on  February 6, 2026, and the second component related to the subsequent acquisition of the remaining outstanding equity in FLYTE on  March 9, 2026. See Note 3, Business Combination, for additional information. The Company was obligated to issue to the sellers an aggregate of 11,028 shares of the Company’s Series D Convertible Preferred Stock. In accordance with ASC Topic 815, Derivatives and Hedging ("ASC Topic 815"), this obligation failed to meet the equity classification criteria in ASC Topic 815-40-25. Therefore, it did not qualify for the scope exception from derivative accounting. This obligation was classified as a current liability on the condensed consolidated balance sheet and measured at fair value, with changes in fair value reflected in the condensed consolidated statements of operations. The deferred consideration was settled on April 20, 2026, when the Company issued 11,028 shares of Series D Convertible Preferred Stock to the sellers.

 

The deferred consideration was classified as a Level 3 recurring liability because the valuation utilized certain unobservable inputs that were supported by little or no market data. The fair value of the Series D Convertible Preferred Stock was measured using the if converted method, which included contractual terms such as the number of units issued, the $1,000 issued stated value, and the contractual conversion price. The if converted method also utilized observable inputs, such as the underlying common stock price on the acquisition date, the period end remeasurement date, and the settlement date and incorporated unobservable inputs related to a 20% discount for lack of marketability.

 

The fair value of the first component of deferred consideration initially recorded on  February 6, 2026 was approximately $5.3 million. Upon obtaining control of FLYTE on  March 9, 2026, the Company recorded the second component of the deferred consideration of approximately $5.8 million. The Company remeasured the total deferred consideration through its settlement on April 20, 2026, resulting in a decrease in fair value of approximately $3.2 million during the nine months ended  September 30, 2026. The change in fair value was recognized as a gain in the condensed consolidated statements of operations. 

 

Deferred Stock Issuance Liability

 

On June 28, 2026, the Company received advance proceeds of $0.6 million from an investor in exchange for the future issuance of 601 shares of Series C-3 Convertible Preferred Stock pursuant to the Securities Purchase Agreements dated February 6, 2026 and March 9, 2026. The issuance of the Series C-3 Convertible Preferred Stock was contingent upon the effectiveness of the registration statement covering the resale of the underlying common stock, which became effective on July 10, 2026. In accordance with ASC Topic 815, Derivatives and Hedging ("ASC Topic 815"), this obligation failed to meet the equity classification criteria in ASC Topic 815-40-25. Therefore, it did not qualify for the scope exception from derivative accounting. This obligation was classified as a liability and measured at fair value, with changes in fair value reflected in change in fair value of deferred stock issuance liability, in the condensed consolidated statements of operations. The deferred stock issuance liability was settled on July 15, 2026, when the Company issued 601 shares of Series C-3 Convertible Preferred Stock to the investor.

 

The deferred stock issuance liability was classified as a Level 3 liability because the valuation utilized certain unobservable inputs that were supported by little or no market data. The fair value of the Series C-3 Convertible Preferred Stock was measured using the if-converted method, which included contractual terms such as the number of shares issuable, the $1,000 stated value, and the contractual conversion price. The if-converted method also utilized observable inputs, such as the underlying common stock price on the initial measurement and subsequent remeasurement dates, and incorporated unobservable inputs related to a 20% discount for lack of marketability.

 

The fair value of the deferred stock issuance liability initially recorded on June 28, 2026 was approximately $0.6 million. The Company remeasured the deferred stock issuance liability as of June 30, 2026 and immediately prior to settlement on July 15, 2026, resulting in a gain of approximately $0.2 million and $0.2 million during the three and nine months ended September 30, 2026, respectively. The changes in fair value were recognized in change in fair value of deferred stock issuance liability, in the condensed consolidated statements of operations. No deferred stock issuance liability remained outstanding as of September 30, 2026.

 

13

 

The following tables summarize the significant unobservable inputs used in Level 3 financial instruments as of September 30, 2026, including royalty liabilities associated with discontinued operations:

 

Instrument

Valuation Technique

Unobservable Input

Input Range

 

Royalties payable

Discounted future cash flows

Revenue adjusted discount rate

 19.5%

 

The significant unobservable inputs used for royalties payable as of December 31, 2025 are the same as those displayed above for September 30, 2026. 

 

The Level 3 fair value reconciliations presented below include financial instruments associated with continuing operations. Royalties payable due to related parties associated with the Disposal Group have been excluded from these reconciliations, as the related Level 3 fair value activity is separately presented in Note 4, Discontinued Operations and Assets Held for Sale.

 

The table below summarizes the change in account balance for Level 3 financial instruments associated with continuing operations for the three and nine months ended September 30, 2026 (in thousands):

 

 

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
 

Royalties Payable

 

Deferred Stock Issuance Liability

 

Deferred Consideration

 

Convertible Notes Payable

 

Balance at January 1, 2026

$160 $— $— $298 

Fair value at issuance

 —  —  11,028  — 

Change in fair value

 —  —  (2,877) — 

Balance at March 31, 2026

 160  —  8,151  298 

Fair value at issuance

 —  601  —  — 

Change in fair value

 —  46  (318) — 

Settlement of financial instruments

 —  —  (7,833) (403)

Realized (gains) and losses

 —  —  —  105 

Balance at June 30, 2026

 160  647  —  — 

Change in fair value

 —  (206) —   

Settlement of financial instrument

 —  (441) —  — 

Balance at September 30, 2026

$160 $— $— $— 

 

The table below summarizes the change in account balance for Level 3 financial instruments for the three and nine months ended September 30, 2025 (in thousands):

 

 

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
 

Royalties Payable

 

Trading Debt Securities

 

Balance at January 1, 2025

$160 $— 

Change in fair value

 —  — 

Balance at March 31, 2025

 160  — 

Purchased

 —  864 

Change in fair value

 —  10 

Balance at June 30, 2025

 160  874 

Change in fair value

 —  107 

Balance at September 30, 2025

$160 $981 

 

Increases or decreases in the fair value of royalties payable and deferred stock issuance liability can result from updates to assumptions. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Changes or updates to assumptions could have a material impact on the reported fair value, the change in fair value, and the results of operations in any given period.

 

During the three months ended September 30, 2026, the Company measured the Disposal Group at fair value less costs to sell on a nonrecurring basis using Level 2 inputs. Refer to Note 4, Discontinued Operations and Assets Held for Sale, for additional information regarding the valuation methodology, fair value measurement and related impairment.

 

14

 

Accounts Receivable and Allowances for Credit Losses

 

Accounts receivable consists of trade receivables recorded at invoiced amounts. Accounts receivable are presented net of any discounts and allowance for credit losses, are unsecured and do not bear interest. Accounts receivable are evaluated for collectability based on historical credit loss experience, adjusted for asset specific risk characteristics, current economic conditions, and reasonable forecasts, including the probability of future collection and estimated loss rates based on aging schedules. 

 

Changes in the estimated collectability of accounts receivable are recorded in the condensed consolidated statements of operations in the period in which the estimate is revised. Accounts receivable are written off as uncollectible after all means of collection are exhausted. Any subsequent recoveries are credited to the allowance for credit losses. As of  September 30, 2026 and December 31, 2025, the allowance for credit losses related to accounts receivable was immaterial.

 

Property and Equipment

 

Property and equipment are recorded at cost, less accumulated depreciation. Property and equipment are depreciated on a straight-line basis over their estimated useful lives as follows: 

 

Computer hardware and software

  1 - 5 years 

Furniture, fixtures and equipment

  7 years 

Capitalized software development costs

  5 years 

 

The Company periodically reviews the residual values and estimated useful lives of each class of its property and equipment for ongoing reasonableness, considering the long-term views of their intended use and the level of planned improvements to maintain and enhance those assets. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from their respective account balances, and any resulting gain or loss is recognized in the Company’s condensed consolidated statements of operations. The cost of repairs and maintenance is expensed as incurred, whereas significant renewals and betterments are capitalized. Depreciation and amortization cease for long-lived assets upon classification as held for sale.

 

Business Combination

 

The Company accounts for business combinations using the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations ("ASC Topic 805"). The purchase price of an acquisition is allocated to the underlying tangible and identifiable intangible assets acquired and liabilities assumed based on their respective estimated fair values as of the acquisition date. The excess of the purchase price over the estimated fair value of the identifiable net assets acquired is recorded as goodwill. Transaction costs related to business combinations, such as legal, accounting, valuation, and other professional or consulting fees, are expensed as incurred and included in selling, general and administrative expenses in the condensed consolidated statements of operations.

 

The Company may adjust the preliminary purchase price allocation, as necessary, for up to one year after the acquisition closing date (the “measurement period”) as it obtains more information regarding asset valuations and liabilities assumed that existed at the acquisition date. Measurement period adjustments are recorded in the period in which the adjustments are determined.

 

15

 

Deferred tax assets and liabilities are recognized for the tax effects of temporary differences between the tax bases and the recognized amounts of assets acquired and liabilities assumed in accordance with ASC Topic 740, Income Taxes ("ASC Topic 740").

 

Goodwill and Indefinite-Lived Intangible Assets

 

Goodwill and indefinite-lived intangible assets are not amortized. Goodwill and indefinite-lived intangible assets are tested for impairment annually during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects to bypass the qualitative assessment, or if the qualitative assessment indicates it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative test is performed. An impairment charge for goodwill is recognized for the amount by which the carrying amount of the reporting unit exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. An impairment charge for indefinite-lived intangible assets is recognized for the amount by which the carrying amount of the indefinite-lived intangible asset exceeds its fair value.

 

The Company completed a qualitative assessment and determined that there was no evidence of impairment to the balance of its goodwill and indefinite-lived intangible assets as of September 30, 2026. The Company did not have goodwill nor indefinite-lived intangible assets as of  December 31, 2025.

 

Impairment of Long-lived Assets

 

The Company periodically reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value of the long-lived assets may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the assets carrying value over its fair value is recorded in the Company’s condensed consolidated statements of operations at that date. 

 

In September 2026, the Company classified its VIVO and LockeT businesses as discontinued operations and the related Disposal Group as held for sale. Upon classification, the Disposal Group was measured at the lower of its carrying amount or fair value less costs to sell in accordance with ASC 360, resulting in a noncash loss on impairment of assets held for sale of approximately $12.5 million for the three and nine months ended September 30, 2026. The loss was recognized at the Disposal Group level, with a corresponding valuation allowance recorded against assets held for sale from discontinued operations. No impairment charges were recorded during the nine months ended September 30, 2025. The impairment charge is presented within loss from discontinued operations, net of tax, in the condensed consolidated statements of operations. Refer to Note 4, Discontinued Operations and Assets Held for Sale, for further details.

 

Capitalized Software Development Costs

 

The Company capitalizes certain costs incurred to develop internal-use software in accordance with ASC 350-40, Intangibles — Goodwill and Other — Internal-Use Software. Costs are capitalized during the application development stage, after the preliminary project stage has been completed, once management has authorized and committed to funding the project and it is probable that the project will be completed and the software will be used to perform its intended function. Costs incurred before these criteria are met, as well as costs related to training, maintenance, and data conversion, are expensed as incurred. Capitalized software development costs are included in property and equipment, net, and are amortized on a straight-line basis over the estimated useful life of the software once it is ready for its intended use. Costs of upgrades and enhancements that provide additional functionality are capitalized, while other post-implementation costs are expensed as incurred. Capitalized software is evaluated for impairment consistent with the Company’s policy for long-lived assets.

 

Royalties Payable

 

The Company is obligated to pay royalties related to sales of the AMIGO System under various royalty agreements executed by Old Catheter. The Company recognizes a liability for royalty fees incurred and payable based on actual sales of products as the underlying royalty obligations are incurred. The Company also recognizes a liability for estimated future royalty payments at fair value, with amounts classified as current or noncurrent based on their expected settlement dates. The royalties payable are remeasured at each reporting period. Changes in fair value of royalties payable are recorded in the condensed consolidated statements of operations in the period in which they occur. Royalty obligations associated with the discontinued operations are presented within liabilities held for sale from discontinued operations in the condensed consolidated balance sheets. See Note 10, Royalties Payable, and Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

16

 

Asset Acquisitions and In-process Research and Development

 

The Company accounts for acquisitions of assets or a group of assets that do not meet the definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which includes certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition.

 

Assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as in-process research and development (“IPR&D”) in the condensed consolidated balance sheets. Acquired IPR&D that has no alternative future use as of the acquisition date is recognized as acquired-in-process research and development expense in the condensed consolidated statements of operations as of the acquisition date.

 

Contingent consideration in asset acquisitions that is not accounted for as a derivative is measured and recognized when payment becomes probable and reasonably estimable. Subsequent changes in the accrued amount of contingent consideration are measured and recognized at the end of each reporting period and upon settlement as an adjustment to the cost basis of the acquired asset or group of assets, or, if related to IPR&D with no alternative future use, recognized as expense. Contingent consideration that is in the form of a sales or usage-based royalty payment is recognized as an expense as incurred.

 

Debt Securities

 

In May 2025, the Company received two convertible promissory notes issued by QHSLab, Inc. (“QHSLab”) as partial consideration in connection with the May 2025 PIPE Financing (see Note 13, Equity Offerings). The QHSLab Notes were classified as trading debt securities under ASC Topic 320, Investments—Debt Securities, and measured at fair value, with changes in fair value recognized in the condensed consolidated statements of operations.

 

The Company recorded unrealized gains of $107 thousand and $117 thousand related to the QHSLab Notes for the three and nine months ended three and nine months ended September 30, 2025, respectively. The Company sold the QHSLab Notes in November 2025 and held no trading debt securities as of September 30, 2026 or December 31, 2025.

 

Convertible Notes Payable

 

Convertible notes payable represent debt-host financial instruments whose embedded features must be assessed for bifurcation and separate accounting as derivative liabilities under ASC Topic 815, unless the fair value option is elected to measure certain financial assets and liabilities at fair value under ASC Topic 825, Financial Instruments ("ASC Topic 825”). The fair value option  may be elected on a financial instrument-by-financial instrument basis and is irrevocable, unless a new election date occurs. The fair value option simplifies the accounting by requiring the entire financial instrument to be measured at fair value.

 

As permitted under ASC Topic 825, the Company elected the fair value option to account for the convertible notes payable issued on December 26, 2025 (see Note 9, Notes Payable). The Company records convertible notes payable at fair value with any changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations. The change in fair value of convertible notes payable includes interest expense accrued for the convertible notes payable. Any portion of the change in fair value that is attributed to a change in the convertible note payables’ credit risk is recognized as a component of other comprehensive income. As a result of applying the fair value option, any debt issuance costs related to the convertible notes payable were expensed as incurred and were not deferred.

 

The convertible notes payable were settled in June 2026, such that there is no remaining balance as of September 30, 2026. See Note 9, Notes Payable for additional information.

 

Variable Interest Entity

 

A variable interest entity ("VIE") is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights or do not substantively participate in the gains or losses of the entity. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

17

 

The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC Topic 810, Consolidation ("ASC Topic 810"). These evaluations can be complex and judgmental, involving the use of estimates and assumptions based on available information among other factors. Based on these evaluations, if the Company determines it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. The equity owned by other stockholders is presented, as applicable, as non-controlling interests in the accompanying condensed consolidated balance sheets, statements of operations, and statements of stockholders’ equity.

 

If a reconsideration event occurs under ASC Topic 810, the Company performs an assessment to determine whether the entity continues to be a VIE, whether the Company still contains a variable interest in the VIE, and whether the Company continues to be or has become the primary beneficiary of the VIE.

 

Cardionomix

 

Cardionomix is a legal entity that was solely created to hold the assets of and to clinically develop and commercialize the CPNS System. The Company holds 82% of the voting, common stock, while the Company’s Chief Executive Officer and his affiliates hold 12%, and other third parties hold the remaining 6%. The Company determined that its controlling equity interest represents a variable interest in Cardionomix, which meets the definition of a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. Furthermore, the Company has determined that it is the primary beneficiary of the VIE as it has the power to direct the activities that most significantly impact the VIE’s economic performance through its controlling equity interest. The Company therefore consolidates the results of operations, assets, and liabilities of Cardionomix. The Company did not transfer any assets in exchange for its controlling equity interest in Cardionomix, which did not have any assets or liabilities at formation. Accordingly, the Company did not record any gain or loss upon initial consolidation.

 

As of September 30, 2026, Cardionomix only had a note payable with a carrying value of $1.4 million that was issued in May 2025 in connection with the asset acquisition. This note payable is presented under notes payable of variable interest entities, net of discount in the condensed consolidated balance sheets. Cardionomix does not hold any other material assets or liabilities as of September 30, 2026. Creditors of Cardionomix have no recourse to the Company’s general credit and their claims are limited solely to the assets of Cardionomix. Unless Cardionomix can obtain its own dedicated financing, the Company does not currently intend to allocate capital to fund the clinical development of the acquired assets. 

 

The minority equity interest holders are presented as non-controlling interests in the accompanying condensed consolidated balance sheets, statements of operations, and statements of stockholders’ equity.

 

KardioNav

 

KardioNav is a legal entity that was solely created to hold the assets of and to clinically develop and commercialize certain intellectual property related to new cardiac technology. The Company holds 57% of the voting common stock, while the Company’s Chief Executive Officer and his affiliates hold 10%, and other third parties hold the remaining 33%. The Company determined that its controlling equity interest represents a variable interest in KardioNav, which meets the definition of a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. Furthermore, the Company has determined that it is the primary beneficiary of the VIE as it has the power to direct the activities that most significantly impact the VIE’s economic performance through its controlling equity interest. The Company therefore consolidates the results of operations, assets, and liabilities of KardioNav. The Company assigned certain intellectual property related to the VIVO System to KardioNav, which was accounted for as a common control transaction under ASC Topic 810 and carried at the Company's carrying value at inception. Furthermore, the fair value of the intellectual property assigned by Chelak to KardioNav was deemed to be de minimis as the intellectual property solely consists of patents and related know-how at the conceptual stage. Therefore, the Company recognized no gain or loss upon initial consolidation. Creditors of KardioNav have no recourse to the Company’s general credit and their claims are limited solely to the assets of KardioNav. 

 

As of September 30, 2026, KardioNav held intellectual property associated with the VIVO business that had a de minimis carrying value immediately prior to the Disposal Group meeting the criteria for classification as held for sale. This intellectual property was subsequently included in the Disposal Group classified as held for sale (see Note 4, Discontinued Operations and Assets Held for Sale). KardioNav also had short-term notes payable of variable interest entities due to related parties with a carrying value of $315 thousand that remained classified as notes payable of variable interest entities due to related parties in the condensed consolidated balance sheets and were not included in the Disposal Group classified as held for sale. KardioNav does not hold any other material assets or liabilities. In connection with the planned disposition of its intellectual property, the Company no longer intends to provide financial support to KardioNav for the development of its cardiac electrophysiology technologies.

 

The minority equity interest holders are presented as non-controlling interests in the accompanying condensed consolidated balance sheets, statements of operations, and statements of stockholders’ equity.

 

Distinguishing Liabilities from Equity

 

The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480, Distinguishing Liabilities from Equity (“ASC Topic 480”). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company’s equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company’s equity shares, or variations inversely related to changes in fair value of the Company’s equity shares.

 

If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC Topic 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC Topic 815-40. The Company further assesses whether the equity classified shares should be classified as temporary equity. Equity classified shares that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event not solely within the Company's control are classified in temporary equity in accordance with ASC Topic 480. Otherwise, such shares are classified in permanent equity.

 

See Note 13, Equity Offerings and Note 14, Preferred Stock for additional information on the freestanding financial instruments assessed under ASC Topic 480 and ASC Topic 815-40 for equity or liability classification.

 

18

 

Revenue Recognition

 

In accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”), the Company accounts for contracts with customers when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenue is measured as the amount of consideration expected to be received in exchange for transferring promised goods or services. The amount of consideration to be received and revenue recognized may vary due to discounts. A performance obligation is a promise in a contract to transfer a distinct good or service. If there are multiple performance obligations in the customer contract, the Company allocates the transaction price in the contract to each performance obligation based on the relative standalone selling price. The Company does not adjust revenue for the effects of a significant financing component for contracts if the period between the transfer of control and corresponding payment is expected to be one year or less. Revenue from continuing operations is recognized when performance obligations in the customer contract are satisfied. This generally occurs when the customer obtains control of a promised good at a point in time or when a customer receives a promised service over time.

 

Pursuant to ASC Topic 606, the Company applies the following five steps to each customer contract:

 

Step 1: Identify the contract with the customer

 

Step 2: Identify the performance obligations in the contract

 

Step 3: Determine the transaction price

 

Step 4: Allocate the transaction price to the performance obligations in the contract

 

Step 5: Recognize revenue when the Company satisfies a performance obligation

 

The Company has elected as a practical expedient to expense as incurred any costs incurred to obtain a contract as the related amortization period would be one year or less.

 

19

 

Private Aviation Charter Services

 

The Company's revenue from continuing operations is generated through two primary private aviation services: Hops and Luxe.

 

Hops refers to Flyte’s short-haul private charter service, through which Flyte arranges charter routes using leased jets and pilots dedicated to Flyte’s operations. These flights are conducted on Company-managed aircraft and typically service high-demand regional routes throughout the New York Metro Area, Long Island, New England and the Eastern seaboard, to any destination within 400 nautical miles of the Company’s base in Farmingdale, New York. Each flight represents a performance obligation. For Hops arrangements, the Company acts as the principal because it controls the specified flight service before it is transferred to the customer, is primarily responsible for operating and fulfilling the flight, and has discretion in establishing pricing. Accordingly, Hops revenue is presented on a gross basis in the condensed consolidated statements of operations. Revenue includes base charter rates, repositioning fees, and ancillary charges.

 

Luxe is the Company’s brokerage division, offering clients access to on-demand charters through a vetted network of independent third-party aircraft operators. For Luxe arrangements, the Company evaluates whether it controls the specified flight service before it is transferred to the customer or whether the Company’s performance obligation is to arrange for a third-party operator to provide the flight service. The Company has determined that it acts as an agent in Luxe arrangements because the third-party aircraft operator is primarily responsible for operating and fulfilling the flight, and the Company does not control the underlying flight service before it is provided to the customer. Accordingly, Luxe revenue is presented on a net basis in the condensed consolidated statements of operations and represents the commission, brokerage fee, or other net amount retained by the Company after amounts payable to the third-party aircraft operator.

 

For both Hops and Luxe, the performance obligation is satisfied over the duration of each flight. Because flights are generally completed within a single day, the Company recognizes revenue upon completion of each flight segment. The Company generally does not issue refunds for flights unless there is a failure to meet its service obligations. For roundtrip flights, revenue is recognized upon arrival at the destination for each flight. Customer payments received in advance are recorded as deferred revenue until the related performance obligation is satisfied.

 

Disaggregation of Revenue

 

The following table summarizes revenue from continuing operations disaggregated by geographic area (in thousands):

 

 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 
 

2026

 

2025

 

2026

  

2025

 

Revenue

             

US

$1,813 $— $2,746  $— 

International

 25  —  25   — 

Total Revenue

$1,838 $— $2,771  $— 

 

Revenue associated with the Disposal Group is excluded from the table above and included in the results of discontinued operations. See Note 4, Discontinued Operations and Assets Held for Sale.

 

20

 

Deferred Revenue

 

Deferred revenues primarily consist of contract liabilities and represent amounts billed to, or collected from, customers in advance of the Company satisfying the related performance obligations. The Company recognizes revenue from deferred revenue as the related products or services are transferred to customers in accordance with the terms of the underlying customer contract.

 

The Company’s contract liabilities were assumed in connection with the acquisition of FLYTE and relate to customer arrangements of the acquired business for which consideration had been received, or amounts had been billed, prior to the satisfaction of the related performance obligations. The Company had de minimis contract liabilities prior to the acquisition of FLYTE. As of September 30, 2026, the Company had no contract assets related to contracts with customers. Deferred revenue is presented as a current liability in the condensed consolidated balance sheets to the extent the Company expects to recognize the related revenue within the next twelve months. 

 

The following table summarizes the changes in the deferred revenue balance as follows (in thousands):

 

  

Nine Months Ended September 30,

 
  

2026

  

2025

 

Deferred revenue, beginning of period

 $—  $— 

Deferred revenue assumed as part of acquisition (see Note 3)

  171   — 

Revenue recognized from deferred revenue during the period

  (206)  — 

Additional amounts billed or received and deferred during the period

  265   — 

Deferred revenue, end of period

 $230  $— 

 

Advertising and Marketing

 

Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the unaudited condensed consolidated statements of operations. Advertising costs were $320 thousand and $473 thousand during the three and nine months ended September 30, 2026, respectively. The Company incurred no advertising costs during the three and nine months ended September 30, 2025.

 

Patents

 

The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.

 

Research and Development

 

Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred.

 

Stock-based Compensation

 

The Company recognizes stock-based compensation expense associated with stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) issued to employees, members of the Company’s board of directors and consultants in accordance with ASC Topic 718, Compensation – Stock Compensation (“ASC Topic 718”). The Company evaluates whether stock-based awards should be classified and accounted for as liability or equity awards on the date of grant. Furthermore, the Company measures all stock-based awards granted based on their fair value on the date of grant. Stock options are measured at fair value using the Black-Scholes option pricing valuation model (the “Black-Scholes model”), which incorporates various assumptions, including expected term, volatility and risk-free interest rate. The expected term of the options is the estimated period of time until exercise and was determined using the SEC’s safe harbor rules, using an average of vesting and contractual terms, as the Company did not have sufficient historical experience of similar awards. Expected stock price volatility is based on historical volatilities of certain “guideline” companies, as the Company does not have sufficient historical stock price data. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent term. Stock-based compensation expense for all stock-based awards is recognized over the requisite service period, which is generally the vesting period of the respective stock award. Stock-based compensation expense for stock-based awards with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not probable or is not met, no stock-based compensation expense is recognized, and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.

 

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other income (expense), net respectively.

 

On July 4, 2025, the One Big Beautiful Bill Act was signed into law. The legislation did not have a material impact on our income tax expense for the nine months ended September 30, 2026.

 

21

 

Basic and Diluted Net Income (Loss) per Share

 

Earnings per share attributable to Flyte Aviation, Inc. common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company’s common shares and participating securities. The Company’s Series X Convertible Preferred Stock and Series B Convertible Preferred Stock, of which no shares were outstanding as of September 30, 2026, as well as Series C Convertible Preferred Stock, Series D Convertible Preferred Stock, Series J Convertible Preferred Stock, and outstanding warrants are participating securities as they contain participating rights in distributions made to common stockholders. Since the participating securities do not include a contractual obligation to share in the losses of the Company, undistributed losses are not allocated to participating securities under the two-class method. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted net income (loss) per share when their inclusion would be antidilutive based on income (loss) from continuing operations available to common stockholders. The Company presents basic and diluted net income (loss) per share separately for continuing operations, discontinued operations, and total net loss attributable to Flyte Aviation, Inc. common stockholders.

 

Diluted net income (loss) per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. When discontinued operations are reported, income (loss) from continuing operations available to common stockholders is used to determine whether potential common shares are dilutive or anti-dilutive. The same diluted weighted-average number of common shares is used to calculate diluted net income (loss) per  share for continuing operations, discontinued operations, and total net loss. In periods in which the Company reports a loss from continuing operations available to Flyte Aviation, Inc. common stockholders, diluted net income (loss) per share attributable to Flyte Aviation, Inc. common stockholders is the same as basic net income (loss) per share attributable to Flyte Aviation, Inc. common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net income (loss) per share is equivalent to basic net income (loss) per share for the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, because potential common shares were anti-dilutive. For the three months ended September 30, 2026, certain convertible preferred stock was dilutive under the if-converted method, resulting in separate basic and diluted net income (loss) per share amounts (see Note 12, Net Income (Loss) per Share).

 

 

Net income (loss) attributable to Flyte Aviation, Inc. common stockholders consists of net income or loss attributable to Flyte Aviation, Inc., as adjusted for actual and deemed dividends and deemed contributions, if applicable. 

 

Recently Announced Accounting Pronouncements

 

In  November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), Clarifying the Effective Date ("ASU 2025-01"). ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to provide enhanced transparency into the expense captions presented on the face of the income statement. ASU 2024-03, as clarified by ASU 2025-01, is effective for the Company’s Annual Report on Form 10-K for the fiscal year ending  December 31, 2027 and for interim periods beginning in 2028. The guidance  may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on its condensed consolidated financial statements.

 

In  July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets ("ASU 2025-05"), which provides a practical expedient for entities to estimate expected credit losses on current accounts receivable and current contract assets arising from revenue transactions accounted for under ASC Topic 606. ASU 2025-05 is effective for the Company for annual periods beginning after  December 15, 2025, and interim periods within those annual periods. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.

 

In  December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements ("ASU 2025-11"), which is intended to clarify and improve certain aspects of interim financial reporting, including the requirements for interim disclosures and the application of recognition and measurement guidance in interim periods. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after  December 15, 2027, with early adoption permitted. Adoption can be applied prospectively or retrospectively. The Company is currently evaluating the potential impact that ASU 2025-11  may have on its condensed consolidated financial statements and related disclosures. The Company does not expect this update to have a material effect on the Company's condensed consolidated financial statements.

 

In December 2025, the FASB issued ASU 2025-12, Codification Improvements ("ASU 2025-12"), which is intended to clarify, correct errors in and make improvements across various topics in the FASB Accounting Standards Codification ("ASC"). ASU 2025-12 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026, with early adoption permitted. Adoption can be applied prospectively or retrospectively. The Company is currently evaluating the potential impact that ASU 2025-12  may have on its condensed consolidated financial statements and related disclosures. The Company does not expect this update to have a material effect on the Company's condensed consolidated financial statements.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal - Use Software (Topic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed, and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its condensed consolidated financial statements.

 

22

 
 

Note 3. Business Combination

 

On February 6, 2026, the Company entered into a Securities Purchase Agreement with SEG Jets, whereby the Company agreed to acquire 19.98% of the issued and outstanding shares of common stock of FLYTE. The Company was obligated to issue to the sellers an aggregate of 5,250 shares of the Company’s Series D Convertible Preferred Stock which was recorded as the first component of deferred consideration as of February 6, 2026.

 

On March 9, 2026, the Company entered into a Stock Purchase Agreement with Creatd and acquired the remaining 80.02% of the issued and outstanding shares of common stock of FLYTE and 100% of the membership interests of Ponderosa. The Company was obligated to issue to the sellers an aggregate of 5,778 additional shares of the Company’s Series D Convertible Preferred Stock, which was recorded as the second component of deferred consideration as of March 9, 2026. The purpose of the Acquisition was to acquire FLYTE’s and Ponderosa’s operations related to aviation, assets, and technology platform.

 

After obtaining a controlling interest in FLYTE, the Company remeasured its previously held minority equity interest to fair value as of the Acquisition date and recorded a change in fair value of minority equity interest of $2.3 million in the condensed consolidated statements of operations. This effectively reduced the fair value of the minority equity interest from $5.2 million to $2.9 million as of the Acquisition date. The fair value of the investment was determined based on the implied transaction value of FLYTE, which was derived from the purchase price paid to acquire the remaining 80.02% interest in FLYTE. 

 

In consideration for the Acquisition, the Company paid cash at closing, settled certain indebtedness on behalf of the seller, issued a short-term promissory note, and recorded the deferred consideration obligation to issue 5,778 additional shares of the Company’s Series D Convertible Preferred Stock. The total purchase consideration for the Acquisition was $14.8 million, which consists of the following estimated fair value amounts (in thousands):

 

Description

 

Fair Value

 

Cash proceeds to seller

 $685 

Fair value of promissory note

  4,788 

Payment of indebtedness

  554 

Fair value of previously held minority equity interest of step acquiree

  2,948 

Fair value of deferred consideration

  5,778 

Total purchase price

 $14,753 

 

The Acquisition is being accounted for as a business combination in accordance with ASC Topic 805. The Company estimated the fair values of the assets acquired and liabilities assumed in the Acquisition. These values have been prepared based on preliminary estimates of the fair value of the consideration paid, assets acquired, and liabilities assumed. The Company has not yet completed its evaluation and determination of certain assets acquired and liabilities assumed, primarily the final valuation of goodwill and intangible assets; therefore, the final fair value of the assets acquired and liabilities assumed, which will be completed within the measurement period of up to one year from the acquisition date,  may vary from the Company’s preliminary estimates. The Company will continue to evaluate and refine the allocation based on additional information obtained during the measurement period in accordance with ASC 805.

 

23

 

During the measurement period, there were changes to the preliminary purchase price allocation based on adjustments to the fair value of the acquired assets and assumed liabilities. During the three months ended September 30, 2026, the Company recorded additional measurement-period adjustments consisting of decreases of approximately $0.7 million in short-term notes payable, $0.1 million in accrued expenses, net, and $31.0 thousand in deferred tax liability, resulting in a corresponding decrease of approximately $0.8 million in goodwill. The measurement-period adjustments did not have a material impact on the condensed consolidated statements of operations. The following table summarizes the preliminary purchase price allocations relating to the Acquisition as of the Acquisition date and related adjustments thereafter (in thousands):

 

Description

 

As Originally Reported

  

Measurement Period Adjustments

  

As Adjusted

 

Assets acquired:

            

Cash and cash equivalents

 $29  $—  $29 

Accounts receivable

  1   —   1 

Prepaid expenses and other current assets

  74   —   74 

Property and equipment

  68   —   68 

Operating lease right-of-use assets

  948   —   948 

Intangible assets

  7,450   (3,333)  4,117 

Goodwill

  9,430   2,731   12,161 

Other non-current assets

  49   —   49 

Total assets acquired

 $18,049  $(602) $17,447 
             

Liabilities assumed:

            

Accounts payable

 $204  $—  $204 

Accrued expenses

  509   (110)  399 

Current portion of operating lease liabilities

  554   —   554 

Deferred revenue

  171   —   171 

Deferred tax liability

  —   168   168 

Short-term notes payable

  1,400   (660)  740 

Notes payable

  64   —   64 

Operating lease liabilities

  394   —   394 

Total liabilities assumed

  3,296   (602)  2,694 

Total purchase price

 $14,753  $—  $14,753 

 

The Company recognized $12.2 million in total goodwill as of  September 30, 2026 which shows the net impact of the measurement period adjustments recorded as of September 30, 2026. The identifiable intangible assets acquired include both definite-lived intangible assets subject to amortization and an indefinite-lived intangible asset that is not subject to amortization. The associated estimated acquisition-date fair values and estimated useful lives are as follows (in thousands except for estimated useful life which is in years):

 

  

Estimated

 

Estimated

 

Intangible Assets

 

Fair Value

 

Useful Life

 

Applications

 $200  5 

FAA Part 135 Operating Certificate

  2,417 

Indefinite

 

Trademarks/ trade names

  1,300  15 

Customer list/ relationships

  200  15 
  $4,117    

 

 

24

 

Transaction costs incurred in connection with this business combination amounted to approximately $0.1 million during the nine months ended September 30, 2026, and are included within selling, general and administrative expenses in the condensed consolidated statements of operations.

 

Pro Forma Financial Information

 

The following table represents the revenue and net loss from continuing operations of the combined Company, as reported on a pro forma basis, as if the Acquisition occurred on January 1, 2025. These pro forma results are not necessarily indicative of the results that would have occurred if the Acquisition had occurred on the first day of the period presented, nor does the pro forma financial information purport to represent the results of operations for future periods. The unaudited pro forma financial information excludes the results of the VIVO and LockeT businesses, which are presented as discontinued operations for all periods. The following information for three and nine months ended September 30, 2026 and 2025 is presented in thousands:

 

 

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 
 

2026

 

2025

 

2026

 

2025

 

Total revenues, net

$1,838 $640 $3,294 $1,621 

Loss from continuing operations

$(1,853)$(1,211)$(4,665)$(3,922)

 

 

Note 4. Discontinued Operations and Assets Held for Sale

 

In September 2026, the Company classified its VIVO and LockeT businesses as discontinued operations and the related disposal group (the "Disposal Group") as held for sale in connection with its plan to sell these businesses as part of its strategic shift toward private aviation. These businesses were historically included in the Company's cardiac electrophysiology reportable segment. The contemplated sale includes substantially all assets necessary to operate the VIVO and LockeT businesses, including intellectual property, inventory, property and equipment, and certain related liabilities. The planned disposition does not encompass the entire cardiac electrophysiology reportable segment. Certain other assets and activities historically included in that segment, including AMIGO related assets and Cardionomix’s CPNS related assets and activities, are not included in the planned disposition and remain included in continuing operations. As of September 30, 2026, the Company had not entered into a definitive sale agreement and anticipates completing the disposition within twelve months.

 

The Company determined that the planned disposition of the Disposal Group represents a strategic shift that has a major effect on the Company's operations and financial results. Accordingly, the Company concluded that the Disposal Group met the criteria to be classified as held for sale and discontinued operations as of September 30, 2026, in accordance with ASC 360, Property, Plant, and Equipment, and ASC 205-20, Discontinued Operations.

 

Impairment of Assets Held for Sale

 

Upon classification as held for sale in September 2026, the Company measured the Disposal Group at the lower of its carrying amount or estimated fair value less costs to sell, resulting in a noncash loss on impairment of assets held for sale of approximately $12.5 million for the three and nine months ended September 30, 2026. The impairment loss represents the excess of the Disposal Group's carrying amount over its estimated fair value less costs to sell. The loss was recognized within discontinued operations in the condensed consolidated statements of operations, with a corresponding valuation allowance recorded against the assets of the Disposal Group. The valuation allowance is presented separately in the table of assets and liabilities held for sale below and has not been allocated to the individual major classes of assets and liabilities.

 

The estimated fair value of the Disposal Group was determined using a market approach based on the selling price negotiated with an unrelated prospective third party buyer during the Company’s ongoing sale process. The Company determined that the negotiated selling price was representative of market participant pricing and that no significant unobservable adjustments were necessary. The fair value measurement was performed on a nonrecurring basis as of September 30, 2026 and classified within Level 2 of the fair value hierarchy. Estimated costs directly attributable to the sale were deducted from the estimated fair value in determining the Disposal Group's fair value less costs to sell. The estimated fair value may change as additional information becomes available during the sale process.

 

The following table summarizes the major classes of assets and liabilities associated with discontinued operations included in the condensed consolidated balance sheets (in thousands):

 

September 30, 2026

 

December 31, 2025

 
 

(Unaudited)

    

ASSETS HELD FOR SALE FROM DISCONTINUED OPERATIONS

      

Inventories

$71 $86 

Current assets held for sale from discontinued operations

 71  86 

Property and equipment, net

 43  64 

Intangible assets, net

 14,174  15,236 

Valuation allowance

 (12,490) — 

Non-current assets held for sale from discontinued operations

 1,727  15,300 

Total assets held for sale from discontinued operations

$1,798 $15,386 
       

LIABILITIES HELD FOR SALE FROM DISCONTINUED OPERATIONS

      

Current portion of royalties payable due to related parties

$30 $51 

Current liabilities held for sale from discontinued operations

 30  51 

Royalties payable due to related parties

 632  632 

Non-current liabilities held for sale from discontinued operations

 632  632 

Total liabilities held for sale from discontinued operations

$662 $683 

 

The following table summarizes the results of discontinued operations included in the condensed consolidated statements of operations (in thousands):

  

For the Three Months Ended September 30,

 

For the Nine Months Ended September 30,

 
  

2026

 

2025

 

2026

 

2025

 

Revenues

 $280 $226 $798 $581 

Cost of revenues

  28  18  81  43 

Gross profit

  252  208  717  538 

Operating expenses

             

Selling, general and administrative

  911  1,762  3,222  5,797 

Research and development

  114  276  404  532 

Loss on impairment of assets held for sale

  12,490  —  12,490  — 

Total operating expenses

  13,515  2,038  16,116  6,329 

Operating loss

  (13,263) (1,830) (15,399) (5,791)

Other income (expense), net

             

Change in fair value of royalties payable due to related parties

  —  726  —  (2,104)

Other expenses, net

  (5) (5) (19) (6)

Total other income (expense), net

  (5) 721  (19) (2,110)

Loss from discontinued operations, net of tax

 $(13,268)$(1,109)$(15,418)$(7,901)

 

Fair Value Measurements of Royalties Payable Due to Related Parties

 

Royalties payable due to related parties associated with the Disposal Group continue to be measured at fair value on a recurring basis using significant unobservable inputs (Level 3). The fair value of these liabilities is determined using discounted future cash flows based on estimated future royalty payments and a revenue adjusted discount rate. Changes in fair value are recognized within loss from discontinued operations, net of tax, in the condensed consolidated statements of operations. Refer to Note 2, Summary of Significant Accounting Policies, for additional information regarding the Company's fair value measurement policies, valuation techniques and significant unobservable inputs.

 

The following tables summarize the changes in the fair value of royalties payable due to related parties associated with discontinued operations, which are classified within Level 3 of the fair value hierarchy, for the nine months ended September 30, 2026 and 2025 (in thousands):

 

 

2026

 

2025

 

Balance at January 1

$632 $9,053 

Change in fair value of royalties payable due to related parties

 —  2,104 

Balance at September 30

$632 $11,157 

 

The cash flows attributable to discontinued operations are included within the respective operating, investing and financing activities in the accompanying condensed consolidated statements of cash flows. The following table presents supplemental cash flow related information attributable to discontinued operations (in thousands):

 

  

For the Three Months Ended

  

For the Nine Months Ended

 
  

September 30,

  

September 30,

 
  

2026

  

2025

  

2026

  

2025

 

Depreciation

 $13  $19  $40  $56 

Amortization

 $353  $510  $1,061  $1,532 

Impairment of assets held for sale

 $12,490  $—  $12,490  $— 

Change in fair value of royalties payable due to related parties

 $—  $(726) $—  $2,104 

Capital expenditures

 $7  $10  $18  $28 

 

 

 

25

 

Note 5. Marketable Securities

 

On June 7, 2026, the Company entered into a Securities Purchase Agreement with Volato Group, Inc. ("Volato"), whereby the Company agreed to purchase 2,941,176 unregistered shares of Volato common stock, par value $0.0001 per share, ("Volato Shares") at a purchase price of $0.34 per share, for an aggregate cash purchase price of $1 million in a private placement transaction. As consideration for the Company’s participation in the transaction as the Lead Investor, Volato agreed to deliver to the Company 451,901 shares of registered common stock of flyExclusive Inc. (“FLYX”) (“FLYX Shares”), par value $0.0001 per share. In connection with the transaction, the Company and Volato entered into a Registration Rights Agreement pursuant to which Volato agreed to register for resale the Volato Shares. As of July 2, 2026, the Volato Shares were registered with the SEC and the registration statement had been declared effective. 

 

On June 18, 2026, all closing conditions were met and the Volato Shares and FLYX Shares were issued on that date. The Company acquired a minority equity interest in Volato and FLYX. The investments are passive in nature, such that the Company does not participate in the management nor operations of Volato and FLYX. Accordingly, the Company does not have the ability to exercise significant influence over the investees and accounts for the investments as equity securities under ASC 321.

 

The Company initially recognized each investment at its fair value on  June 18, 2026. Because the aggregate fair value of the Volato Shares and FLYX Shares of $1.5 million exceeded the $1.0 million of cash consideration transferred to Volato, the Company recognized a day 1 gain of approximately $0.5 million upon issuance. The investments were subsequently measured at fair value, with changes in fair value recognized in gains on marketable securities, net, in the condensed consolidated statements of operations.

 

During the three months ended September 30, 2026, the Company sold all remaining Volato Shares and FLYX Shares. Net gains of $162 thousand and $540 thousand were recognized for the three and nine months ended September 30, 2026, respectively. The net gain for the nine-month period included the day 1 gain recognized in June 2026. As all marketable securities were sold during the nine months ended September 30, 2026, the Company held no equity securities at September 30, 2026, and therefore had no unrealized gains or losses related to securities held at that date. The Company held no marketable securities as of September 30, 2026 or December 31, 2025.

 

 

Note 6. Property and Equipment

 

Property and equipment, net consisted of the following (in thousands):

 

 September 30, December 31, 
 

2026

 

2025

 

Computer hardware and software

$5 $5 

Capitalized software development costs

 136  — 

Furniture, fixtures and equipment

 18  — 

Property and equipment, gross

 159  5 

Accumulated depreciation

 (18) (5)

Property and equipment, net

$141 $— 

 

Depreciation expense was $4 thousand and $13 thousand for the three and nine months ended September 30, 2026, respectively, and $1 thousand and $2 thousand for the three and nine months ended September 30, 2025, respectively.

 

26

 
 

Note 7. Goodwill and Other Intangible Assets

 

The Company's carrying amount of goodwill in the condensed consolidated balance sheet as of  September 30, 2026 represents the excess fair value of the consideration transferred over the fair value of the identifiable net assets acquired and liabilities assumed in the acquisition of FLYTE. See Note 3, Business Combination, for additional information.

 

The following table summarizes the Company’s goodwill and other intangible assets as of  September 30, 2026 (in thousands):

 

  

Estimated

             
  

Useful Life

  

Gross Carrying

  

Accumulated

  

Net Carrying

 
  

( Years)

  

Amount

  

Amortization

  

Value

 

Amortized intangible assets:

                
                 

Private aviation segment

                

Applications

  5  $200  $(23) $177 

Trademarks/ trade names

  15   1,300   (49)  1,251 

Customer list/ relationships

  15   200   (7)  193 
      $1,700  $(79) $1,621 

Indefinite life intangible assets:

                

Private aviation segment

                

Goodwill

  —   12,161   —   12,161 

FAA Part 135 Operating Certificate

  —   2,417   —   2,417 
                 

Total

     $16,278  $(79) $16,199 

 

The Company had no goodwill or other intangible assets related to continuing operations as of December 31, 2025.

 

27

 

The estimated future amortization expense for the next five years and thereafter is as follows (in thousands):

 

  

Future

 
  

Amortization

 

Years ending December 31,

 

Expense

 

Remainder of 2026

 $38 

2027

  140 

2028

  140 

2029

  140 

2030

  140 

Thereafter

  1,023 

Total

 $1,621 

 

The Company uses the straight-line method to determine amortization expense for its definite lived intangible assets. Amortization expense, included within selling, general and administrative expenses in the condensed consolidated statements of operations, for the Company's intangible assets was approximately  $35 and $79 thousand for the three and nine months ended September 30, 2026, respectively, and $0 for both the three and nine months ended September 30, 2025.

 

Note 8. Accrued Expenses

 

Accrued expenses consisted of the following (in thousands):

 

 September 30, December 31, 
 

2026

 

2025

 

Legal expenses

$300 $135 

Offering costs

 1,356  1,356 

Compensation and related benefits

 135  75 

Professional fees

 15  — 

Other accrued expenses

 160  131 

Accrued expenses

$1,966 $1,697 

  

28

 
 

Note 9. Notes Payable

 

Note Payable - Director and Officer Liability Insurance

 

The Company purchased director and officer liability insurance coverage on January 31, 2026 for $277 thousand. A down payment of $55 thousand was made and the remaining balance of $221 thousand was financed over 9 months through a short-term financing arrangement. The interest rate on the loan is 9.39%. Interest expense on this loan was $2 thousand and $9 thousand for the three and nine months ended September 30, 2026, respectively. The loan balance was $25 thousand as of September 30, 2026, and is recorded under short-term notes payable in the condensed consolidated balance sheets.

 

Note Payable - Aviation Insurance

 

The Company purchased aviation insurance coverage on May 5, 2026 and subsequently purchased three additional coverages on June 1, 2026, June 10, 2026 and September 4, 2026 for a total premium of $267 thousand. A down payment of $37 thousand was made and the remaining balance of $230 thousand was financed over 12 months through a short-term financing arrangement with its insurance carrier. The interest rate on the loan is 8.99%. Interest expense on this loan was $3 thousand and $4 thousand for the three and nine months ended September 30, 2026, respectively. The loan balance was $163 thousand as of September 30, 2026, and is recorded under short-term notes payable in the condensed consolidated balance sheets.

 

Note Payable Issued for the Cardionomic Asset Acquisition

 

In connection with the asset acquisition of the CPNS System previously held by Cardionomic, on May 5, 2025, Cardionomix issued a promissory note with a face amount of $1.5 million and stated interest rate of 4% per annum (the "Note Payable"). No interest or principal is payable until the maturity date of the Note Payable, which is three years following the date of issuance. All outstanding principal plus accrued but unpaid interest becomes immediately due and payable upon voluntary or involuntary bankruptcy filings. The Note Payable  may be prepaid by Cardionomix at any time at its own discretion.

 

The Note Payable was initially measured at its present value of $1.3 million net of a discount of $254 thousand based on an effective interest rate of 10% per annum. The discount is amortized under the effective interest method over the term of the Note Payable.

 

Interest expense on this note was $35 thousand and $103 thousand for the three and nine months ended September 30, 2026, respectively. Interest expense on this note was $32 thousand and $51 thousand for the three and nine months ended September 30, 2025, respectively. The Note Payable and related accrued interest totaled $1.4 million as of  September 30, 2026, which included a principal balance of $1.5 million and accrued interest of $84 thousand net of unamortized discounts of $151 thousand. The Note Payable and related accrued interest totaled $1.3 million as of December 31, 2025, which included a principal balance of $1.5 million and accrued interest of $39 thousand net of unamortized discounts of $209 thousand, respectively. The Note Payable and related accrued interest was recorded under notes payable of variable interest entities on the condensed consolidated balance sheets.

 

Promissory Notes (Collectively, the "Related Party Notes")

 

During 2024, Mr. Jenkins and certain of his affiliates, including FatBoy Capital, L.P. and the Jenkins Family Charitable Institute, loaned the Company an aggregate of $1.5 million in exchange for short-term promissory notes (collectively, the “Related Party Notes”). On August 23, 2024, the Related Party Notes were amended to extend the maturity date to January 31, 2026 and increase the interest rate to 12% per annum, which was accounted for as a debt modification.

 

On  December 31, 2025, the Company entered into the second amendment of the Related Party Notes, which extended the maturity date of the notes payable to the Jenkins Family Charitable Institute to  January 31, 2028, and the notes payable to FatBoy Capital, L.P. and Mr. Jenkins to  January 31, 2029. As part of the second amendment, the Company issued 17,000 Series M Warrants to each of FatBoy Capital L.P. and Mr. Jenkins, and transferred the Perikard membership interests to Mr. Jenkins for de minimis proceeds. All other terms and conditions remained unchanged. The second amendment was accounted for as a debt extinguishment since the amended terms and conditions were substantially different from prior terms and conditions. In accordance with ASC Topic 470-50, the Company derecognized the net carrying amount of the original Related Party Notes and recorded the amended Related Party Notes at fair value. Since the fair value of the amended Related Party Notes of $1.7 million was greater than the principal balance of $1.5 million, the Company recognized a premium of $0.2 million as of December 31, 2025. The difference between the reacquisition price, which is the sum of the fair values of the amended Related Party Notes, Perikard membership interests, and Series M Warrants, and the net carrying amount of the original Related Party Notes of $0.6 million was recorded as loss on debt extinguishment in the consolidated statement of operations for the year ended  December 31, 2025. See Note 13, Equity Offerings, and Note 16, Asset Acquisitions, for additional information on the Series M Warrants issued and the Perikard patents transferred in connection with the debt extinguishment, respectively. 

 

29

 

The Related Party Notes, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owed when due, material breach of the Company’s representations or warranties (unless waived by the holders of the Related Party Notes or cured within 10 days following notice), certain events involving the discontinuation of the Company’s business and/or certain types of proceedings involving insolvency, bankruptcy, receivership and the like.

 

On June 24, 2026, the Company issued a short-term promissory note with a face value of $400 thousand to FatBoy Capital, L.P. (the “June 2026 Note”). The June 2026 Note bears interest at 12% per annum and matures on the earlier of the Series C-3 Preferred Stock funding or September 24, 2026. Principal and accrued interest are payable on the maturity date, and the Company may prepay all or any portion of the June 2026 Note without penalty. The June 2026 Note was repaid in full during the three months ended September 30, 2026 with a portion of the proceeds from the Series C-3 Convertible Preferred Stock financing. The June 2026 Note, together with the previously issued Related Party Notes described above, are collectively referred to as the “Related Party Notes".

 

Interest expense on these notes was $44 thousand and $124 thousand for the three and nine months ended September 30, 2026, respectively. Interest expense on the Related Party Notes was $45 thousand and $135 thousand for the three and nine months ended September 30, 2025, respectively.

 

The Related Party Notes and related accrued interest totaled $1.9 million as of  September 30, 2026, of which $235 thousand related to unamortized premiums that arose from the debt extinguishment of the original Related Party Notes and $135 thousand related to accrued interest. The Related Party Notes totaled $1.7 million as of December 31, 2025, of which $248 thousand related to unamortized premiums that arose from the debt extinguishment of the original Related Party Notes. The Related Party Notes, including accrued interest and unamortized premiums, are recorded under the notes payable due to related parties on the condensed consolidated balance sheets.

 

Notes Payable Issued by KardioNav

 

On July 11, 2025, two short-term promissory notes with a face amount of $150 thousand each were issued by KardioNav to the Company's Chief Executive Officer and Lifestim, Inc., a company controlled by the Company's Chief Executive Officer. The promissory notes have a maturity date of July 11, 2026, and interest rates of 4.2% per annum, payable upon maturity (the "Notes Payable").

 

The Notes Payable, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owed when due, material breach of the Company’s representations or warranties (unless waived by the holders or cured within 10 days following notice), certain events involving the discontinuation of the Company’s business and/or certain types of proceedings involving insolvency, bankruptcy, receivership and the like.

 

Interest expense on this note was $3 thousand and $9 thousand for the three and nine months ended September 30, 2026, respectively. The Notes Payable and related accrued interest totaled $315 thousand as of  September 30, 2026, which included a principal balance of $300 thousand and accrued interest of $15 thousand. The Notes Payable and related accrued interest totaled $306 thousand as of December 31, 2025, of which $6 thousand related to accrued interest. The Notes Payable and related accrued interest are recorded under short-term notes payable of variable interest entities due to related parties on the condensed consolidated balance sheets.

 

The Notes Payable matured on July 11, 2026 and remained outstanding as of  September 30, 2026 such that the Notes Payable is in default as of  September 30, 2026. The Notes Payable shall continue to accrue interest at 4.2% per annum on the outstanding principal balance until repaid in full.

 

Convertible Notes Payable

 

On  December 26, 2025, the Company issued an unsecured convertible note payable with a principal amount of $102 thousand and a discount of $2 thousand to Boot Capital LLC for cash proceeds of $100 thousand. The Company further issued an unsecured convertible note payable with a principal amount of $204 thousand and a discount of $4 thousand to Vanquish Funding Group Inc. for cash proceeds of $200 thousand. The convertible notes payable have a maturity date of  September 30, 2026 and stated interest rate of 10% per annum, which shall be payable when the principal amount is due. Any principal amount or interest that is not paid when due shall bear the default interest of 22% per annum. Changes in fair value of convertible notes payable along with interest expense are recorded under change in fair value of convertible notes payable in the condensed consolidated statements of operations. 

 

30

 

The Company has the right to prepay the outstanding balance of the convertible notes payable, which is defined as the sum of the outstanding principal amount, accrued and unpaid interest, default interest, and any other amounts due and payable, with three days’ prior written notice. If the Company pays within 90 days of the issuance date, the Company must pay 120% of the outstanding balance. If the Company pays within 90 to 180 days after the issuance date, the Company must pay 125% of the outstanding balance.

 

On June 22, 2026, the Company prepaid the outstanding balance of the convertible notes payable of $0.3 million by paying $0.4 million in cash, which equals the 125% prepayment amount required for prepayments made between 90 and 180 days after issuance. The Company recognized a loss on debt extinguishment of $0.1 million in the condensed consolidated statements of operations. There is no remaining balance for the convertible notes payable as of September 30, 2026. 

 

Bridge Notes

 

From January 12 through June 5, 2026, the Company issued several short-term promissory notes to SEG Opportunity Fund, LLC, C/M Capital Master Fund LP and WVP Emerging Manager Onshore Fund, LLC with aggregate principal of $2.4 million (collectively, the “Bridge Notes”). The Bridge Notes bear interest at 12% per annum, had original maturity dates ranging from February 11 through July 5, 2026, and are prepayable at any time without penalty or premium. Amounts not paid when due bear default interest at 18% per annum.

 

During the nine months ended September 30, 2026, the Company repaid the  aggregate principal amount of $2.4 million, together with the related accrued interest. Accordingly, no Bridge Notes remained outstanding as of September 30, 2026. Interest expense related to the Bridge Notes was $6 thousand and $30 thousand for the three and nine months ended September 30, 2026, respectively.

 

Notes Payable Assumed in Connection with the FLYTE Acquisition
 
In connection with the acquisition of FLYTE, the Company assumed an outstanding secured promissory note payable to the former Chief Executive Officer of FLYTE with an outstanding principal balance of $365 thousand (the “Sellouk Note”). The Sellouk Note accrues interest at a flat rate of $3 thousand per month and had an amended maturity date of   February 27, 2026. The Sellouk Note is currently in default and shall continue to accrue interest at a flat rate of $3 thousand per month until it is paid.  The Company recognized the Sellouk Note at its acquisition-date fair value of $365  thousand. Interest expense on the Sellouk Note was $9 thousand and $20 thousand for the three and nine months ended September 30, 2026 , respectively. The Sellouk Note had a principal balance of $115 thousand and no accrued interest as of September 30, 2026 . The Sellouk Note is recorded under short-term notes payable, net of discount on the condensed consolidated balance sheet.

 

Furthermore, in connection with the acquisition of FLYTE on March 9, 2026, the Company assumed certain notes payable issued by FLYTE to various lenders, including certain related parties (collectively, the “Assumed Notes”). See Note 3, Business Combination for additional information regarding the Assumed Notes. The Assumed Notes were issued between December 8, 2022 and August 17, 2023, have stated maturity dates ranging from April 21, 2024 to August 17, 2024, including certain notes that were subsequently extended, and bear stated interest rates of 8% per annum.
 
All of the Assumed Notes had matured prior to the acquisition date and were in default as of September 30, 2026. The Assumed Notes continue to accrue interest at their stated interest rates. 
 
Certain of the Assumed Notes include automatic conversion provisions that would be triggered upon an initial public offering of FLYTE, generally at a conversion price equal to 75% of the initial public offering price, subject to customary adjustments. Certain other Assumed Notes include conversion provisions based on 45% of the initial public offering price or, alternatively, an optional conversion price of $1.80 per share or a valuation-based price. The Company determined that these conversion provisions are required to be bifurcated and accounted for as derivatives under ASC Topic 815. The estimated fair value of these embedded derivatives was deemed to be de minimis as of the acquisition date and at  September 30, 2026.
 
As of the acquisition date, the Assumed Notes and related accrued interest totaled  $463 thousand, which included a principal balance of $375 thousand and accrued interest of  $88 thousand. As of  September 30, 2026, the Assumed Notes and related accrued interest totaled  $480 thousand, which included a principal balance of $375 thousand and accrued interest of  $105 thousand. The Assumed Notes are recorded under short-term notes payable, net of discount in the condensed consolidated balance sheets. The Company recognized interest expense of  $8 thousand and  $17 thousand related to the Assumed Notes for the three and nine months ended September 30, 2026, respectively.

 

31

 

SBA Loan Assumed in Connection with the FLYTE Acquisition

 

In connection with the acquisition of FLYTE, the Company assumed a loan payable to the United States’ Small Business Administration (“SBA Loan”). The SBA Loan was issued on June 13, 2020, with an original principal amount of $63,800. The loan accrues interest at 3.75% per annum and is payable in fixed installments of $311 monthly, beginning 12 months from the date of issuance. The outstanding principal and interest of the SBA Loan shall be fully repaid thirty years from the date of issuance. The Company recognized the SBA Loan at its acquisition-date fair value of $63 thousand. Interest expense on the SBA Loan was $1 thousand and $2 thousand for the three and nine months ended September 30, 2026,respectively. The SBA Loan balance was $63 thousand as of  September 30, 2026, and is recorded under notes payable on the condensed consolidated balance sheet.

 

Note Payable Issued in Connection with the FLYTE Acquisition

 

In connection with the acquisition of FLYTE, on March 9, 2026, the Company issued a promissory note to Creatd, with a principal balance of $5.0 million as partial consideration for the business acquired (the “FLYTE Note Payable”). The FLYTE Note Payable bears interest at 0% per annum and is payable in installments through December 15, 2026. If any payment is not made within three business days following the applicable installment date, interest will accrue on such overdue payment at a rate of 4% per annum. Upon the occurrence and continuation of an event of default, the holder may declare the entire unpaid principal balance, together with all accrued penalties and late fees, immediately due and payable, and the outstanding principal balance will bear default interest at 18% per annum.

 

The FLYTE Note Payable was initially measured at its fair value of $4.8 million, net of a discount of $212 thousand, based on an effective interest rate of 10% per annum. The discount is amortized under the effective interest method over the term of the FLYTE Note Payable. Interest expense on the FLYTE Note Payable was $77 thousand and $162 thousand for the three and nine months ended September 30, 2026, respectively. The FLYTE Note Payable totaled $1.7 million as of September 30, 2026, which included a principal balance of $1.8 million, net of unamortized discount of $57 thousand. The FLYTE Note Payable is recorded under short-term notes payable, net of discounts in the condensed consolidated balance sheets.

 

Future maturities for long-term debts as of  September 30, 2026 were as follows (in thousands):

 

  

September 30,

 
  

2026

 

2026

 $— 

2027

  — 

2028

  2,000 

2029

  1,000 

2030

  — 

Thereafter

  63 

Total principal

 $3,063 

Plus: accrued interest

  219 

Plus: premium

  235 

Less: discount

  (152)

Total

 $3,365 

 

32

 
 

Note 10. Royalties Payable

 

AMIGO System Royalty

 

During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter's AMIGO System, receiving a total of $1.6 million from the foundation. The agreement calls for the payment of the following sales-based royalties by Old Catheter to the foundation upon successful commercialization of the AMIGO System (in thousands, except for percentages):

 

  

Until Royalty Payment

 

Royalty Percentage

 

Reaches a Total of

 

4%

 $1,589 

2%

 $3,179 

1%

 

In perpetuity

 

 

The Company is not actively marketing and selling the AMIGO System, such that there was no royalty expense recorded for the three and nine months ended September 30, 2026 and 2025 in relation to the AMIGO System.

 

As of  September 30, 2026 and December 31, 2025, the fair value of the royalty payable related to AMIGO System was $160 thousand. The Company recorded no change in the fair value of the royalties payable during the three and nine months ended September 30, 2026 and 2025.

 

 

Note 11. Leases

 

The Company determines if an arrangement contains a lease at contract inception based on its ability to control a physically distinct asset in exchange for consideration. If the arrangement contains a lease, the Company then determines the classification of the lease as either operating or finance. For the nine months ended September 30, 2026, and the year ended  December 31, 2025, the Company only had operating leases.

 

For operating leases, right-of-use (“ROU”) assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The present values of future lease payments are discounted using the interest rate implicit in the lease if it is readily determinable. As most leases do not provide an implicit rate, the Company applies an incremental borrowing rate based on the information available at commencement date to determine the present value of future lease payments over the lease term. The Company benchmarked itself against other companies with similar credit ratings and of comparable quality to derive an incremental borrowing rate. Lease expense is recognized on a straight-line basis over the lease term in the condensed consolidated statements of operations.

 

The Company elected to utilize the short-term lease exemption to exclude recognition of ROU assets and lease liabilities from the condensed consolidated balance sheet for leases with an initial term of 12 months or less, with payments instead being expensed on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period.

 

The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of ROU assets and liabilities. Variable costs are expensed when the events determining the amount of variable consideration to be paid have occurred.

 

33

 

FLYTE Leases

 

In connection with the acquisition of FLYTE, the Company assumed or entered into certain operating leases related to FLYTE’s aviation operations, including hangar, office space and aircraft leases. The Company evaluated each assumed or newly executed lease arrangement upon acquisition or commencement and recognized operating lease right-of-use-assets and operating lease liabilities for leases with remaining terms greater than 12 months. For leases acquired in connection with the FLYTE acquisition, the Company measured the lease liabilities as if the acquired leases were new leases of the Company at the acquisition date, using the Company’s incremental borrowing rate when the rate implicit in the lease was not readily determinable. The FLYTE lease agreements generally require fixed monthly payments, payable in advance, and do not include residual value guarantees or purchase options that the Company is reasonably certain to exercise.

 

Hangar and Office Space Lease

 

In connection with the acquisition of FLYTE, the Company assumed a lease for hangar and office space with Stratosphere Development Co LLC DBA Republic Jet Center. The leased space is used to support FLYTE’s aviation operations, including hangar and office use. The lease commenced on  August 18, 2021, and was amended on August 27, 2024, with a remaining lease term of 17 months. The lease does not contain a purchase option or residual value guarantee. The Company did not include any extension period in the lease terms because it was not reasonably certain to exercise the extension rights.

 

Aircraft Leases

 

In connection with the acquisition of FLYTE, the Company assumed two aircraft leases with SEG Jets LLC and entered into one additional aircraft lease with SEG Jets LLC in March 2026. The assumed aircraft leases were originally entered into in September 2025 and February 2026 and were amended on March 1, 2026. The additional aircraft lease was entered into in March 2026. At the respective acquisition, commencement or modification dates, these aircraft leases had remaining lease terms ranging from approximately 18 months to 24 months. The aircraft leases do not transfer ownership of the aircraft to the Company and do not contain residual value guarantees. The Company did not include any extension period in the lease terms because it was not reasonably certain to exercise the extension rights.

 

In May 2026, the Company entered into two additional aircraft leases with SEG Jets LLC. The aircraft leases commenced on June 1, 2026 for a lease term of 24 months each. The aircraft leases do not transfer ownership of the aircraft to the Company and do not contain residual value guarantees. The Company did not include any extension period in the lease terms because it was not reasonably certain to exercise the extension rights. See Note 19, Related Parties, for additional information regarding the aircraft leases with SEG Jets LLC.

 

The Company recognizes loss contingencies when a loss is probable and reasonably estimable. During September 2026, one of the Company's leased aircraft sustained damage. As of September 30, 2026, the Company accrued approximately $75 thousand for estimated repair obligations, which was recorded in accrued expenses and other expense, net, in the accompanying condensed consolidated financial statements. No related insurance recovery was recognized as of September 30, 2026.

 

South Carolina Office Lease Agreement

 

On September 27, 2022, Old Catheter entered into a lease agreement for office space located in Fort Mill, South Carolina. The space is used for office and general use. The lease term began on October 1, 2022 for 38 months, and included two months of free rent from the commencement date of the lease. The original lease agreement contains two distinct 36-month renewal periods, which require 180 days’ notice of the Company's intention to exercise. In June 2025, the Company notified the landlord of its intent to exercise its option to extend the lease for an additional 36-month period through the end of December 1, 2028. Accordingly, the Company remeasured the lease liability on the basis of the revised lease payments and lease term, such that the first extension option of 36 months has been included in operating right-of-use-assets and operating lease liabilities in the condensed consolidated balance sheet as of September 30, 2026. 

 

As of September 30, 2026, the Company does not intend to exercise the second extension option and the second option is therefore excluded from operating right-of-use assets and operating lease liabilities in the condensed consolidated balance sheet as of September 30, 2026.

 

34

 

New Jersey Office Lease Agreement

 

On December 7, 2022, Old Catheter entered into a lease agreement for office space located in Augusta, New Jersey. The space is used for office and general use. The lease term began on January 1, 2023 for 24 months. The lease contained one 24-month renewal period, which required 9 months’ notice of the Company’s intent to exercise. In March 2024, the Company notified the landlord of its intent to extend the lease for a 12-month period. In April 2024, a lease extension agreement was entered into extending the lease through December 31, 2025. 

 

On July 8 2025, the Company entered into a second lease extension agreement to extend the lease for an additional 24-month period through December 31, 2027. Accordingly, the Company remeasured the lease liability on the basis of the revised lease payments and lease term, such that the extension option of 24 months has been included in operating right-of-use-assets and operating lease liabilities in the condensed consolidated balance sheet as of September 30, 2026.

 

Park City Office Lease Agreement

 

On March 19, 2023, the Company entered into a lease agreement for office space located in Park City, Utah. The space is used for office and general use. The lease term began on May 1, 2023 for 36 months. The lease contains one 36-month renewal period, which requires 180 days’ notice of the Company's intention to exercise.

 

On March 4, 2026, the Company entered into the first amendment to the lease, which extended the lease termination date from April 30, 2026 to April 30, 2027. The lease contains one 36-month renewal period, which requires 180 days’ notice of the Company's intention to exercise.  As of September 30, 2026, the Company does not intend to exercise the 36-month renewal option and the option is therefore excluded from operating right-of-use assets and operating lease liabilities in the condensed consolidated balance sheet as of September 30, 2026.

 

Long Island, New York Office Lease Agreement

 

In July 2026, the Company, together with Ayre Aviation, an unrelated third party, entered into a lease agreement with FF 534 LLC for approximately 3,082 square feet of office space located in Melville, New York. The leased space is used for general and administrative office purposes. The lease is scheduled to commence on October 1, 2026 and has an initial lease term of seven years. Accordingly, the Company had not recognized a corresponding right-of-use asset or lease liability as of September 30, 2026. The lease includes one five-year extension option and an early termination option exercisable effective in the 60th month following the lease commencement date, subject to 180 days’ prior written notice. The lease does not contain a purchase option or residual value guarantee. 

 

The following tables present supplemental condensed consolidated balance sheet information related to operating leases for the three and nine months ended September 30, 2026 and 2025 (in thousands):

 

 

For the Three Months Ended

 

For the Nine Months Ended

 
 

September 30,

 

September 30,

 
 

2026

 

2025

 

2026

 

2025

 

Operating lease expense

$446 $27 $948 $76 

Cash paid for leases

$628 $25 $923 $78 

 

 

 September 30,  December 31, 
 

2026

  

2025

 

Weighted average remaining lease term (in years) - operating leases

 1.44   2.67 

Weighted average discount rate - operating leases

 10.00%  9.67%

 

Future minimum lease payments for all lease obligations for the following five fiscal years and thereafter are as follows (in thousands):

 

Years ending December 31:

Operating Leases

 

Remainder of 2026

$418 

2027

 1,525 

2028

 373 

Total minimum lease payments

 2,316 

Less effects of discounting

 (46)

Present value of future minimum lease payments

$2,270 

 

35

 

Operating lease right-of-use assets and lease liabilities were recorded in the condensed consolidated balance sheets as follows (in thousands):

 

  September 30,  December 31, 
  

2026

  

2025

 

Operating lease right-of-use assets, net

 $2,150  $162 

Current portion of operating lease liabilities

 $1,495  $63 

Operating lease liabilities

  775   101 

Total operating lease liabilities

 $2,270  $164 

 

 

Note 12. Net Income (Loss) per Share

 

The Company’s Series X Convertible Preferred Stock and Series B Convertible Preferred Stock, of which no shares were outstanding as of  September 30, 2026, Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series C-3 Convertible Preferred Stock, Series C-4 Convertible Preferred Stock, Series D Convertible Preferred Stock, Series J Convertible Preferred Stock, and warrants to purchase common stock have participation rights to any dividends that may be declared in the future, such that they are participating securities. Under the two-class method, undistributed earnings are allocated to participating securities based on their contractual participation rights. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. For the three months ended September 30, 2026, the Company reported an overall net loss available to common stockholders, and accordingly, no undistributed earnings were allocated to the participating securities.

 

For the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, the Company incurred losses from continuing operations available to common stockholders, and potential common shares were excluded from diluted net income (loss) per share to the extent their inclusion would have been antidilutive. For the three months ended September 30, 2026, the Company reported income from continuing operations available to common stockholders after giving effect to deemed contributions and dividends from preferred stock transactions. Accordingly, the Company evaluated potentially dilutive securities using income from continuing operations available to common stockholders as the control number. Certain Series C Convertible Preferred Stock was determined to be dilutive and included in the computation of diluted net income (loss) per share for the three months ended September 30, 2026. Other potential common shares, including stock options, warrants, and certain convertible preferred stock, were excluded from the computation because their inclusion would have been antidilutive.

 

For the three months ended September 30, 2026, the loss from continuing operations attributable to Flyte Aviation, Inc. of $1.9 million, adjusted for net deemed contributions of $2.5 million, resulted in income from continuing operations available to common stockholders of $0.6 million used to compute basic net income (loss) per share. Under the if-converted method, deemed contributions of $0.6 million, $0.9 million and $1.0 million attributable to the dilutive Series C-2, Series C-3 and Series C-4 Convertible Preferred Stock, respectively, were reversed, resulting in a loss from continuing operations available to common stockholders of $1.9 million used to compute diluted net income (loss) per share. Weighted-average common shares used to compute diluted net income (loss) per share of 1,956,534 consisted of basic weighted-average common shares of 1,548,281 plus 166,496, 145,387 and 96,370 shares from the assumed conversion of Series C-2, Series C-3 and Series C-4 Convertible Preferred Stock, respectively, for the period prior to the August 10, 2026 extinguishment. For the three months ended September 30, 2025 and the nine months ended September 30, 2026 and 2025, the numerators and denominators used to compute basic and diluted net loss per share were the same.

 

The following table presents the potential common shares issuable from securities outstanding as of September 30, 2026 and 2025 that were excluded from diluted net income (loss) per share for the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, because their inclusion would have been antidilutive:

 

       
 

September 30,

 
 

2026

 

2025

 

Warrants for common stock

 113,659  107,893 

Employee stock options

 50,763  16,436 

Series B Convertible Preferred Stock

 —  33,521 

Series C-1 Convertible Preferred Stock

 608,696  — 

Series C-2 Convertible Preferred Stock

 785,217  — 

Series C-3 Convertible Preferred Stock

 1,020,435  — 

Series C-4 Convertible Preferred Stock

 3,183,043  — 

Series D Convertible Preferred Stock

 2,960,435  — 

Series J Convertible Preferred Stock

 608,269  — 

Series X Convertible Preferred Stock

 —  6,661 

Restricted stock awards

 —  600 

Total common stock equivalents

 9,330,517  165,111 

 

36

 
 

Note 13. Equity Offerings

 

May 2025  PIPE Financing
 
On May 12, 2025, the Company sold shares of Series B Convertible Preferred Stock and Series L common stock purchase warrants (“Series L Warrants”) in a private placement (the “May 2025 PIPE Financing”), and issued placement agent warrants to purchase 1,353 shares of common stock (the “Placement Agent Warrants”). All Series L Warrants were exercised in  February 2026 pursuant to the Letter Agreement described below, and all shares of Series B Convertible Preferred Stock were converted or repurchased during the nine months ended September 30, 2026 (see Note 14, Preferred Stock). The Placement Agent Warrants remain outstanding and are equity-classified.
 
At the Market Offering Agreement
 
On May 19, 2025, the Company entered into an At the Market Offering Agreement (“ATM Agreement”) with Ladenburg. Under the ATM Agreement, the Company may offer and sell up to $1.3 million of shares of common stock, par value $0.0001 per share, through Ladenburg. On June 13, 2025, the Company filed a prospectus supplement increasing the aggregate amount available to be sold to $3.2 million under the ATM (“Shares”). On August 7, 2025, the Company filed a prospectus supplement, which supersedes and replaces the prospectus supplement dated June 13, 2025, increasing the aggregate amount of shares available to be sold to $4.3 million. The Shares have been and will continue to be issued pursuant to the Company’s previously filed and effective Registration Statement on Form S- 3 (File No. 333- 284217), which was initially filed with the Securities and Exchange Commission on January 10, 2025 and declared effective on January 22, 2025.

 

 

The Company has no obligation to sell, and Ladenburg is not obligated to buy or sell, any of the Shares under the ATM Agreement and may at any time suspend offers under the ATM Agreement. The ATM Agreement will terminate upon the earlier of (i) the issuance and sale of all of the shares through Ladenburg on the terms and subject to the conditions set forth in the ATM Agreement or (ii) termination of the ATM Agreement as otherwise permitted thereby. The ATM Agreement may be terminated at any time by either party upon five ( 5) business days’ prior notice, or by Ladenburg at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.

 

 
The Company has agreed to pay Ladenburg a commission equal to 3% of the aggregate gross proceeds from sale of its shares of common stock.
 
As of December 31, 2025, 88,785 shares of common stock had been sold under the ATM Agreement for gross proceeds of $4.0 million before deduction of commission and offering expenses of $0.3 million. During the nine months ended  September 30, 2026, no additional shares of common stock had been sold under the ATM Agreement.

 

February 2026 Private Placement

 

On February 6, 2026, the Company entered into a Securities Purchase Agreement (the “February 2026 SPA”) with certain accredited investors for a private placement financing. Pursuant to the February 2026 SPA, the Company completed the first closing and issued an aggregate of (i) 39,261 shares of the Company's common stock, par value $0.0001 per share, at a purchase price of $14.30 per share, and (ii) 1,617 shares of newly designated Series C-1 Convertible Preferred Stock. The Company collected gross proceeds of $2.2 million before deducting direct and incremental offering expenses of $0.2 million.

 

The investors agreed to purchase 1,617 shares of newly designated Series C-2 and Series C-3 Convertible Preferred Stock under additional closings for aggregate gross proceeds of $1.6 million per closing (the "Second Tranche" and "Third Tranche", respectively). Furthermore, the investors have the right, but not the obligation, to purchase up to an aggregate of $39.2 million of Series C-4 Convertible Preferred Stock in one or more closings (the "Additional Investment Right").

 

The additional closings are subject to certain closing conditions, including stockholder approval to issue shares of common stock in excess of 19.99% of the Company’s issued and outstanding shares of common stock and to effect a reverse stock split (“Stockholder Approval”). Solely with respect to the closing of the Third Tranche and any additional closings under the Additional Investment Right, the closing is subject to the declaration of the effectiveness of a Registration Statement filed for the resale of the common stock underlying the Series C-1, Series C-2, Series C-3, and Series C-4 Convertible Preferred Stock (collectively, the "Series C Convertible Preferred Stock"). The Additional Investment Right is exercisable for a period of twelve months following the later of the Stockholder Approval Date and the date the Registration Statement is first declared effective by the SEC, subject to a minimum gross proceeds threshold of $500,000 for each such additional closing. On June 23, 2026, the Company filed the Registration Statement on Form S-1 with the SEC, and on July 10, 2026, the Registration Statement was declared effective by the SEC. 

 

The Company evaluated the Series C-1 Convertible Preferred Stock as well as the additional closing rights related to the Series C-2, Series C-3, and Series C-4 Convertible Preferred Stock. The Company determined that, except as described in Note 14, Preferred Stock, with respect to certain contingent payment provisions embedded in the Series C Convertible Preferred Stock, these instruments do not require liability classification pursuant to ASC 480 and do not contain net cash settlement provisions that would preclude equity classification under ASC 815-40. Accordingly, these instruments were recorded to additional paid-in capital in the consolidated balance sheets. See Note 14, Preferred Stock, for additional information on the convertible preferred stock issued under the February 2026 SPA.

 

In connection with the February 2026 SPA, the Company also entered into a registration rights agreement with the investors requiring the Company to register for resale the shares of common stock issuable upon conversion of the Series C Convertible Preferred Stock. Failure to timely comply with certain registration obligations may require the Company to make cash payments to the investors. Upon the Registration Statement being declared effective on July 10, 2026, the Company ceased accruing additional registration delay payments.

 

On April 15, 2026, the Company obtained Stockholder Approval described above. On April 21, 2026, the Company closed the Second Tranche and issued 1,617 shares of Series C-2 Convertible Preferred Stock for aggregate gross proceeds of $1.6 million. On July 15, 2026, following the effectiveness of the Registration Statement, the Company closed the Third Tranche and issued 1,617 shares of Series C-3 Convertible Preferred Stock for aggregate gross proceeds of approximately $1.6 million. 

 

 

February 2026 Letter Agreement

 

On February 6, 2026, the Company entered into a letter agreement (the “Letter Agreement”) with the holders of the Company’s Series B Convertible Preferred Stock and Series L Warrants, which were originally issued pursuant to the Securities Purchase Agreement dated May 12, 2025. Pursuant to the Letter Agreement, the Company agreed to reduce the conversion price of the Series B Convertible Preferred Stock and the exercise price of the Series L Warrants to $17.80 per share, and the holders agreed to immediately exercise all of their Series L Warrants for cash. Following the execution of the Letter Agreement, the holders exercised 22,556 Series L Warrants to purchase 22,556 shares of common stock at the reduced exercise price of $17.80 per share, resulting in aggregate gross proceeds to the Company of approximately $0.4 million. There are no Series L Warrants outstanding as of September 30, 2026.

 

Pursuant to the Letter Agreement, the Company and the holders also agreed that the beneficial ownership limitation applicable to the Series L Warrants would be increased from 4.99% to 9.99%, effective immediately as of the date of the agreement, with the holders waiving any prior notice period requirements. Additionally, the holders agreed to certain trading volume restrictions.

 

The Company accounted for the reduction in the exercise price of the Series L Warrants as a modification of equity-classified warrants. The incremental fair value of the Series L Warrants resulting from the modification, which was measured as of the modification date using a Black-Scholes valuation model, was recognized as an equity issuance cost within additional paid-in capital in the condensed consolidated balance sheets. The Company accounted for the settlement of the Series L Warrants pursuant to the Letter Agreement as an induced exercise of equity-classified warrants. The incremental fair value of the additional consideration provided to the holders in connection with the settlement, including the incremental fair value attributable to the modified Series B Convertible Preferred Stock, was recognized as a deemed dividend within additional paid-in capital in the condensed consolidated balance sheets. See Note 14, Preferred Stock, for additional information.

 

March 2026 Private Placement

 

On March 9, 2026, the Company entered into an additional Securities Purchase Agreement (the “March 2026 SPA”) with certain accredited investors for a private placement financing. Pursuant to the March 2026 SPA, the Company completed the first closing and issued 1,853 shares of Series C-1 Convertible Preferred Stock. The Company collected gross proceeds of $1.9 million before deducting direct and incremental offering expenses of $0.1 million.

 

The investors agreed to purchase 1,853 shares of newly designated Series C- 2 and Series C- 3 Convertible Preferred Stock under additional closings (the "Second Tranche" and "Third Tranche," respectively) for aggregate gross proceeds of $1.9 million per closing. Furthermore, the investors have the right, but not the obligation, to purchase up to an aggregate of $39.2 million of Series C- 4 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share, in one or more closings (the "Additional Investment Right").

 

The closing conditions, the Additional Investment Right, the registration rights and the Company’s equity classification conclusions under the March 2026 SPA are substantially the same as those under the February 2026 SPA described above.

 

37

 

On April 15, 2026, the Company obtained Stockholder Approval described above. On April 21, 2026, the Company closed the Second Tranche and issued 1,853 shares of Series C-2 Convertible Preferred Stock for aggregate gross proceeds of $1.9 million. On July 15, 2026, following the effectiveness of the Registration Statement, the Company closed the Third Tranche and issued 1,853 shares of Series C-3 Convertible Preferred Stock for aggregate gross proceeds of approximately $1.9 million. On July 30, 2026, pursuant to the Additional Investment Right under the March 2026 SPA, the Company issued 2,821 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of approximately $2.8 million. In August 2026, pursuant to the Additional Investment Right under the March 2026 SPA, certain investors purchased an additional 4,500 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $4.5 million. The Series C-4 Convertible Preferred Stock issued in August 2026 had an initial conversion price of $2.30 per share. See Note 14, Preferred Stock, for additional information regarding the terms of the Series C Convertible Preferred Stock. The Company used a portion of the net proceeds from the Series C-4 Convertible Preferred Stock issuance to fund the repurchase of all outstanding shares of Series B Convertible Preferred Stock as described in Note 14, Preferred Stock.

 

In connection with the Series C-3 Convertible Preferred Stock issuances under the February and March 2026 SPAs, the Company incurred aggregate direct offering costs of approximately $267 thousand. In connection with the Series C-4 Convertible Preferred Stock issuances under the March 2026 SPA, the Company incurred aggregate direct offering costs of approximately $528 thousand. The Company used approximately $2.2 million of the net proceeds from the Series C-3 Convertible Preferred Stock issuance to repay outstanding principal and accrued interest under the Bridge Notes and the June 2026 Note that were outstanding as of June 30, 2026, with the remaining net proceeds used to fund operations.

 

Warrants

 

The following table presents the number of common stock warrants outstanding:

 

Warrants outstanding, December 31, 2025

141,893 

Issued

— 

Exercised

(22,556)

Expired

(5,678)

Warrants outstanding, September 30, 2026

113,659 

 

As of  September 30, 2026 and December 31, 2025, all warrants outstanding are recorded in additional paid-in capital in the condensed consolidated balance sheets. The following table presents the number and type of common stock purchase warrants outstanding, their exercise price, and expiration dates as of September 30, 2026:

 

  

Warrants

         

Warrant Type

 

Outstanding

  

Exercise Price

  

Expiration Date

 

February 2022 Series B Warrants

  206  $26,600.00  

2/4/2029

 

July 2022 Series C Warrants

  149  $26,600.00  

7/22/2027

 

September 2024 Series J Warrants

  18,836  $190.00  

9/3/2029

 

September 2024 Representative Warrants

  1,130  $294.50  

8/29/2029

 

October 2024 Series K Warrants

  56,295  $133.00  

7/13/2030

 

October 2024 Placement Agent Warrants

  1,690  $206.15  

4/25/2030

 

Placement Agent Warrants May 2025

  1,353  $103.08  

6/6/2030

 

December 2025 Series M Warrants

  34,000  $15.60   3/30/2032 
   113,659         

 

 

38

 

As of September 30, 2026, the warrants issued by the Company had a weighted average exercise price of $192.46.

 

Placement Fees

 

In connection with offerings completed by the Company in 2022, (the "2022 Offerings"), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximat ely $1.4 million r elated to the 2022 Offerings is included in accrued expenses in the condensed consolidated balance sheets as of  September 30, 2026 and December 31, 2025. Additionally, the agreement called for the issuance of warrants with the following terms:

 

Number of shares

 

Exercise Price

 

Expiration

17 $59,375.00 

5 years

16 $33,250.00 

5 years

 

 

Note 14. Preferred Stock

 

Series X Convertible Preferred Stock

 

Pursuant to the Merger Agreement, the Company designated Series X Convertible Preferred Stock as consideration to former Old Catheter common stockholders and holders of convertible promissory notes. On December 5, 2025, holders converted 12,656 shares of Series X Convertible Preferred Stock into 6,658 shares of common stock. As of September 30, 2026 and December 31, 2025, the Company had no shares of Series X Convertible Preferred Stock outstanding.

 

Series B Convertible Preferred Stock

 

On May 12, 2025, pursuant to the May 2025 PIPE Financing, the Company issued 3,000 shares of Series B Convertible Preferred Stock. Each share of the Series B Convertible Preferred Stock has a par value of $0.0001 and a stated value of $1,000.

 

On February 6, 2026, the Company entered into the Letter Agreement described in Note 13, Equity Offerings and agreed to reduce the conversion price of the Series B Convertible Preferred Stock to an alternative price of $17.80 per share. Pursuant to the Letter Agreement, the beneficial ownership limitation for the Series B Convertible Preferred Stock was increased from 4.99% to 9.99%, effective immediately, with the holders waiving any prior notice period requirements. The shares of common stock underlying the Series B Convertible Preferred Stock are subject to the same trading volume restriction provisions described in Note 13, Equity Offerings. In consideration for the reduction in conversion price and subsequent to the exercise of the Series L Warrants described, the holders agreed to convert their Series B Convertible Preferred Stock at the reduced conversion price such that the holders would collectively hold 9.99% of the outstanding shares of the Company’s common stock immediately after giving effect to such conversions and warrant exercises.

 

The amendment to the Series B Convertible Preferred Stock pursuant to the Letter Agreement was accounted for as an extinguishment. Upon extinguishment, the Company derecognized the original Series B Convertible Preferred Stock at its carrying amount, and recognized the amended Series B Convertible Preferred Stock at fair value. The resulting difference of $1.4 million was recorded as an adjustment to additional paid-in capital and recognized as a deemed dividend during the nine months ended September 30, 2026. 

 

On June 23, 2026, the Company’s Board of Directors approved a further reduction in the conversion price of the Company’s outstanding Series B Convertible Preferred Stock from $17.80 to $14.30 per share, effective June 22, 2026. The amendment was accounted for as an extinguishment. Upon extinguishment, the Company derecognized the amended Series B Convertible Preferred Stock pursuant to the Letter Agreement at its carrying amount, and recognized the newly amended Series B Preferred Stock at fair value. The resulting difference of $0.7 million was recorded as an adjustment to additional paid-in capital and recognized as a deemed contribution during the nine months ended September 30, 2026. 

 

On July 29, 2026, the Company entered into a letter agreement with the holders of its Series B Convertible Preferred Stock pursuant to which the Company agreed to repurchase and cancel all 321 remaining outstanding shares of Series B Convertible Preferred Stock for aggregate cash consideration of $321 thousand. The Company used a portion of the net proceeds from the Series C- 4 Convertible Preferred Stock issuance to fund the repurchase. Upon completion of the repurchase, all outstanding shares of Series B Convertible Preferred Stock were retired and cancelled, and the Company had no continuing obligations with respect to the Series B Convertible Preferred Stock. The excess of the cash consideration paid of $321 thousand over the net carrying amount of the Series B Convertible Preferred Stock of $195 thousand, or $126 thousand, was recognized as a deemed dividend and was recorded as an adjustment to additional paid-in capital during the nine months ended September 30, 2026. 

 

39

 

Series B Convertible Preferred Stock were converted as follows:

 

Date of Conversion

 

Series B Shares Converted

 

Common Shares Issued

 

June 11, 2025

 

771

 

11,591

 
March 10, 2026 597 33,535 
June 23, 2026 576 40,306 
June 24, 2026 735 51,394 

 

As of   September 30, 2026 and December 31, 2025, the Company had 0 and 2,229 shares, respectively, of Series B Convertible Preferred Stock outstanding.

 

Series C Convertible Preferred Stock

 

In February and March 2026, pursuant to the February 2026 Private Placement and the March 2026 Private Placement, the Company issued 1,617 shares and 1,853 shares, respectively, of its newly designated Series C-1 Convertible Preferred Stock. Each share of the Series C-1 Convertible Preferred Stock has a par value of $0.0001 and a stated value of $1,000. On April 21, 2026, pursuant to the Securities Purchase Agreements dated February 6, 2026 and March 9, 2026, the Company issued an aggregate of 3,470 shares of the Company’s newly designated Series C-2 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share.

 

On July 15, 2026, pursuant to the Securities Purchase Agreements dated February 6, 2026 and March 9, 2026, the Company issued an aggregate of 3,470 shares of its newly designated Series C-3 Convertible Preferred Stock. On July 30, 2026, pursuant to the Securities Purchase Agreement dated March 9, 2026, the Company issued 2,821 shares of its newly designated Series C-4 Convertible Preferred Stock. In August 2026, pursuant to the Additional Investment Right under the Securities Purchase Agreement dated March 9, 2026, the Company issued an additional 4,500 shares of the Company’s Series C-4 Convertible Preferred Stock. Each share of Series C-3 and Series C-4 Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 per share.

 

Subject to certain limitations described below, the Series C-1 Convertible Preferred Stock are convertible into shares of the Company’s common stock at the option of the holder at an initial conversion price of $14.30, subject to adjustment in certain circumstances as set forth in the Certificate of Designations. Following the date that the registration statement filed pursuant to the related registration rights agreement is first declared effective by the Securities and Exchange Commission (the “Effective Date”) and the date stockholder approval is obtained under applicable exchange rules (the "Stockholder Approval Date"), the conversion price is reduced to the lower of (i) the conversion price in effect immediately prior to the Effective Date and (ii) 80% of the lower of (A) the official closing price of the Company’s common stock immediately prior to the applicable date of determination or (B) the five-day volume weighted average price of the Company’s common stock immediately prior to the applicable date of determination (the “Applicable Price”) on such date. In each case, the conversion price is subject to a floor price of $3.50, unless waived by the Company in its sole discretion. In the event of a stock dividend, reverse stock split, stock combination, reclassification or similar event affecting the Company’s common stock, the conversion price shall be adjusted based on the number of shares of common stock outstanding immediately before and after such event. The conversion of the Series C-1 Convertible Preferred Stock is also subject to stockholder approval and certain beneficial ownership limitations. Prior to the Stockholder Approval Date, the Series C Convertible Preferred Stock may only be converted into shares of common stock up to the maximum amount permitted under applicable exchange rules.

 

Except for the initial conversion price and the automatic reduction in conversion price upon the Stockholder Approval Date, the Series C-2 Convertible Preferred Stock has the same conversion features as the Series C-1 Convertible Preferred Stock discussed above. The Series C-2 Convertible Preferred Stock had an initial conversion price of $8.83 per share.​​​​​ The Series C-3 Convertible Preferred Stock had an initial conversion price of $6.32 per share. The 2,821 shares of Series C-4 Convertible Preferred Stock issued on July 30, 2026 had an initial conversion price of $3.50 per share. The 4,500 shares of Series C-4 Convertible Preferred Stock issued in August 2026 had an initial conversion price of $2.30 per share. Except for their respective initial conversion prices, the other material terms of the Series C-3 and Series C-4 Convertible Preferred Stock are substantially consistent with those of the Series C-1 and Series C-2 Convertible Preferred Stock described above.

 

On April 15, 2026, the Company obtained stockholder approval under applicable exchange rules (the “Stockholder Approval Date”). Pursuant to the adjustment provisions of the Series C-1 Certificate of Designations, the conversion price of the Series C-1 Convertible Preferred Stock was reduced from $14.30 to $8.83 per share as of the Stockholder Approval Date. On July 10, 2026, the registration statement filed pursuant to the applicable registration rights agreements was declared effective by the SEC. Pursuant to the adjustment provisions of the respective Certificates of Designation, the conversion prices of both the Series C-1 and Series C-2 Convertible Preferred Stock were reduced to $6.32 per share as of July 10, 2026. On August 10, 2026, the Company waived the $3.50 floor price applicable to the outstanding Series C Convertible Preferred Stock and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3 and Series C-4 Convertible Preferred Stock to $2.30 per share. Accordingly, as of September 30, 2026, the conversion price of each series of Series C Convertible Preferred Stock was $2.30 per share. 

 

The August 10, 2026 waiver of the floor price and reduction of the conversion price of the outstanding Series C Convertible Preferred Stock was accounted for as an extinguishment. Upon extinguishment, the Company derecognized the outstanding Series C Convertible Preferred Stock at its carrying amount and recognized the amended Series C Convertible Preferred Stock at fair value. The aggregate deemed contribution resulting from the modifications of the Series C and Series D Convertible Preferred Stock was approximately $2.6 million and was recorded as an adjustment to additional paid-in capital during the three and nine months ended September 30, 2026.

 

40

 

Notwithstanding the foregoing, the holders of shares of Series C Convertible Preferred Stock do not have the right to convert any portion of their Series C Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own a number of shares of common stock in excess of 4.99% of the shares of common stock then outstanding (the “Beneficial Ownership Limitation”). At the holder’s option, the holder may increase the Beneficial Ownership Limitation to 9.99% of the shares of common stock then outstanding, with any such increase becoming effective upon 61 days’ prior notice to the Company.

 

Holders of Series C Convertible Preferred Stock are entitled to receive dividends when and as declared by the Board of Directors, in its sole discretion, on the stated value of such shares. In addition, upon certain rights offerings or other distributions to holders of common stock, the holders of Series C Convertible Preferred Stock are entitled to participate on an as-if-converted-to-common-stock basis, in each case subject to the Beneficial Ownership Limitation and applicable issuance limitations.

 

Upon any liquidation, dissolution or winding-up of the Company, the holders of Series C Convertible Preferred Stock are entitled to receive, prior and in preference to any distribution to holders of Junior Securities, an amount equal to the stated value of such shares, plus any accrued and unpaid dividends thereon, if any, and any other fees or liquidated damages then due and owing.

 

In the event of certain fundamental transactions, upon any subsequent conversion of the Series C Convertible Preferred Stock, the holders will be entitled to receive, for each share of common stock that would otherwise have been issuable upon conversion immediately prior to such transaction, the same kind and amount of securities, cash or other property that would have been received by a holder of common stock, and the conversion price will be adjusted accordingly.

 

The Company evaluated the contingent payment provisions embedded in the Series C Convertible Preferred Stock under ASC 815 and determined that certain provisions required bifurcation and separate accounting as embedded derivatives. The estimated fair values of these embedded derivatives were deemed to be de minimis at issuance and as of  September 30, 2026.

 

Except as otherwise required by law, and subject to certain protective provisions, the Series C Convertible Preferred Stock do not have voting rights.

 

Series C Convertible Preferred Stock were converted as follows:

  

Date of Conversion

 

Series C Shares Converted

 

Common Shares Issued

 

July 13, 2026

  623  98,556 

July 14, 2026

  410  64,873 

July 15, 2026

  1,699  268,771 

July 16, 2026

  332  52,530 

July 20, 2026

  25  3,955 

July 24, 2026

  80  12,659 

July 28, 2026

  382  60,444 

August 6, 2026

  46  7,279 

August 10, 2026

  432  68,355 

August 17, 2026

  610  265,517 

August 19, 2026

  215  93,478 

August 20, 2026

  3  1,304 

 

As of September 30, 2026, the Company had 1,400 shares of Series C-1 Convertible Preferred Stock, 1,806 shares of Series C-2 Convertible Preferred Stock, 2,347 shares of Series C-3 Convertible Preferred Stock and 7,321 shares of Series C-4 Convertible Preferred Stock outstanding.

 

Series D Convertible Preferred Stock

 

On April 20, 2026, in connection with the Company’s previously disclosed acquisition of FLYTE the Company issued an aggregate of 11,028 shares of its newly designated Series D Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the “Series D Preferred Stock”), as follows (i) 5,250 shares of Series D Preferred Stock to SEG Jets LLC (“SEG Jets”) as consideration for SEG Jets’ transfer to the Company of common stock of FLYTE representing 19.98% of the issued and outstanding equity interests of FLYTE, pursuant to that certain Securities Purchase Agreement, dated February 6, 2026;and (ii) 5,778 shares of Series D Preferred Stock to Creatd as partial consideration for Creatd’s transfer to the Company of the remaining 80.02% of the issued and outstanding equity interests of FLYTE, pursuant to that certain Stock Purchase Agreement, dated March 9, 2026.

 

Subject to certain limitations described below, the Series D Preferred Stock are convertible into shares of the Company's common stock at the option of a holder at an initial conversion price of $11.038 per share, subject to adjustment in certain circumstances as set forth in the Certificate of Designations. Following the date on which the registration statement filed pursuant to the related registration rights agreement is first declared effective by the Securities and Exchange Commission (the "Effective Date”), the conversion price shall be reduced to equal the lower of (i) the conversion price in effect immediately prior to the Effective Date and (ii) the Applicable Price on the Effective Date. In each case, the conversion price is subject to a floor price of $3.50, unless waived by the Company in its sole discretion. In the event of a stock dividend, reverse stock split, stock combination, reclassification or similar event affecting the Company’s common stock, the conversion price shall be adjusted based on the number of shares of common stock outstanding immediately before and after such event. The conversion of the Series D Convertible Preferred Stock is subject to stockholder approval and certain beneficial ownership limitations. Prior to the Stockholder Approval Date, the Series D Convertible Preferred Stock may only be converted into shares of common stock up to the maximum amount permitted under applicable exchange rules. On July 10, 2026, the registration statement filed pursuant to the applicable registration rights agreements was declared effective by the SEC. Pursuant to the adjustment provisions of the Series D Certificate of Designations, the conversion price of the Series D Convertible Preferred Stock was reduced from $11.038 to $7.90 per share as of July 10, 2026. On August 10, 2026, the Company waived the $3.50 floor price applicable to the Series D Convertible Preferred Stock and reduced the conversion price of all outstanding shares of Series D Convertible Preferred Stock to $2.30 per share. Accordingly, as of September 30, 2026, the conversion price of the Series D Convertible Preferred Stock was $2.30 per share.

 

The August 10, 2026 waiver of the floor price and reduction of the conversion price of the Series D Convertible Preferred Stock was accounted for as an extinguishment. Upon extinguishment, the Company derecognized the outstanding Series D Convertible Preferred Stock at its carrying amount and recognized the amended Series D Convertible Preferred Stock at fair value. The aggregate deemed contribution resulting from the modifications of the Series C and Series D Convertible Preferred Stock was approximately $2.6 million and was recorded as an adjustment to additional paid-in capital during the three and nine months ended September 30, 2026.

 

The beneficial ownership limitation, dividend, liquidation preference, fundamental transaction, embedded derivative and voting provisions of the Series D Convertible Preferred Stock are substantially the same as those of the Series C Convertible Preferred Stock described above.

 

Series D Convertible Preferred Stock were converted as follows:

 

Date of Conversion

 

Series D Shares Converted

 

Common Shares Issued

 

July 13, 2026

  293  37,088 

July 14, 2026

  315  39,873 

July 15, 2026

  1,222  154,683 

July 16, 2026

  633  80,126 

July 20, 2026

  602  76,203 

July 21, 2026

  145  18,355 

July 22, 2026

  330  41,773 

August 17, 2026

  426  185,218 

August 27, 2026

  230  100,000 

September 17, 2026

  23  10,000 

 

As of  September 30, 2026, the Company had 6,809 shares of Series D Convertible Preferred Stock outstanding. 

 

41

 

Series J Convertible Preferred Stock

 

On December 31, 2025, pursuant to Exchange Agreements with David A. Jenkins, the Company’s Executive Chairman and Chief Executive Officer, and FatBoy Capital, L.P., an entity controlled by Mr. Jenkins, the Company issued 9,490 shares of its newly designated Series J Convertible Preferred Stock in exchange for the extinguishment of accrued and future royalty rights associated with the Company’s discontinued operations (see Note 4, Discontinued Operations and Assets Held for Sale). The Series J Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 per share. The Company recognized the fair value of the Series J Convertible Preferred Stock of $5.3 million in additional paid-in capital in the consolidated balance sheets.

 

Subject to the beneficial ownership limitations described below, each share of Series J Convertible Preferred Stock is convertible at the option of the holder into a number of shares of common stock equal to its stated value divided by the conversion price. As of September 30, 2026, the conversion price was $15.60 per share, and the outstanding Series J Convertible Preferred Stock was convertible into an aggregate of approximately 608,269 shares of common stock. The conversion price is subject to proportionate adjustment for stock dividends, stock splits, reverse stock splits, combinations and reclassifications of the common stock.

 

On September 30, 2026, at the Company’s annual meeting of stockholders, the stockholders approved an amendment to the Certificate of Designation of Preferences, Rights and Limitations of the Series J Convertible Preferred Stock. The amendment authorizes the Board of Directors to reduce the conversion price of the Series J Convertible Preferred Stock below $15.60 per share. Any reduced price is subject to a floor equal to the lower of (i) $2.30 per share and (ii) the lowest conversion price then in effect for any outstanding shares of Series C Convertible Preferred Stock, in each case as adjusted for the Reverse Stock Split.  The Board did not reduce the conversion price of the Series J Convertible Preferred Stock on or before September 30, 2026. See Note 20, Subsequent Events, for the subsequent reductions of the conversion price to $2.30 per share on October 1, 2026 and to $1.00 per share on October 10, 2026.

 

Holders may not convert any portion of their Series J Convertible Preferred Stock to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% of the shares of common stock then outstanding (the “Beneficial Ownership Limitation”). At the holder’s option, the holder may increase the Beneficial Ownership Limitation to 9.99% of the shares of common stock then outstanding, effective 61 days after notice to the Company.

 

Holders of Series J Convertible Preferred Stock are entitled to receive dividends and distributions on an as-if-converted-to-common-stock basis and in the same form as dividends and distributions actually paid on shares of common stock, as well as dividends when and as declared by the Board of Directors. No dividends have been declared on the Series J Convertible Preferred Stock.

 

The Series J Convertible Preferred Stock has no preference upon any liquidation, dissolution or winding-up of the Company. Upon certain fundamental transactions, the holders will be entitled to receive, upon any subsequent conversion, the same kind and amount of securities, cash or other property that would have been received by a holder of the number of shares of common stock issuable upon conversion immediately prior to such transaction. Except as otherwise required by law, the Series J Convertible Preferred Stock does not have voting rights.

 

As of September 30, 2026, the Company had 9,490 shares of Series J Convertible Preferred Stock outstanding, all of which were held by Mr. Jenkins and FatBoy Capital, L.P. See Note 19, Related Parties.

 

 
Note 15. Stock-Based Compensation
 

2023 Equity Incentive Plan

 

In July 2023, the Company’s stockholders approved the 2023 Plan, which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. Stock options granted under the 2023 Plan to employees and consultants generally will vest annually over a five-year period or as determined by the Board’s Compensation Committee (the "Committee"), while grants to non-employee directors vest as determined by the Committee. As of  September 30, 2026 and  December 31, 2025,  693,701 and  19,452 shares of common stock were reserved for issuance pursuant to future awards under the 2023 Plan. The number of shares available for issuance under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board.
 
On September 30, 2026, at the Annual Meeting of Stockholders of the Company, the stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares of the Company’s common stock reserved for issuance thereunder by 500,000 shares. The Board of Directors had previously approved the amendment, subject to stockholder approval.
 
At the Annual Meeting, the Company’s stockholders also approved a one-time repricing (the “Repricing”) of outstanding stock options with an exercise price greater than the fair market value of the Company’s common stock on the date of stockholder approval. As a result of the Repricing, the exercise price of the affected outstanding stock options was reduced to $1.52 per share, which represented the closing price of the Company’s common stock on the NYSE American on September 30, 2026. The Repricing did not modify the number of shares underlying the affected options, their expiration dates or their vesting schedules.

 

The Company accounted for the Repricing as a modification of the affected stock option awards pursuant to ASC Topic 718. The incremental fair value of the modified awards was measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately prior to the modification. The Repricing resulted in incremental stock-based compensation cost of approximately $27 thousand, of which approximately $20 thousand was recognized during the three and nine months ended September 30, 2026. The remaining $7 thousand of unrecognized incremental compensation cost will be recognized over the remaining requisite service periods of the unvested modified awards.

 

42

 

For the nine months ended September 30, 2026. the Committee approved the grant of 20,000 stock options with service-based conditions. The options vest in equal installments over requisite service period of 180 days. No stock options with performance-based conditions were granted during the nine months ended September 30, 2026. 

 

The options granted for the 2023 Plan for the  nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes model based on the following assumptions on the date of issue:
 
Options with Time-Based Vesting Conditions
  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  4.11%  4.29 - 4.55%

Volatility

  105.06   97.40 - 100%

Expected dividend yield

  0%  0%

Expected life (in years)

  5.5   5.5 - 6.5 

 

Options with Performance-Based Vesting Conditions

  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  —   4.55%

Volatility

  —   98.00 - 98.40%

Expected dividend yield

  —   0%

Expected life (in years)

  —   5.3 - 5.5 

 

 

The following is a summary of stock option activity for the 2023 Plan options for the nine months ended September 30, 2026:

 

      

Weighted

  

Weighted

     
      

Average

  

Average

  

Aggregate

 
  Stock  Exercise  Remaining  Intrinsic Value 
  

Options

  

Price

  

Life

  

(in thousands)

 

Outstanding at December 31, 2025

  12,368  $80.72   9.29  $— 

Options exercised

  —   —   —   — 

Options granted

  20,000   11.50   —   — 

Cancelled/forfeited

  (1,736)  98.63   —   — 

Outstanding at September 30, 2026

  30,632  $1.52   9.16  $— 

Vested and expected to vest at September 30, 2026

  30,632  $1.52   9.16  $— 

Exercisable at September 30, 2026

  23,798  $1.52   9.32  $— 

 

The weighted-average grant-date fair value of the 2023 Plan options granted during the nine months ended September 30, 2026 and 2025 was $3.99 and $44.06 per share, respectively.

 

43

 

Non-Plan Options Issued

 

On January 6, 2025, the Board approved and issued a total of 2,631 Non-Plan Options as an employee incentive to the Chief Financial Officer. The options vest monthly over 3 years with an exercise price of $1.52 and an expiration date of January 6, 2035.

 

For the nine months ended September 30, 2026 the Board approved and issued a total of 17,500 Non-Plan Options as an employee incentive to Marc Sellouk. The options vest 100% on grant date with an exercise price of $1.52 and an expiration date of April 1, 2036.

 

The Non-Plan Options issued for the nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes model based on the following assumptions on the date of issue:

 

  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  4.33%  4.62%

Volatility

  105.31   97.00%

Expected dividend yield

  0%  0%

Expected life (in years)

  5.5   5.8 

 

The following is a summary of stock option activity for the Non-Plan options for the nine months ended September 30, 2026:

 

      

Weighted

  

Weighted

     
      

Average

  

Average

  

Aggregate

 
  Stock  Exercise  Remaining  Intrinsic Value 
  

Options

  

Price

  

Life

  

(in thousands)

 

Outstanding at December 31, 2025

  2,631  $100.70   9.02  $— 

Options exercised

  —   —   —   — 

Options granted

  17,500   11.50   —   — 

Cancelled/forfeited

  —   —   —   — 

Outstanding at September 30, 2026

  20,131  $1.52   9.35  $— 

Vested and expected to vest at September 30, 2026

  20,131  $1.52   9.35  $— 

Exercisable at September 30, 2026

  18,961  $1.52   9.41  $— 

 

The weighted-average grant-date fair value of the Non-Plan options granted during the nine months ended September 30, 2026 and 2025 was $3.70 and $79.21 per share, respectively.

 

Stock-based compensation expense is recorded in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense for the three and nine months ended September 30, 2026 was $161 thousand and $491 thousand, respectively, which includes $20 thousand of incremental stock-based compensation expense recognized in connection with the Repricing described above. Stock-based compensation for the three and nine months ended September 30, 2025 was $70 thousand and $259 thousand, respectively. 

 

44

 

Total unrecognized estimated stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized at  September 30, 2026 was as follows:

 

  

Unrecognized Expense (in thousands)

  

Remaining Weighted Average Recognition Period

 

Stock options (Non-Plan Options)

 $140   0.01 

Stock options (2023 Plan Options)

 $228   2.91 

 

 

Note 16. Asset Acquisitions

 

On January 24, 2025, the Company acquired 100% of the membership interests of Perikard, LLC, which was accounted for as an asset acquisition consisting primarily of a single patent for pericardial access technology. The Company issued 1,447 shares of its common stock valued at $113 thousand as consideration and is obligated to make royalty payments equal to 10% of net sales of the pericardial access kit for five years following the closing date. The patent was determined to be IPR&D with no alternative future use, and accordingly, the Company recognized $119 thousand, consisting of $113 thousand of stock consideration and $6 thousand of direct transaction costs for the nine months ended September 30, 2025. The Perikard membership interests were transferred to Mr. Jenkins on December 31, 2025 (see Note 9, Notes Payable). 

 

On May 5, 2025, Cardionomix acquired certain assets from Cardionomic. The assets primarily related to Cardionomic’s CPNS System, which represents a novel technology for the late-stage treatment of acute decompensated heart failure. 

 

The acquisition was accounted for as an asset acquisition consisting primarily of an IPR&D Asset (the CPNS System). The Company issued 5,263 shares of its restricted common stock valued at $0.3 million, and Cardionomix issued a promissory note recorded at a carrying amount of $1.3 million (the "Note Payable"), as consideration to Cardionomic. The IPR&D Asset was determined to have no alternative future use, and accordingly, the Company expensed the costs of acquisition of $1.9 million, consisting of $0.3 million in stock consideration, $1.3 million of promissory note, and $0.3 million in direct transaction costs, as acquired research and development expenses in the condensed consolidated statement of operations for the nine months ended September 30, 2025.

 

See Note 9, Notes Payable for additional information on the Note Payable.

 

45

 
 

Note 17. Income Taxes

 

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business.

 

For the three and nine months ended September 30, 2026, the Company recorded federal income tax benefit of $0.5 million and $1.0 million, respectively, and no state income tax provision or benefit. For the three and nine months ended  September 30, 2025, the Company recorded federal income tax provision of $78 thousand and federal income tax benefit of $1,596 thousand, respectively, and no state income tax provision or benefit. The federal income tax benefit primarily relates to an increase in net operating losses that are not subject to limitations under Section 382 of the Internal Revenue Code. The Company’s net deferred tax assets generated mainly from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.

 

The Company has no open income tax audits with any taxing authority as of September 30, 2026.

 

 

Note 18. Commitments and Contingencies

 

In the normal course of business, the Company is at times subject to pending and threatened legal actions. In management’s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company.

 

Employment Litigation

 

In connection with the FLYTE acquisition, the Company assumed certain contingent liabilities, including an employment dispute with a former FLYTE employee alleging wrongful termination. The matter is currently proceeding through arbitration. While the Company disputes these allegations, the Company determined a loss was probable and reasonably estimable and recorded an estimated liability of $0.3 million under accrued expenses in the condensed consolidated balance sheets as of September 30, 2026. No amounts have been paid related to this matter as of September 30, 2026.

 

Promissory Note Settlement

 

Prior to the Company’s acquisition of FLYTE, FLYTE was involved in a legal proceeding regarding a defaulted unsecured subordinated promissory note. On March 9, 2026, FLYTE entered into a settlement and judgment satisfaction agreement pursuant to which FLYTE agreed to pay an aggregate settlement amount of $0.3 million in two installments of $150 thousand each. The first installment was paid during the three months ended March 31, 2026, and the remaining $150 thousand installment was paid during the three months ended June 30, 2026. As of September 30, 2026, the settlement had been paid in full and the Company had no remaining obligation related to the matter.

 

46

 
 

 

Note 19. Related Parties

 

On  December 31, 2025, pursuant to an Exchange Agreement, the Company issued an aggregate of  9,490 shares of the Company’s newly designated Series J Convertible Preferred Stock to Mr. Jenkins and his affiliate. As of  September 30, 2026  and December 31, 2025,  9,490 shares of Series J Convertible Preferred Stock were held by these related parties. Refer to Note  14, Preferred Stock, for additional information over the Series J Convertible Preferred Stock.

 

See Note 9, Notes Payable, for a description of the Related Party Notes held by Mr. Jenkins and his affiliates, the notes payable issued by KardioNav to Mr. Jenkins and Lifestim, Inc., an entity controlled by Mr. Jenkins, and the June 2026 Note issued to FatBoy Capital, L.P., and Note 13, Equity Offerings, for the Series M Warrants. The following table summarizes these related party notes as of September 30, 2026 (in thousands):

 

Related Party

Issuance Date

 

Principal Amount

  

Premium

  

Interest Accrued

 

David Jenkins

5/30/2024

 $500  $78  $45 

FatBoy Capital, L.P.

6/25/2024

 $150  $24  $14 

FatBoy Capital, L.P.

7/1/2024

 $250  $38  $22 

FatBoy Capital, L.P.

7/18/2024

 $100  $16  $9 

Jenkins Family Charitable Institute

7/25/2024

 $500  $78  $45 

David Jenkins

7/11/2025

 $150  $—  $8 

Lifestim, Inc.

7/11/2025

 $150  $—  $8 

 

 

47

 

Following the Company's acquisition of FLYTE in February and March 2026, the Company leases aircrafts from SEG Jets. The aircraft leases are used in connection with FLYTE’s aviation operations. The aircraft leases commenced between March and June 2026. At the respective acquisition, commencement or modification dates, these aircraft leases had remaining lease terms ranging from approximately 18 months to 24 months. The leases require fixed monthly lease payments.

 

Note 20. Subsequent Events

 

Issuance of Series C-4 Convertible Preferred Stock and Reduction of Conversion Prices of Series C, Series D and Series J Convertible Preferred Stock

 

On October 1, 2026, the Company reduced the conversion price of its outstanding Series J Convertible Preferred Stock from $15.60 to $2.30 per share. On October 9, 2026, pursuant to the Additional Investment Right under the Securities Purchase Agreement dated March 9, 2026, certain existing investors agreed to purchase an additional 2,050 shares of the Company’s Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $2.05 million. On October 9, 2026, with the consent of the requisite holders, the Company waived the applicable floor prices and reduced the conversion price of all outstanding shares of Series C and Series D Convertible Preferred Stock from $2.30 to $1.00 per share. In addition, on October 10, 2026, the Company reduced the conversion price of its outstanding Series J Convertible Preferred Stock to $1.00 per share. See Note 14, Preferred Stock, for the terms of the Series C, Series D and Series J Convertible Preferred Stock.

 

Convertible Preferred Stock Conversions

 

Subsequent to September 30, 2026, from October 6 through November 4, 2026, holders converted an aggregate of 134 shares of Series C-2 Convertible Preferred Stock, 349 shares of Series C-3 Convertible Preferred Stock and 1,811 shares of Series D Convertible Preferred Stock. In connection with these conversions, the Company issued an aggregate of 1,295,638 shares of its common stock.
 
Name Change and Reverse Stock Split

 

Effective October 5, 2026, the Company changed its name to Flyte Aviation, Inc. and effected a 1-for-10 reverse stock split of its common stock. See Note 1, Organization and Nature of Operations.

 

Letter of Intent for Sale of the Disposal Group

 

On November 1, 2026, the Company entered into a non-binding letter of intent, dated October 30, 2026 for the sale of the Disposal Group. The letter of intent is non-binding, and there can be no assurance that a definitive agreement will be entered into or that the sale will be completed on the terms contemplated or at all.

 

48

 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Special Note Regarding Forward Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,”, “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or our prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in our filings with the SEC, including our most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from us. We may not actually achieve the goals or plans described in our forward-looking statements, and such forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Investors should not place undue reliance on these statements. We assume no obligation and do not intend to update these forward-looking statements, except as required by law. 

 

Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. Actual outcomes or results may differ from anticipated results, sometimes materially. Factors that could cause actual results to differ include, but are not limited to: the ability of the combined company to achieve the identified synergies; the ability to integrate the FLYTE business into the Company and realize the anticipated strategic benefits of the transaction within the expected time-frames or at all; that such integration may be more difficult, time-consuming or costly than expected; that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers or suppliers) may be greater than expected following the closing of the transaction; the retention of certain key employees of FLYTE; the expected benefits and success of FLYTE’s business model; general economic conditions that are less favorable than expected; geopolitical developments and additional changes in international trade policies and relations, including tariffs; and the ability of our products and product candidates to compete effectively against current and future competitors.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025, and the following: our ability to continue as a going concern and to raise sufficient additional capital, on acceptable terms or at all, to fund our operations and repay our indebtedness as it comes due, including the remaining installments on the promissory note issued to Creatd and the notes that are currently in default; the substantial dilution that has resulted, and may continue to result, from conversions of our Series C, Series D and Series J Convertible Preferred Stock, the conversion prices of which were reduced to $1.00 per share in October 2026, and from future financings; our ability to maintain the listing of our common stock on the NYSE American, including its stockholders’ equity and low selling price standards, particularly because NYSE American rules limiting cumulative reverse stock split ratios may restrict our ability to effect another reverse stock split in the near term; our ability to integrate, operate and grow FLYTE’s private aviation business, which has historically generated losses and depends on a small fleet of leased aircraft, all of which are currently leased from SEG Jets LLC; our dependence on maintaining the FAA Part 135 operating certificate held by Ponderosa Air, LLC and on compliance with FAA and other aviation regulations; aviation accidents, incidents and related liabilities, and the availability and cost of insurance; the availability and cost of qualified pilots, aviation fuel, maintenance and third-party aircraft operator capacity; competition in the private aviation market; our ability to enter into a definitive agreement for, and complete, the sale of our VIVO and LockeT businesses on the terms currently contemplated or at all, and the risk that the proceeds of any such sale may be less than expected; our ability to fund, monetize or otherwise realize value from our retained cardiac electrophysiology assets, including the CPNS System held by Cardionomix; the material weaknesses in our internal control over financial reporting that we have previously identified; the potential concentration of ownership by our Chief Executive Officer and his affiliates upon conversion of the Series J Convertible Preferred Stock; litigation and other legal proceedings; disruptions in our information technology systems or those of third parties; and general economic, geopolitical and market conditions, including inflation, interest rates and tariffs, and the volatility of the market price of our common stock.

 

49

 

References to “we”, “us”, “our”, and “the Company” refer to Flyte Aviation, Inc.

 

Overview

 

Flyte Aviation, Inc. (formerly known as Catheter Precision, Inc.) (the "Company”) was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. The Company, then known as Ra Medical Systems, Inc., was initially formed to develop, commercialize, and market its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. On January 9, 2023, we merged with the former Catheter Precision, Inc. ("Old Catheter”), a privately held Delaware corporation (the "Merger”), which became our wholly owned subsidiary. Prior to our acquisition of FLYTE in 2026, our operating activities primarily related to Old Catheter's historical business, which included the design, manufacture and sale of medical technologies focused in the field of cardiac electrophysiology ("EP"). Following the acquisition of FLYTE and the classification of the VIVO and LockeT businesses as discontinued operations in September 2026, our continuing operations primarily relate to private aviation.

 

On February 17, 2025, we formed Cardionomix, Inc. ("Cardionomix"), an 82%-owned subsidiary. On May 5, 2025, Cardionomix acquired certain assets primarily related to the Cardiac Pulmonary Nerve Stimulation ("CPNS") System, a technology for the late-stage treatment of acute decompensated heart failure.

 

On February 6, 2026, we entered into a Securities Purchase Agreement with SEG Jets LLC ("SEG Jets"), whereby we agreed to acquire 19.98% of the issued and outstanding shares of common stock of Fly Flyte, Inc. ("FLYTE") held by SEG Jets in exchange for 5,250 shares of Series D Convertible Preferred Stock, par value of $0.0001 per share and stated value of $1,000 per share, for an aggregate stated value of $5.3 million. On March 9, 2026, we entered into a Stock Purchase Agreement with Creatd, Inc. ("Creatd"), whereby we acquired the remaining 80.02% of the issued and outstanding shares of common stock of FLYTE and all of FLYTE’s wholly owned consolidated subsidiaries, which included 100% equity ownership interest in Ponderosa Air, LLC ("Ponderosa"). As consideration for the acquired equity interests in FLYTE and Ponderosa, we agreed to pay $11.5 million as follows: (A) cash consideration of $0.7 million due at closing, (B) promissory note with a principal amount of $5.0 million, and (C) 5,778 shares of Series D Convertible Preferred Stock for an aggregate stated value of $5.8 million. As a result of these transactions, we now own 100% of the issued and outstanding common stock of FLYTE and its wholly owned consolidated subsidiaries. FLYTE and all of its wholly owned consolidated subsidiaries operate as a single business.

 

Effective October 5, 2026, the Company changed its legal name from Catheter Precision, Inc. to Flyte Aviation, Inc. In connection with the name change, the ticker symbol for the Company’s common stock listed on the NYSE American changed from “VTAK” to “VJET” effective October 5, 2026.

 

Following the acquisition of FLYTE, we now operate in two reportable segments: (i) cardiac electrophysiology and (ii) private aviation charter services. In September 2026, we classified the VIVO and LockeT businesses within the cardiac electrophysiology segment as discontinued operations and the related Disposal Group as held for sale. The planned disposition does not encompass all of our cardiac electrophysiology activities. See Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

Cardiac Electrophysiology Segment

 

Historically, our cardiac electrophysiology operations included the VIVO System, a non-invasive imaging system that provides three-dimensional cardiac mapping to assist in identifying the origin of certain ventricular arrhythmias, and LockeT, a suture retention device used to facilitate vascular access site closure following certain medical procedures. We began commercial sales of VIVO in the United States in 2021 and LockeT in 2024.

 

50

 

Private Aviation Segment

 

Through our wholly owned subsidiary, FLYTE, we operate a private aviation platform supported by a mobile application and website that facilitates access to private air travel at competitive price points. We offer regional and long-range private jet charter services throughout the United States, Canada, Mexico and the Caribbean through a combination of leased aircraft and third-party operator relationships. Customers book flights directly or place bids on available empty-leg flights in real time. We are also developing a local and regional air-taxi service intended to expand access to private aviation for middle-market travelers by offering shorter-distance flights at lower price points relative to traditional charter services.

 

Business Strategy

 

Our business strategy is focused on expanding our private aviation operations following the acquisition of FLYTE in 2026. In connection with this strategic focus, in September 2026, we classified our VIVO and LockeT businesses as discontinued operations and the related Disposal Group as held for sale. While we continue to retain certain cardiac electrophysiology activities and technologies, our primary strategic focus is on growing our private aviation business.

 

FLYTE is a technology-enabled regional air mobility company operating a growing fleet of leased Cirrus Vision Jets. Focused on high frequency, short haul markets, FLYTE provides a faster, safer, and more efficient alternative to commercial and existing private charter air travel. Flight operations are conducted through FLYTE’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, FLYTE is seeking to build a disciplined, asset-backed aviation infrastructure designed to serve underserved regional markets.

 

Recent Developments

 

Discontinued Operations and Assets Held for Sale

 

In September 2026, we classified our VIVO and LockeT businesses as discontinued operations and the related Disposal Group as held for sale in connection with our plan to sell these businesses as part of our strategic shift toward private aviation. These businesses were historically included in our cardiac electrophysiology reportable segment. The contemplated sale includes substantially all assets necessary to operate the VIVO and LockeT businesses, including intellectual property, inventory, property and equipment, and certain related liabilities. The planned disposition does not encompass our entire cardiac electrophysiology reportable segment, as certain other assets and activities, including AMIGO-related assets and Cardionomix's CPNS-related assets and activities, will be retained in continuing operations. As of September 30, 2026, we had not entered into a definitive sale agreement and anticipate completing the disposition within twelve months. On November 1, 2026, we entered into a non-binding letter of intent, dated October 30, 2026 for the sale of these businesses. There can be no assurance that a definitive agreement will be entered into or that the sale will be completed.

 

We determined that the planned disposition represents a strategic shift that has a major effect on our operations and financial results. Accordingly, the VIVO and LockeT businesses met the criteria for classification as held for sale and discontinued operations as of September 30, 2026. Upon classification as held for sale, we recognized a noncash loss on impairment of assets held for sale of approximately $12.5 million during the three and nine months ended September 30, 2026, which is included in discontinued operations. The results of these businesses have been presented as discontinued operations for all periods presented in our condensed consolidated statements of operations. See Note 4, Discontinued Operations and Assets Held for Sale, in the condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information.

 

Corporate Name Change and Reverse Stock Split

 
Effective October 5, 2026, we also changed our corporate name from Catheter Precision, Inc. to Flyte Aviation, Inc. 
On the same date, we effected a 1-for-10 reverse stock split of our issued and outstanding common stock. All common share and per-share amounts presented in our condensed consolidated financial statements for all periods have been retrospectively adjusted to reflect the reverse stock split. The number of common shares issuable upon exercise or conversion of outstanding options, warrants and convertible securities, together with the applicable exercise and conversion prices, were proportionately adjusted. 
In connection with the name change, our common stock began trading on the NYSE American under the ticker symbol "VJET," replacing our former ticker symbol "VTAK." See Note 1, Organization and Nature of Operations, in the condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information.
 
Financing Transactions

 

During the nine months ended September 30, 2026, we raised aggregate gross proceeds of approximately $18.7 million through the sale of common stock and

 

Series C-1, C-2, C-3 and C-4 Convertible Preferred Stock under the February 2026 SPA and the March 2026 SPA and the induced exercise of our Series L Warrants, and we issued 11,028 shares of Series D Convertible Preferred Stock as consideration in the FLYTE acquisition. In accordance with their terms, the conversion prices of the Series C and Series D Convertible Preferred Stock were reduced upon stockholder approval on April 15, 2026 and upon the effectiveness of the related resale registration statement on July 10, 2026. In connection with our waiver of the applicable floor prices, the conversion prices of our Series C and Series D Convertible Preferred Stock were reduced to $2.30 per share on August 10, 2026, and subsequently to $1.00 per share on October 9, 2026. During the three months ended September 30, 2026, holders converted 4,857 shares of Series C and 4,219 shares of Series D Convertible Preferred Stock into an aggregate of 1,741,040 shares of common stock, and as of September 30, 2026, 12,874 shares of Series C and 6,809 shares of Series D Convertible Preferred Stock remained outstanding. All outstanding shares of our Series B Convertible Preferred Stock were converted or repurchased during the period. In October 2026, we reduced the conversion price of the Series J Convertible Preferred Stock held by our Chief Executive Officer and his affiliate to $2.30 per share and subsequently to $1.00 per share, and certain existing investors agreed to purchase an additional 2,050 shares of Series C-4 Convertible Preferred Stock for gross proceeds of $2.05 million. See Note 13, Equity Offerings, Note 14, Preferred Stock, and Note 20, Subsequent Events, in the condensed consolidated financial statements included elsewhere in this Quarterly Report.

 

FLYTE Acquisition

 

As discussed above, we own 100% of the issued and outstanding common stock of FLYTE and 100% of the membership interests of Ponderosa as of March 9, 2026.


FLYTE is a technology-powered, private air transportation company. Founded in August 2018, FLYTE’s mission is to make private air travel a passenger-first, more inclusive and accessible mode of transportation, made possible through properly applied technology, use of more conveniently located existing infrastructure and operational efficiencies. FLYTE provides two distinct air travel services: Flyte Hops and Luxe. Flyte Hops operates short-haul charter routes using its own fleet of leased Cirrus Vision jets flown by pilots that are full-time employees of Flyte. Flyte manages marketing, customer booking, flight scheduling, and pricing, collects payment, purchases jet fuel, files the flight plan, uses its own aircraft flown by its own pilots to fly the customers, and maintains all necessary FAA certifications. Flyte Luxe matches passengers seeking airplanes larger than the Cirrus Vision or with longer range with appropriate third party aircraft and crews, providing private aviation coordination and bespoke travel experiences. We believe FLYTE is positioned to compete with operators focused on the emerging urban air mobility (“UAM”), regional air mobility (“RAM”) and advanced air mobility (“AAM”) markets, each of which is likely to consist primarily of short-range electric-powered aircraft using short take-off and vertical take-off and landing technology. 


The financial results of FLYTE are included in our unaudited condensed consolidated financial statements beginning March 10, 2026. As a result, the consolidated results of operations for the three and nine months ended September 30, 2026 reflect a full quarter and approximately seven months of contribution from FLYTE, respectively. The comparative consolidated results of operations for the three and nine months ended September 30, 2025 do not include any results of FLYTE. Investors are cautioned that period over period comparisons of our consolidated results of operations are not directly comparable as a result of the Acquisition. Additionally, the results of the VIVO and LockeT businesses are presented as discontinued operations for all periods, as discussed above.

 

Additional information regarding the FLYTE acquisition is set forth in our Current Report on Form 8-K filed with the SEC on February 6, 2026 and March 9, 2026 and in Note 3, Business Combination, of the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Trends and Uncertainties Relating to FLYTE

 

Unpredictable changes in economic conditions, including the effects of inflation, elevated interest rates, slowing or contracting gross domestic product, geopolitical instability, changes in international trade policy (including the imposition or escalation of tariffs), increased governmental intervention, and other macroeconomic factors, may adversely affect our general business strategy. Persistent or renewed inflationary pressure generally affects us by increasing our cost of labor, costs associated with our retained medical technology activities, and, with respect to FLYTE, our cost of aviation fuel and our cost of access to third-party aircraft operator capacity. Declining general economic, business or industry conditions, inflation, or a recession may have a material adverse effect on our future results of operations, liquidity and financial condition. We have also observed a continuing trend of higher third-party aircraft operator costs in the private aviation market, which could impact FLYTE’s short-term and long-term margins and profitability.

 

Substantially all of our revenue from continuing operations is generated by our Hops service, which is operated on a small fleet of Cirrus Vision Jets, all of which are currently leased from SEG Jets LLC under leases with remaining terms of approximately 11 to 19 months. As a result, our results of operations depend on the continued availability and utilization of these aircraft and on our ability to renew or replace these leases on acceptable terms, and the loss of, or extended maintenance downtime for, even one aircraft could materially reduce our revenue. Our Luxe charter brokerage business relies on third-party aircraft operators, and higher third-party operator costs, aircraft supply constraints or the failure of an operator to perform could result in delayed or cancelled flights, service credits or reduced margins in that business.

 

In addition, our results of operations for periods following the FLYTE acquisition will reflect, among other things, the amortization of acquired intangible assets, the depreciation of acquired property and equipment at stepped-up fair values, the remeasurements of our previously held minority equity interest and deferred consideration prior to settlement, the valuation of the preferred stock issued as part of the consideration for the FLYTE acquisition, and integration-related costs. These items did not affect our results of operations in periods preceding the FLYTE acquisition, and as a result, period-over-period comparisons of our results of operations may not be directly comparable.

 

See “Results of Operations” and “Liquidity and Capital Resources” below.

 

Supply Chain and Pilot Availability Relating to FLYTE

 

The execution of FLYTE’s business strategy is dependent on, among other things, the availability of aviation fuel at acceptable prices and our ability to hire and retain qualified pilots to support our Hops service. The supply of qualified pilots to the airline and private aviation industries has remained constrained, and demand for pilots may continue to outpace supply for the foreseeable future. Continued periods of significant disruption in the supply of aviation fuel, sustained increases in fuel prices, or difficulty in attracting and retaining qualified pilots could have a significant negative impact on our operating results, liquidity and financial condition.

 

Environmental Relating to FLYTE 

 

FLYTE is subject to increasingly rigorous federal, state, local and foreign laws and regulations relating to the protection of the environment and noise, including those relating to emissions to the air, discharges to surface and subsurface waters, safe drinking water, and the use, management, disposal and release of, and exposure to, hazardous substances, oils and waste materials. FLYTE may be subject to new laws and regulations that may have a material adverse effect on its operations. In addition, U.S. airport authorities continue to explore ways to limit de-icing fluid discharges. Any such existing, future, new or potential laws and regulations, including any future regulation of greenhouse gas emissions from aviation activities, could have a material adverse impact on our business, results of operations and financial condition.

 

2023 Equity Incentive Plan Amendment and Stock Option Repricing

 

On September 30, 2026, at our Annual Meeting of Stockholders, our stockholders approved an amendment to our 2023 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance under the plan. Our stockholders also approved a one-time repricing of outstanding stock options with exercise prices greater than the fair market value of our common stock on the date of approval. The repricing did not modify the number of shares underlying the affected stock options, their expiration dates or their vesting schedules. We recognized approximately $20 thousand of incremental stock-based compensation expense during the three and nine months ended September 30, 2026. See Note 15, Stock-Based Compensation, in the condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information.

 

Components of our Results of Operations for the Three and Nine Months Ended September 30, 2026 and 2025

 

 

51

 

Revenue

 

We generate service revenue through two primary private aviation charter services, (i) Hops and (ii) Luxe.

 

Hops is our short-haul private charter service, operated on aircraft that we lease, under the Part 135 certificate held by our subsidiary, Ponderosa Air, LLC. We act as principal for Hops flights and present Hops revenue on a gross basis. Luxe is our charter brokerage service, through which we arrange on-demand charters with third-party aircraft operators. We act as agent for Luxe flights and present Luxe revenue on a net basis. We recognize revenue upon completion of each flight segment. See Note 2, Summary of Significant Accounting Policies, in the condensed consolidated financial statements included elsewhere in this Quarterly Report. During the three and nine months ended September 30, 2026, approximately 1% of our revenue was derived from customers outside of the United States. The Company did not recognize any revenue from continuing operations during the three and nine months ended September 30, 2025.

 

Cost of revenues

 

Cost of revenues consists of primarily labor costs, fuel costs and landing fees related to our Hops aviation charter services.

 

Selling, general and administrative expenses

 

Selling, general and administrative (“SG&A”) expenses consist of employee-related costs, including salaries, benefits and stock-based compensation expenses. Other SG&A expenses include amortization of intangible assets, depreciation of fixed assets, professional services fees, including legal, audit and tax fees, insurance fees, general corporate expenses and facility-related expenses.

 

Acquired in-process research and development expenses

 

Assets that are acquired in an asset acquisition for use in research and development activities that have an alternative future use are capitalized as IPR&D. Acquired IPR&D that has no alternative future use as of the acquisition date is recognized as research and development expense as of the acquisition date.

 

Results of Operations for the Three and Nine Months Ended September 30, 2026 and 2025

 

The following table sets forth the results of the Company's operations for the periods presented (in thousands):

 

 

Three Months Ended September 30,

       

For the Nine Months Ended September 30,

       
 

2026

 

2025

 

Change

 

2026

 

2025

 

Change

 

Revenue

$ 1,838   $ —   $ 1,838   $ 2,771   $ —   $ 2,771  

Cost of revenues

  1,514     —     1,514     2,424     —     2,424  

Gross profit

  324     —     324     347     —     347  
                                     

Selling, general and administrative expenses

  2,780     1,191     1,589     6,939     3,522     3,417  

Research and development expenses

  —     —     —     —     2     (2 )

Acquired in-process research and development expenses

  —     —     —     —     1,967     (1,967 )

Change in fair value of minority equity interest

  —     —     —     (2,302 )   —     (2,302 )

Change in fair value of deferred consideration

  —     —     —     3,195     —     3,195  

Change in fair value of deferred stock issuance liability

  206     —     206     160     —     160  

Loss on debt extinguishment

  —     —     —     (105 )   —     (105 )

Gains on marketable securities, net

  162     —     162     540     —     540  

Other income (expense), net (1)

  (228 )   34     (262 )   (545 )   (51 )   (494 )

Loss from continuing operations before income taxes

  (2,316 )   (1,157 )   (1,159 )   (5,649 )   (5,542 )   (107 )

Income tax benefit (provision)

  463     (78 )   541     950     1,596     (646 )

Loss from continuing operations

  (1,853 )   (1,235 )   (618 )   (4,699 )   (3,946 )   (753 )

Loss from discontinued operations, net of tax

  (13,268 )   (1,109 )   (12,159 )   (15,418 )   (7,901 )   (7,517 )

Net loss

  (15,121 )   (2,344 )   (12,777 )   (20,117 )   (11,847 )   (8,270 )

 

(1)          Constitutes the operating activities within other income (expense), net in the condensed consolidated statements of operations, change in fair value of minority equity interest, change in fair value of deferred consideration, change in fair value of deferred stock issuance liability, loss on debt extinguishment and gains on marketable securities, net that are presented separately in the table above.

 

52

 

Revenues

 

The increase in revenue of approximately $1.8 million and $2.8 million for the three and nine months ended September 30, 2026 respectively, as compared to the corresponding periods in the prior year was due to the acquisition of FLYTE during the period, which contributed a revenue stream private aviation charter services.

 

Cost of revenues

 

The increase in cost of revenues of approximately $1.5 million and $2.4 million for the three and nine months ended September 30, 2026, as compared to the corresponding periods in the prior year was primarily due to an increase in cost of revenues associated with the increase in private charter aviation services following the acquisition of FLYTE.

 

Selling, general and administrative expenses

 

Selling, general and administrative expenses increased approximately $1.6 million and $3.4 million for the three and nine months ended September 30, 2026, respectively, as compared to the corresponding periods in the prior year. This is primarily due to an increase of $0.2 million and $1.0 million in professional fees, respectively, such as accounting and legal fees, an increase of $0.3 million and $0.6 million in salaries and benefits, respectively, related to the personnel costs within the newly acquired private charter aviation services and an increase of $0.3 million and $0.5 million in marketing, respectively, related to advertising expenses incurred within the newly acquired private charter aviation services. In addition, there was an overall increase of $0.4 million and $0.9 million in other selling, general and administrative expenses incurred following the acquisition of FLYTE during the year.

 

Research and development expenses

 

We did not incur research and development expenses during the three and nine months ended September 30, 2026. We incurred minimal research and development expenses of $2 thousand during the nine months ended September 30, 2025 related to Cardionomix operations.

 

53

 

Acquired in-process research and development expenses

 

We did not incur any acquired in-process research and development expenses during the three and nine months ended September 30, 2026. 

 

The decrease in acquired in-process research and development expenses of approximately $2.0 million for the nine months ended September 30, 2026, as compared the corresponding period in the prior year primarily relates to the two asset acquisitions completed in 2025. On January 24, 2025, we acquired 100% of the membership interests of Perikard, LLC, which was accounted for as an asset acquisition consisting primarily of a single patent for pericardial access technology. The patent was determined to be IPR&D with no alternative future use, and accordingly, we recognized $0.1 million as acquired in-process research and development in the condensed consolidated statements of operations for the three months ended March 31, 2025. On May 5, 2025, we acquired certain assets primarily related to Cardionomic’s CPNS System, which were deemed to be IPR&D assets with no alternative future use. Accordingly, we recognized $1.9 million, consisting of $0.3 million in stock consideration, $1.3 million in note payable, and $0.3 million in direct transaction costs, as acquired in-process research and development in the condensed consolidated statements of operations for the nine months ended September 30, 2025.

 

Change in fair value of minority equity interest

 

The decrease of $2.3 million during the nine months ended September 30, 2026 represents the change in fair value of our initial minority equity interest of 19.98% in FLYTE from $5.2 million as of February 6, 2026 to $2.9 million as of March 9, 2026, the date we acquired a controlling equity interest in FLYTE. The fair value of the investment was determined based on the implied transaction value of FLYTE, which was derived from the purchase price paid to acquire the remaining 80.02% interest in FLYTE. 

 

Change in fair value of deferred consideration

 

Prior to its settlement on April 20, 2026, the fair value of the deferred consideration payable incurred in connection with the FLYTE Acquisition was remeasured at fair value. The gain of $3.2 million recognized for the nine months ended September 30, 2026 as compared to the corresponding period in the prior year reflects the decrease in fair value of the Series D Convertible Preferred Stock issuable to the sellers, primarily due to the decline in our common stock price between the acquisition dates and the April 20, 2026 settlement.

 

Change in fair value of deferred stock issuance liability 

 

On June 28, 2026, we received advanced proceeds of $0.6 million from an investor in exchange for the future issuance of the Series C-3 Convertible Preferred Stock pursuant to the February and March 2026 SPAs. The advanced proceeds were recorded as a deferred stock issuance payable that was subject to remeasurement at each reporting period. The increase of $0.2 million in the change in fair value of deferred stock issuance liability for the three and nine months ended September 30, 2026 as compared to the corresponding periods in prior year, is due to the remeasurement gain recorded during the periods. The deferred stock issuance liability was settled on July 15, 2026, when we issued 601 shares of Series C-3 Convertible Preferred Stock to the investor, such that no deferred stock issuance liability remained outstanding as of September 30, 2026.

 

Loss on debt extinguishment

 

On June 22, 2026, we prepaid the outstanding balance of the convertible notes payable of $0.3 million by paying $0.4 million in cash. As a result, we recognized a loss on debt extinguishment of $0.1 million for the nine months ended September 30, 2026.

 

Gains on marketable securities, net

 

In June 2026, we invested $1.0 million in shares of common stock of Volato Group, Inc. and received shares of flyExclusive, Inc. common stock as additional consideration for our participation as lead investor. The combined investments had an estimated fair value of $1.5 million on the day of settlement. During the three and nine months ended September 30, 2026, we sold all Volato Shares and FLYX Shares and recognized net gains of $0.2 million and $0.5 million, respectively. 

 

We did not have any similar investments in the three and nine months ended September 30, 2025.

 

Other income (expense), net

 

The increase in other expense of $0.3 million and $0.5 million for the three and nine months ended September 30, 2026 respectively, as compared to the corresponding periods in the prior year, primarily relates to an increase in interest expense of cumulatively $0.1 million and $0.3 million, respectively, primarily associated with the promissory note issued to Creatd, Inc. and the assumed notes in connection with the FLYTE Acquisition in March 2026. In addition, the increases in other expense were attributable to the absence of gains from changes in fair value of trading debt securities of approximately $0.1 million for each of the corresponding periods in the prior year.

 

Income tax benefit (provision)

 

The increase in income tax benefit of approximately $0.5 million for the three months ended September 30, 2026, and decrease in income tax benefit of approximately $0.6 million for the nine months ended September 30, 2026, as compared to the corresponding periods in the prior year primarily relates to changes in the estimated amount of net operating losses that are not subject to limitations under Section 382 of the Internal Revenue Code.

 

Loss from discontinued operations, net of tax

 

Loss from discontinued operations, net of tax, increased approximately $12.2 million and $7.5 million for the three and nine months ended September 30, 2026, respectively, compared to the corresponding periods in the prior year. These increases were primarily attributable to a noncash loss on impairment of assets held for sale of approximately $12.5 million recognized during the three months ended September 30, 2026 in connection with the planned disposition of the VIVO and LockeT businesses. Excluding this impairment, losses from discontinued operations decreased approximately $0.3 million and $5.0 million for the three and nine months ended September 30, 2026, respectively, compared to the corresponding periods in the prior year, reflecting lower operating expenses and changes in the fair value of royalties payable due to related parties. See Note 4, Discontinued Operations and Assets Held for Sale, for additional information.

 

Liquidity and capital resources

 

As of September 30, 2026, we had cash and cash equivalents of $2.4 million and an accumulated deficit of $329.6 million. For the nine months ended September 30, 2026, net cash used in operating activities was $10.2 million. We have incurred recurring net losses from operations and negative cash flows from operating activities since inception. 

 

In February and March 2026, we raised gross proceeds of $4.1 million in connection with the February and March 2026 SPAs. We also raised gross proceeds of $0.4 million through the induced exercise of certain existing warrants. The related conversions of the Series B Convertible Preferred Stock into common stock were noncash transactions. In April 2026, we raised gross proceeds of $3.5 million in connection with the Second Tranche of the February 2026 and March 2026 SPAs. In addition, in July 2026, we raised gross proceeds of $3.5 million in connection with the Third Tranche of the February and March 2026 SPAs and $2.8 million in connection with the Fourth Tranche of the March 2026 SPA. In addition, we raised gross proceeds of $4.5 million in August 2026 in connection with the Fourth Tranche of the March 2026 SPA. On October 9, 2026, certain existing investors agreed to purchase an additional $2.05 million of Series C-4 Convertible Preferred Stock pursuant to the Fourth Tranche of the March 2026 SPA.

 

As a result of the FLYTE Acquisition, we paid $0.7 million in cash at closing to Creatd and issued a promissory note with a principal amount of $5.0 million and an interest rate of 0% per annum to Creatd. In addition, during the nine-month period ended September 30, 2026, we also issued several Bridge Notes with an aggregate principal balance of approximately $2.4 million and interest rates of 12% per annum. During the nine months ended September 30, 2026, we settled all Bridge Notes, including the accrued interest, such that no Bridge Notes remain outstanding as of September 30, 2026. 

 

We used some of the proceeds from the Bridge Notes to settle the convertible notes payable for $0.4 million and recorded a loss on debt extinguishment of $0.1 million for the nine months ended September 30, 2026. We further invested $1.0 million in shares of common stock of Volato Group, Inc. and received shares of flyExclusive, Inc. common stock as additional consideration for our participation as lead investor in the transaction. During the three and nine months ended September 30, 2026, we sold all remaining shares of both companies for aggregate proceeds of approximately $1.4 million and $1.5 million, respectively. Accordingly, no marketable securities remained outstanding as of September 30, 2026.

 

54

 

We expect operating losses and negative cash flows to continue for the foreseeable future unless our sales and gross profit increase sufficiently to cover our operating expenses. We expect our current operating expenses to remain relatively fixed for the near term, absent entering into a transformative strategic transaction. Our future liquidity requirements may also be affected by our planned disposition of the VIVO and LockeT businesses, which were classified as held for sale and discontinued operations as of September 30, 2026. On November 1, 2026, we entered into a non-binding letter of intent for the sale of these businesses; however, the letter of intent is non-binding, and we cannot assure you that the sale will be completed or as to the amount or timing of any proceeds. We believe that our cash on hand of $1.5 million as of November 10, 2026 will not be sufficient to fund our current operations. Further, we have outstanding short-term notes that are due or past due, including the notes payable of variable interest entities due to related parties that matured in July 2026 and remained outstanding as of September 30, 2026, the notes payable issued to Creatd with monthly installment payments due through December 2026, and Assumed Notes assumed in the FLYTE Acquisition that are past due.

 

We estimate that we will require additional capital over the next twelve months to:

 

●

Support the operations and growth of our private aviation segment, including aircraft lease payments, maintenance, and working capital needs;

 

●

Meet debt service obligations; and
 

●

Address general corporate purposes and working capital requirements.
     

As noted above, as of September 30, 2026, we have debt obligations due within the next twelve months. If we are unable to refinance or extend these obligations prior to maturity, we will be required to repay them from cash on hand or from proceeds of additional financing, which may not be available on acceptable terms or at all.

 

Because expected revenues are not adequate to fund our planned expenditures and anticipated operating costs and liabilities beyond such point, we are currently evaluating potential means of raising cash, as described below, to fund our operations and to pay our debts as they come due. If we are unable to do so, we will be required to reduce our spending to align with expected revenue levels and cash reserves, although there can be no guarantee that we will be successful in doing so. If we are unable to reduce our spending sufficiently, we may be required to suspend a portion or all of our operations and/or potentially seek relief from our creditors. We may not be able to secure financing in a timely manner or on favorable terms, if at all. Due to the challenging economic environment, we have explored and continue to explore a wide variety of possible capital-raising and strategic transactions, including but not limited to private equity offerings, registered issuances, and credit facilities, as well as other innovative and specialty finance strategies or business combinations. There is no guarantee that we will succeed in securing the financing or other strategic transaction needed to sustain our company or that any such transaction will be on our preferred terms.

 

Management's plans to address our liquidity needs include actively pursuing multiple strategies to obtain the capital necessary to continue operations, including equity financing, debt financing, and strategic transactions. We have engaged a financial advisor to assist in evaluating these alternatives. However, there can be no assurance that any strategic transaction will be successfully completed, and any such transaction may not occur on terms favorable to us or our stockholders.

 

As a result of these factors, we have concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date the condensed consolidated financial statements for the quarter ended September 30, 2026 are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should we be unable to continue as a going concern and the outcome of this uncertainty.

 

Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (in thousands)

 

   

For the Nine Months Ended September 30,

 
   

2026

   

2025

 

Net cash provided by (used in):

               

Operating activities

  $ (10,156 )   $ (6,784 )

Investing activities

    (867 )     (51 )

Financing activities

    13,328       5,037  

Net change in cash and cash equivalents

  $ 2,305     $ (1,798 )

 

Net cash used in operating activities

 

During the nine months ended September 30, 2026, net cash used in operating activities of $10.2 million primarily related to the net loss of $20.1 million, a decrease in change in fair value of deferred consideration of $3.2 million, a decrease in operating assets and liabilities of $2.7 million, a decrease in deferred income tax benefit of $1.0 million and a gain on marketable securities of $0.5 million. This was partially offset by non-cash adjustments related to loss on impairment of assets held for sale of $12.5 million, an increase in change in fair value of minority equity interest of $2.3 million and depreciation and amortization of $1.2 million.

 

During the nine months ended September 30, 2025, net cash used in operating activities of $6.8 million primarily related to the net loss of $11.8 million and a decrease in deferred income tax benefit of $1.6 million. This was partially offset by non-cash adjustments related acquired in-process research and development of $2.0 million, a change in fair value of royalties payable due to related parties of $2.1 million, and depreciation and amortization of $1.6 million.

 

55

 

Net cash used in investing activities

 

During the nine months ended September 30, 2026, net cash used in investing activities of $0.9 million primarily related to the FLYTE acquisition of $1.2 million and the purchase of $1.0 million of marketable securities from Volato. This is partially offset by the proceeds from the sales of marketable securities of $1.5 million. 

 

During the nine months ended September 30, 2025, net cash used in investing activities of $51 thousand consisted of purchases of property and equipment of $17 thousand and purchases of acquired in-process research and development of $34 thousand. 

 

Net cash provided by financing activities

 

During the nine months ended September 30, 2026, net cash provided by financing activities of $13.3 million consisted of net proceeds from issuance of common stock and other equity-classified contracts of $16.3 million, proceeds from notes payable of $2.9 million, proceeds from deferred stock issuance payable of $0.6 million, and proceeds from the exercise of warrants of $0.4 million, partially offset by $6.9 million in payments on notes payable and cash consideration paid for the repurchase of Series B preferred stock of $0.3 million.

 

During the nine months ended September 30, 2025, net cash provided by financing activities of $5.0 million primarily consisted of proceeds from issuance of common stock and other equity-classified contracts of $4.9 million and proceeds from notes payable of $0.3 million, partially offset by $0.1 million in payments on notes payable.

 

Off-balance sheet arrangements

 

We have not engaged in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, as a part of our ongoing business. Accordingly, we did not have any off-balance sheet arrangements during any of the periods presented.

 

The Company’s Critical Accounting Estimates

 

The information set forth below relates to our critical accounting policies and estimates. Critical accounting estimates are those that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition and results of operations. Our estimates are based on current facts, historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Accordingly, a different financial presentation could result depending on the judgments, estimates or assumptions that are used. However, we do not believe that actual results will deviate materially from our estimates related to our accounting policies described below but, because application of these accounting policies involves the exercise of judgment and the use of assumptions as to future uncertainties, actual results could differ materially from these estimates. Therefore, we consider an understanding of the variability and judgment required in making these estimates and assumptions to be critical in fully understanding and evaluating our reported financial results.

 

The discussion and analysis of our financial position and results of operations is based on our condensed consolidated financial statements included elsewhere in this Quarterly Report, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We regularly evaluate estimates and assumptions related to asset acquisitions, including the provisions for legal contingencies, income taxes, deferred income tax asset valuation allowances, royalties payable, share based compensation, evaluation of impairment of long-lived assets, valuation of long-lived assets and their associated estimated useful lives, and revenues. 

 

In addition, we regularly evaluate estimates and assumptions related to business combinations, including the determination of the purchase price and related allocations to the fair value of assets acquired and liabilities assumed, provisions for legal contingencies, income taxes, deferred income tax asset valuation allowances, valuation of warranties liabilities, royalties payable, share based compensation, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, and revenues. Our estimates are based on current facts, historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

 

56

 

We believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.

 

Accounting for long-lived assets - estimated useful lives

 

Intangible assets acquired from business combinations are initially measured at their estimated fair values and are then amortized on a straight-line basis over their estimated useful lives. Management evaluates whether events or circumstances have occurred that indicate the remaining useful life or carrying value of the amortizing intangible assets should be revised and adjusted, if necessary. 

 

Accounting for impairment of long-lived assets 

 

We periodically review our long-lived assets for impairment whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value of the long-lived assets may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the assets carrying value over its fair value is recorded in our condensed consolidated statements of operations at that date. In connection with the classification of the VIVO and LockeT businesses as held for sale in September 2026, we measured the related Disposal Group at the lower of its carrying amount or estimated fair value less costs to sell. Determining the estimated fair value less costs to sell requires significant management judgment, including assumptions regarding the anticipated proceeds from the disposition and estimated costs to sell. As a result of this assessment, we recognized a noncash loss on impairment of assets held for sale of approximately $12.5 million during the three and nine months ended September 30, 2026. Changes in the underlying assumptions or the anticipated terms of the disposition could result in additional adjustments to the carrying amount of the Disposal Group.

 

57

 

Royalties payable

 

We are obligated to pay royalties related to the sales of AMIGO System under various royalty agreements executed by Old Catheter. We recognize a liability for royalty fees incurred and payable based on actual sales of products under current portion of royalties payable in the condensed consolidated balance sheets. We recognize a liability for future, estimated royalty payments at fair value under current portion of royalties payable in the condensed consolidated balance sheets if it is payable within the next 12 months and under royalties payable in the condensed consolidated balance sheets if it is payable 12 months after the balance sheet date. The royalties payable are remeasured at each reporting period. Changes in fair value of royalties payable are recorded on the condensed consolidated statements of operations in the period in which they occur. 

 

The fair value measurement of royalties payable includes significant unobservable inputs that are not supported by any market data. Royalties payable equal the present value of estimated future royalty payments. We apply an internally developed, revenue adjusted discount rate (“RADR”) to discount back the forecasted royalty payments. The RADR is based on the Company’s weighted average cost of capital (“WACC”) adjusted for the product revenue’s risk profile. The risk-free rate used to determine the cost of equity for the RADR is adjusted to be commensurate with the term of the royalty agreements. Furthermore, the Beta and Risk Premium used to determine the cost of equity are also adjusted to reflect the product revenue's volatility. All other inputs for the RADR and our WACC are the same. The RADR was 19.5% as of September 30, 2026 and December 31, 2025.

 

Goodwill and Other Intangible Assets

 

We use the acquisition method of accounting, in accordance with ASC Topic 805, “Business Combinations” ("ASC Topic 805") to allocate costs of acquired businesses to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess costs of acquired businesses over the fair values of the assets acquired and liabilities assumed are recognized as goodwill. The valuations of the acquired assets and liabilities will impact the determination of future operating results. Determining the fair value of assets acquired and liabilities assumed requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, revenue growth rates and earnings before interest, taxes, depreciation and amortization, margins, discount rates, customer attrition rates, royalty rates, asset lives and market multiples, among other items. We determine the fair values of intangible assets acquired generally in consultation with third-party valuation advisors. Any fair value adjustments to the assets and liabilities are recognized and the results of operations of the acquired business are included in our condensed consolidated financial statements from the effective date of the acquisition.

 

New Accounting Pronouncements

 

See Note 2 in the condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of new accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position, and cash flows as applicable. 

 

58

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Executive Chairman of the Board and Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2026. Our objective in designing our disclosure controls and procedures is that they provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon this evaluation, management has concluded that our disclosure controls and procedures were effective as of September 30, 2026 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.  Our independent registered public accounting firm, WithumSmith+Brown, PC ("Withum"), is not required to and has not issued an attestation report as of September 30, 2026, because we are not an "accelerated filer" or a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended March 31, 2026 and as noted elsewhere in this Form 10-Q, the Company completed the acquisition of FLYTE. The Company has elected to exclude FLYTE from management's assessment of internal control over financial reporting for the period from the acquisition date through September 30, 2026, and intends to integrate FLYTE into the Company's internal control over financial reporting during the year following the acquisition.

 

Except for the matters set forth above, there have been no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2026, which were identified in connection with management's evaluation required by paragraph (d) of Rule 13a-15 under the Securities Exchange Act of 1934, as amended, and that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

 

Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

59

 

 

 

PART II. — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be involved in litigation that arises through the normal course of business.  As of the date of this filing and except as set forth below, we are neither a party to any litigation nor are we aware of any such threatened or pending litigation which we believe might result in a material adverse effect to our business.

 

In connection with the FLYTE acquisition, the Company assumed certain contingent liabilities, including an employment dispute with a former FLYTE employee alleging wrongful termination. The matter is currently proceeding through arbitration.

 

ITEM 1A. RISK FACTORS

 

Summary Risk Factors

 

Our business, financial condition and results of operations are subject to numerous risks and uncertainties, including those relating to the acquired business of our wholly-owned subsidiary, Fly Flyte, Inc. (“FLYTE”) and our recent equity financings. The following is a summary of the principal risks relating to the aviation industry and the FLYTE business that you should consider, in addition to the other information set forth in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed with the SEC on March 31, 2026. This summary is qualified in its entirety by the more detailed discussion of these and other risks set forth in the remainder of this “Risk Factors” section and elsewhere in this Form 10-Q. The occurrence of any of the following risks could materially and adversely affect our business, financial condition, results of operations, cash flows and the trading price of our common stock.

 

Risks relating to the aviation business of FLYTE

 

 

●

Demand for private aviation services is sensitive to general economic conditions, including recession, persistent inflation and elevated interest rates, and a decrease in demand could have a material adverse effect on FLYTE’s business.

 

 

●

The private aviation industry is highly competitive, and many of FLYTE’s competitors have substantially greater resources and broader operations than FLYTE.

 

 

●

FLYTE relies on a wide range of third-party service providers, and disruptions affecting such providers could adversely affect FLYTE’s operations.

 

 

●

FLYTE’s ability to operate depends on its ability to attract and retain qualified personnel, including pilots, in a constrained labor market, and labor cost increases, work stoppages or unionization could adversely affect FLYTE’s business.

 

 

●

Significant or sustained increases in aviation fuel prices, and the limited availability of sustainable aviation fuel at acceptable prices, could materially increase FLYTE’s operating costs.

 

 

●

FLYTE’s insurance may not be adequate to cover all liabilities that we may incur, and insurance coverage for the aviation industry may become more difficult or expensive to obtain.

 

 

●

FLYTE is exposed to factors beyond its control, including air traffic congestion, weather, natural disasters, climate change, public health emergencies, terrorist activities and geopolitical instability, any of which could disrupt FLYTE’s operations and harm our business.

 

 

●

The market for short-range flights, including the urban, regional and advanced air mobility markets, is in early stages of development, and may not develop as anticipated or on a timeline favorable to FLYTE’s business model.

 

 

●

The safe operation of aircraft is critical to FLYTE’s business, and any accident or incident involving FLYTE or other private aviation operators, or any damage to FLYTE’s reputation or brand, could materially adversely affect demand for FLYTE’s services.

 

 

●

FLYTE’s customer base is concentrated in certain geographic regions of the United States, making us vulnerable to adverse developments in those regions.

 

60

 

Risks relating to FLYTE’s reliance on third-party aircraft operators

 

 

●

FLYTE relies on third-party aircraft operators for substantially all flights other than those operated under its Flewber Hops air-taxi service, and any failure of such operators to perform, or any disruption affecting such operators, could materially adversely affect FLYTE’s operations.

 

 

●

Trends of higher third-party aircraft operator costs, capacity constraints, indemnification obligations to such operators, and potential gaps in insurance coverage relating to third-party operations each expose us to operational and financial risk.

 

Risks relating to FLYTE’s intellectual property and technology

 

 

●

If FLYTE is unable to adequately protect its intellectual property and its proprietary technology, or if FLYTE is found to infringe the intellectual property rights of others, our business could be materially adversely affected.

 

 

●

Failures, interruptions or security breaches affecting FLYTE’s technology infrastructure or the third-party platforms on which FLYTE relies (including cloud hosting providers and mobile application marketplaces) could harm FLYTE’s operations, reputation and customer relationships.

 

 

●

FLYTE’s collection and use of personal information subjects FLYTE to evolving privacy and data protection laws, including the CCPA and the GDPR, the noncompliance with which could result in significant fines, penalties and reputational harm.

 

Legal and regulatory risks relating to FLYTE’s business

 

 

●

FLYTE is subject to significant governmental regulation by the U.S. Department of Transportation, the Federal Aviation Administration, the Transportation Security Administration and other federal, state and local agencies, and changes in laws or regulations, or new interpretations thereof, could have a material adverse effect on FLYTE’s business.

 

 

●

Any suspension, revocation, modification or non-renewal of permits, approvals, authorizations or licenses required for FLYTE’s operations could have a material adverse effect on our business.

 

 

●

FLYTE is subject to environmental, noise and emissions laws and regulations — and to evolving climate-related restrictions on aviation activity — the cost of compliance with which, or the expansion of which to FLYTE’s operations, could materially adversely affect our business.

 

 

●

FAA or manufacturer operating restrictions, airworthiness directives or similar requirements affecting FLYTE’s owned Cirrus SF50 Vision Jet, or any aircraft type on which FLYTE’s third-party aircraft operators rely, could materially disrupt FLYTE’s operations.

 

 

●

From time to time, FLYTE may become involved in litigation or regulatory proceedings, the outcome of which is inherently uncertain and which could have a material adverse effect on our business.

 

Risks relating to dilution from our convertible preferred stock

 

 

●

Conversion of our outstanding Series B, Series C-1, Series C-2, Series C-4, Series C-4, Series D and Series J Convertible Preferred Stock could result in substantial dilution to our existing common stockholders.

 

 

●

The issuance and conversion of additional Series C-4 Convertible Preferred Stock under our existing Securities Purchase Agreements could result in extraordinary additional dilution to our existing common stockholders.

 

 

●

The conversion price of each of our Series C-1, Series C-2, Series C-3, Series C-4 and Series D Convertible Preferred Stock was subject to a floor that we may waive in our sole discretion, which we elected to do on August 10, 2026, and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3, Series C-4 and Series D to $0.23 and such reduction will likely substantially increase the additional dilution to our existing common stockholders.

 

 

●

The existence of these contingent issuance and conversion rights may itself adversely affect the trading price of our common stock.

 

61

 

Risks Related to the Aviation Business of FLYTE

 

FLYTE is exposed to the risk of a decrease in demand for private aviation services.

 

Fly Flyte, Inc. (“FLYTE”) historically has generally provided private aviation services to individuals and individual entities on a per-trip basis, without use of a membership-only program business model. A decrease in demand for private aviation services could materially and adversely impact FLYTE’s operations and revenues. We believe that demand for private aviation services is sensitive to general economic conditions and to customers’ perceptions of the strength of the economy, including the possibility of recession, persistent inflation, elevated interest rates and other macroeconomic factors. A weaker economy or customers’ perception of a weaker economy could result in a decrease in demand for FLYTE’s services leading to future periods in which we generate less revenue from the FLYTE business than we presently expect. If demand for private aviation services decreases, this could result in slower growth, or contraction, in the FLYTE business, which could have a material adverse effect on our business, financial condition and results of operations.

 

In addition, customers may consider private air travel through FLYTE’s products and services to be a luxury item, especially when compared to commercial air travel. As a result, any general downturn in economic, business and financial conditions which has an adverse effect on customers’ spending habits could cause them to travel less frequently and, to the extent they do travel, to travel using commercial air carriers or other means considered to be more economical. In addition, in cases where sufficient hours of private flight are needed, many of the companies and high-net-worth individuals to whom FLYTE provides products and services have the financial ability to purchase their own jets or operate their own corporate flight department should they elect to do so. These circumstances could negatively impact our cash flows from operations, accelerate our liquidity needs and require us to seek alternate sources of capital, which may not be available or on acceptable terms.

 

The private aviation industry is subject to intense competition.

 

Many of the markets in which FLYTE operates are competitive as a result of the continuing expansion of existing private aircraft charter brokerage businesses, on-demand operators, fractional ownership programs, jet card programs, membership-based programs, charter operators and traditional commercial airlines. Some of FLYTE’s competitors have substantially greater financial, technical, marketing and other resources than FLYTE does, longer operating histories, larger customer bases, broader geographic coverage, larger fleets, greater brand recognition and more established relationships with third-party aircraft operators, airports, fixed-base operators and other aviation service providers. We cannot assure investors that FLYTE will be able to compete successfully against current or future competitors, or that competitive pressures will not have a material adverse effect on our business, financial condition and results of operations.

 

If FLYTE experiences problems with any of its third-party service providers, its operations could be adversely affected.

 

FLYTE’s reliance upon others to provide essential services on behalf of its operations may limit our ability to control the efficiency, timeliness and regulatory compliance of those services. FLYTE relies on third parties to provide a wide range of essential services, including, but not limited to, third-party aircraft operators, fixed-base operators, fueling services, ground handling, maintenance and repair services, catering, de-icing, baggage handling, security and other operational services. Any failure of, disruption of, or interruption in, the services provided by such third parties, or any deterioration in the financial condition or business operations of such third parties, could have a material adverse effect on FLYTE’s operations, customer service and reputation, and, in turn, could materially and adversely affect our business, financial condition and results of operations.

 

62

 

The loss of key personnel upon whom FLYTE depends to operate its business, or its inability to attract additional qualified personnel, could materially and adversely affect FLYTE’s operations.

 

We believe that the future success of the FLYTE business will depend in large part on FLYTE’s ability to retain or attract highly qualified management, technical, operational, sales and marketing personnel, including qualified pilots, mechanics and other aviation specialists. Competition for such personnel in the aviation industry is intense, and we may not be able to retain or attract such personnel, or to do so on a cost-effective basis. The loss of one or more members of FLYTE’s senior management team or other key employees, or the failure to attract additional qualified personnel, could have a material adverse effect on FLYTE’s business and on our business, financial condition and results of operations.

 

The supply of qualified pilots is constrained and may negatively affect FLYTE’s operations and financial condition, and increases in labor costs may adversely impact FLYTE’s profitability.

 

The supply of qualified pilots to the aviation industry, including commercial airlines, business aviation operators and private aviation operators, has been constrained for an extended period, and demand for qualified pilots may continue to outpace supply for the foreseeable future. Pilots who operate aircraft for the third-party aircraft operators on which FLYTE’s charter brokerage operations rely, as well as pilots who operate FLYTE’s Cirrus Jet under its Hops air-taxi service, are increasingly being recruited by major commercial airlines and other operators that may offer higher compensation, better benefits or more predictable schedules. Increases in pilot compensation and benefits, including those that may result from collective bargaining, regulatory changes affecting pilot training, qualification or duty-time requirements, or competitive pressures, could substantially increase FLYTE’s labor costs and operating expenses, which could have a material adverse effect on our business, financial condition and results of operations.

 

In addition, FLYTE’s operations and financial condition may be negatively impacted if it is unable to train or qualify pilots in a timely manner to meet the needs of its operations. On occasion, FLYTE may rely on commercial airlines to fly its pilots to a departure location for a Hops flight. Any disruption to such commercial air travel could adversely impact our ability to operate flights as scheduled and could harm FLYTE’s reputation, business and operating results.

 

Pilot attrition may negatively affect FLYTE’s operations and financial condition.

 

In recent years, FLYTE has experienced volatility in pilot attrition, including volatility resulting from pilot wage and bonus changes at competing operators. If FLYTE experiences a sustained increase in pilot attrition, our ability to operate flights on time and as scheduled could be impaired, and FLYTE may incur substantial additional costs to recruit, train and retain replacement pilots, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE may be subject to unionization, work stoppages, slowdowns or increased labor costs, and the unionization of pilots or other employees could materially and adversely affect FLYTE’s operations.

 

FLYTE’s business is labor intensive. While FLYTE’s employees and independent contractors, particularly its pilots and other operational personnel, are not currently represented by a labor union, we may not be able to maintain this status in the future. If any of FLYTE’s employees were to unionize, we could be subject to risks of work stoppages, work slowdowns, strikes and other labor disputes, as well as increased labor costs, all of which could have a material adverse effect on FLYTE’s business and operations and, in turn, on our business, financial condition and results of operations.

 

63

 

Significant increases in fuel costs could have a material adverse effect on FLYTE’s business, financial condition and results of operations.

 

Aviation fuel is essential to the operation of aircraft and to FLYTE’s ability to carry out its transportation services. Fuel costs are subject to wide fluctuations as a result of a number of factors outside of our control, including, but not limited to, changes in global supply and demand, geopolitical events, government taxes and regulations, refining capacity, transportation and storage costs, and seasonality. Significant or sustained increases in aviation fuel prices could materially increase the operating costs of FLYTE’s third-party aircraft operators (which are typically passed through to FLYTE in the form of higher charter rates) and could materially increase the operating costs of FLYTE’s Hops air-taxi service that uses FLYTE’s owned Cirrus Jet.

 

Additionally, sustainable aviation fuel is not currently readily available at prices that are not prohibitive. In the future, if FLYTE elects, or is required by law or regulation, to operate using sustainable aviation fuel, the increased cost of doing so could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE’s insurance may become too difficult or expensive to obtain, and if FLYTE is unable to maintain sufficient insurance, our business could be materially and adversely affected.

 

Hazards are inherent in the aviation industry and may result in loss of life and property, potentially exposing FLYTE and us to substantial liability claims. While FLYTE maintains insurance of types and in amounts that we believe to be customary in the industry, the insurance industry, including aviation insurance, may experience periods of significant cost increases, reduced capacity or restrictive policy terms and conditions, and FLYTE’s insurance coverage may not be adequate to cover all liabilities that we may incur. There can be no assurance that, in the future, FLYTE will be able to obtain insurance coverage of the types and in the amounts that we believe to be appropriate at acceptable cost, or that the coverage FLYTE does obtain will be adequate to protect us from all liabilities and losses that may arise.

 

The loss of insurance coverage, or a reduction in the level of coverage available to FLYTE, could have a material adverse effect on our business, financial condition and results of operations.

 

If FLYTE’s efforts to continue to build its brand identity and improve customer satisfaction and loyalty are not successful, we may not be able to attract or retain customers, and FLYTE’s operating results may be adversely affected.

 

FLYTE must continue to build and maintain a strong brand identity for its products and services, which have expanded over time. We believe that a strong brand identity will continue to be important in attracting customers and retaining their loyalty. If FLYTE’s efforts to promote and maintain its brand are not successful, our operating results, our customer relationships and our reputation could be adversely affected.

 

Decreases in repeat bookings by returning customers could adversely affect FLYTE’s business and financial results.

 

A significant portion of FLYTE’s revenue is based on repeat bookings by its returning customers. There can be no assurance that FLYTE’s returning customers will continue to use FLYTE’s products and services in future periods at historical levels, or at all. A decline in repeat bookings, whether as a result of general economic conditions, competitive pressures, customer dissatisfaction, changes in customer preferences, or other factors, could have a material adverse effect on FLYTE’s revenues and on our business, financial condition and results of operations.

 

64

 

Aviation businesses are often affected by factors beyond their control, including air traffic congestion at airports, air traffic control inefficiencies, adverse weather conditions and increased security measures, any of which could have a material adverse effect on FLYTE’s business.

 

Like other aviation companies, FLYTE’s business is affected by factors beyond our control, including air traffic congestion at airports, air traffic control inefficiencies, adverse weather conditions, increased and enhanced security measures, outbreaks of disease, geopolitical instability, accidents, labor actions and other factors. Each of these factors could result in flight cancellations, delays, diversions or increased costs, any of which could harm FLYTE’s reputation, customer service, operating results, and our business, financial condition and results of operations.

 

Further, the future implementation by the FAA of the Next Generation Air Transport System could result in changes to aircraft routes and ground operations and may require FLYTE and its third-party aircraft operators to invest in new equipment and training, the cost of which could be substantial.

 

The market for short-range flights is still in relatively early stages of development, and the UAM, RAM and AAM markets may not develop as anticipated.

 

FLYTE believes that providing air travelers with access to short-range flights on suitable conventional aircraft, including through the Hops air-taxi service, will enable FLYTE to compete in the developing urban air mobility (“UAM”), regional air mobility (“RAM”) and advanced air mobility (“AAM”) markets. However, the UAM, RAM and AAM markets are still in early stages of development, and the timing, scale and commercial viability of these markets are subject to substantial uncertainty. Currently, there are only a minimal number of electric-powered vertical take-off and landing aircraft and other aircraft using sustainable aviation fuel that are commercially available, and the wider availability of such aircraft is subject to substantial regulatory, technological and commercial uncertainty. If these markets do not develop as anticipated, or develop more slowly than anticipated, or develop with regulatory or technological characteristics that are not favorable to FLYTE’s business model, FLYTE may not realize the benefits we currently expect.

 

Extreme weather, natural disasters and other adverse events could have a material adverse effect on FLYTE’s business, results of operations and financial condition.

 

Adverse weather conditions and natural disasters, such as hurricanes, winter snowstorms, wildfires or earthquakes, can cause flight cancellations or significant delays. Cancellations or delays due to weather conditions or natural disasters affect FLYTE’s revenue, operating costs, customer satisfaction and reputation. Any general reduction in passenger traffic that may result from adverse weather, natural disasters or other adverse events could have a material adverse effect on our business, results of operations and financial condition.

 

FLYTE is subject to risks associated with climate change, including the potential increased impacts of severe weather events and regulatory action.

 

Climate change-related regulatory activity and developments may adversely affect FLYTE’s business and financial results by requiring FLYTE or FLYTE’s third-party aircraft operators to reduce emissions, alter operations, purchase emissions credits, or pay additional taxes, fees or assessments. The potential physical effects of climate change, such as increased frequency and severity of storms, floods, fires, fog, mist, freezing conditions, sea-level rise and other climate-related events, may also adversely affect FLYTE’s operations, increase FLYTE’s operating costs (including insurance, fuel and maintenance costs), reduce customer demand for air travel, or otherwise adversely affect our business, financial condition and results of operations.

 

65

 

FLYTE’s business is primarily focused on certain targeted geographic regions, making us vulnerable to risks associated with having geographically concentrated operations.

 

FLYTE’s customer base is primarily concentrated in certain geographic regions of the United States, including the northeast, southeast and certain other markets. As a result, our business may be more vulnerable to adverse economic, weather, regulatory, security, public health or other developments in those regions than would be the case for a more geographically diversified operator. Adverse developments in these regions, including local recessions, severe weather, natural disasters, terrorist activity, regulatory changes affecting general aviation, airport closures or capacity constraints, or public health emergencies, could have a disproportionate adverse effect on FLYTE’s revenue and operations and, in turn, on our business, financial condition and results of operations.

 

The operation of aircraft is subject to various risks, and failure to maintain an acceptable safety record may have an adverse impact on FLYTE’s ability to obtain customers and generate revenue.

 

The operation of aircraft is subject to various risks, including catastrophic disasters, crashes, mechanical failures, collisions, fire, severe weather, terrorist incidents, cybersecurity events, human error and other operational hazards, any of which could result in loss of life, serious injury, property damage or environmental damage. In addition, any aircraft accident or incident, whether involving FLYTE or other private aircraft operators, could adversely affect public perception of the safety of private aviation generally or of the aircraft types or operators on which FLYTE relies, which could in turn reduce demand for FLYTE’s services and adversely affect our business, results of operations and financial condition.

 

FLYTE incurs considerable costs to maintain the quality of (i) its safety program, (ii) its training programs and (iii) its operational oversight. If FLYTE is unable to maintain an acceptable safety record, or if a serious accident or incident involving FLYTE or its third-party aircraft operators occurs, the resulting reputational, regulatory, operational, insurance and financial consequences could have a material adverse effect on our business, financial condition and results of operations.

 

Any damage to FLYTE’s reputation or brand image could adversely affect our business or financial results.

 

Maintaining a positive reputation is critical to FLYTE’s business. FLYTE’s reputation or brand image could be adversely affected by, among other things, accidents or incidents involving aircraft operated by FLYTE’s third-party aircraft operators, complaints or negative publicity about FLYTE’s services, customer dissatisfaction, security or data privacy incidents, employee conduct, or actions taken by FLYTE’s third-party service providers. FLYTE operates in a highly visible industry that has significant exposure to social media. Negative publicity, whether or not justified, can spread rapidly through traditional and social media channels. Should FLYTE fail to respond in a timely and appropriate manner to address negative publicity, FLYTE’s brand and reputation could be adversely affected, which in turn could have a material adverse effect on our business, financial condition and results of operations.

 

Terrorist activities or warnings have dramatically impacted the aviation industry and will likely continue to do so.

 

The terrorist attacks of September 11, 2001 and subsequent actual or threatened acts of terrorism affecting the aviation industry have had, and any future acts or threatened acts of terrorism would likely have, significant negative impacts on the aviation business, including private aviation. We cannot provide any assurance that future terrorist incidents or threats, or governmental or industry responses to such incidents or threats, will not harm the aviation industry generally, or FLYTE’s operations specifically, in ways that could have a material adverse effect on our business, financial condition and results of operations.

 

66

 

Risks Related to FLYTE’s Reliance on Third-Party Aircraft Operators

 

FLYTE relies on third-party aircraft operators to provide and operate aircraft. If those third-party aircraft operators fail to perform, FLYTE’s business could be materially and adversely affected.

 

With the exception of flights operated under FLYTE’s air-taxi service using FLYTE’s owned Cirrus Jet, all of FLYTE’s flight services are provided by third-party aircraft operators that are certificated air carriers under Title 14 of the Code of Federal Regulations. Pilots, maintenance, hangar, insurance and fuel are all costs borne by FLYTE’s network of third-party aircraft operators. Should FLYTE experience complications with any of these third-party aircraft operators or their aircraft, FLYTE may need to use alternative aircraft operators to fulfill its commitments to customers. There can be no assurance that suitable alternative aircraft operators would be available on commercially acceptable terms, or at all. Any failure of FLYTE’s third-party aircraft operators to perform to our expectations, or any interruption in services provided by such third-party aircraft operators, could result in delayed, cancelled or substandard flights and could have a material adverse effect on FLYTE’s reputation, customer relationships and our business, financial condition and results of operations.

 

FLYTE may incur losses on the cancellation or delay of flights, and on flights booked with third-party aircraft operators.

 

FLYTE’s third-party aircraft operators generally have the ability to cancel, delay or terminate any flight for any reason permitted under their respective regulatory authorizations and contractual arrangements, including weather, mechanical issues, crew availability, regulatory or safety considerations, or unilateral business decisions. FLYTE may incur losses as a result of such cancellations or delays, including the cost of providing alternative transportation, refunds or credits to customers, increased customer dissatisfaction and reputational harm. In addition, if demand for FLYTE’s services grows, FLYTE’s third-party aircraft operators may not be able to match FLYTE’s growth with available aircraft capacity on commercially acceptable terms, or at all, which could limit FLYTE’s ability to grow its business and meet customer demand.

 

FLYTE faces the risk that any of its third-party aircraft operators may not fulfill their contracts and deliver their services on a timely basis, or at all, and FLYTE is subject to the risk of disruption affecting such operators.

 

FLYTE operates a significant portion of its flights through a finite number of certificated third-party aircraft operators. The ability of FLYTE’s third-party aircraft operators to effectively satisfy our requirements could be impacted by financial difficulty experienced by any such third-party aircraft operator, damage to its operations caused by fire, terrorist attack, natural disaster, public health emergency or other events, or its inability to hire or retain skilled personnel, including qualified pilots and mechanics. Union strikes or staff shortages among airport workers or certain pilots of third-party aircraft operators may also result in disruption to FLYTE’s operations. In addition, if potential competitors establish cooperative or strategic relationships with the third-party aircraft operators on which FLYTE relies, the availability of capacity to FLYTE could be reduced, and FLYTE’s cost of access to capacity could increase, in each case in ways that could have a material adverse effect on our business, financial condition and results of operations.

 

67

 

FLYTE may be negatively impacted by increases in third-party aircraft operator costs.

 

In recent years, there has been a trend of higher third-party aircraft operator costs across the private aviation industry, driven by, among other things, higher pilot compensation, higher maintenance costs, higher insurance costs, higher fuel costs and constraints on the supply of available aircraft. Since FLYTE currently relies on third-party aircraft operators to generate the substantial majority of its revenue, sustained increases in third-party aircraft operator costs could materially compress FLYTE’s margins, particularly to the extent FLYTE is unable to pass through such cost increases to its customers, which could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE could suffer losses and adverse publicity stemming from any accident involving aircraft models operated by FLYTE’s third-party aircraft operators.

 

Certain aircraft models on which FLYTE’s third-party aircraft operators rely, including the Cirrus SF50 Vision Jet that FLYTE owns and operates as part of its Hops air-taxi service, have experienced accidents while operated by third parties. If other operators of such aircraft models, or FLYTE itself, experience additional accidents or incidents, regulators may issue operating restrictions or airworthiness directives affecting such aircraft, manufacturers may issue recalls or service bulletins, or public perception of the safety of such aircraft may be adversely affected, any of which could have a material adverse effect on FLYTE’s operations and on our business, financial condition and results of operations.

 

FLYTE’s agreements with third-party aircraft operators may contain obligations for FLYTE to indemnify such third-party aircraft operators against certain claims.

 

Many of the agreements FLYTE has with third-party aircraft operators include indemnification obligations of FLYTE to those third-party aircraft operators. Although FLYTE generally requires its customers to indemnify FLYTE for many of the claims and damages for which FLYTE is obligated to indemnify its third-party aircraft operators, there can be no assurance that FLYTE’s customers will be financially able to honor those indemnification obligations or that FLYTE’s insurance will cover the resulting exposure. As a result, FLYTE could be required to make payments under such indemnification obligations that exceed the available insurance coverage and any customer indemnification recoveries, which could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE may not have sufficient insurance coverage for damages relating to flights provided by third-party aircraft operators.

 

Incidents related to aircraft operations involving the third-party aircraft operators on which FLYTE relies could result in claims against FLYTE that exceed the insurance coverage available to FLYTE. Additionally, to the extent FLYTE’s third-party aircraft operators maintain insurance covering liability arising from the operation of their aircraft, there can be no assurance that such insurance will be adequate to cover all liabilities that may arise, or that FLYTE will be named as an additional insured or otherwise have the benefit of such coverage. Inadequate insurance coverage could expose FLYTE to material uninsured liabilities and could have a material adverse effect on our business, financial condition and results of operations.

 

68

 

Risks Related to FLYTE’s Intellectual Property and Technology

 

If FLYTE is unable to adequately protect its intellectual property interests, or is found to be infringing on intellectual property rights of others, FLYTE may incur significant costs or be required to alter or cease using such intellectual property.

 

FLYTE’s intellectual property includes its trademarks, domain names, website, mobile and web applications, software, trade secrets and certain proprietary algorithms. FLYTE protects its intellectual property through a combination of trademark, copyright and trade secret laws, contracts and technical safeguards. However, the steps FLYTE takes to protect its intellectual property may be inadequate or ineffective, and FLYTE may be unable to prevent competitors from acquiring trademarks or domain names that are similar to, infringe upon or diminish the value of FLYTE’s intellectual property.

 

In addition, FLYTE’s business is subject to the risk of third parties infringing FLYTE’s intellectual property. FLYTE may not always detect such infringement, and protecting FLYTE’s intellectual property is expensive and time-consuming, may not be successful and may divert management’s attention from other matters. Companies in the aviation and technology industries are frequently subject to litigation based on allegations of infringement or other violations of intellectual property rights. If FLYTE is found to infringe the intellectual property rights of others, FLYTE could be required to pay damages, alter FLYTE’s products or services or cease using the intellectual property in question, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

A delay or failure to identify, invest in and implement important technology, business and other initiatives could have a material adverse effect on FLYTE’s business.

 

In order to operate its business, achieve its goals and remain competitive, FLYTE continuously seeks to identify and develop important technology, business and other initiatives, improvements to FLYTE’s booking and operations platforms, and adoption of new aircraft technologies. FLYTE’s business and the aircraft FLYTE operates are characterized by changing technology, the introduction and enhancement of products and services, evolving customer expectations and evolving industry standards. If FLYTE is unable to upgrade its operations or fleet with the latest technological advances in a timely manner, or at all, FLYTE’s ability to compete effectively could be impaired, which could have a material adverse effect on our business, financial condition and results of operations.

 

A failure in FLYTE’s technology or breaches of the security of its information technology infrastructure may adversely affect FLYTE’s business, may result in losses, and may damage FLYTE’s reputation.

 

The performance and reliability of the technology that FLYTE and its third-party aircraft operators use are critical to FLYTE’s ability to compete effectively. As part of FLYTE’s ordinary business operations, FLYTE collects and stores sensitive data, including personally identifiable information of its customers, employees and contractors, as well as proprietary information about its business and the businesses of its third-party aircraft operators. Methods used to obtain unauthorized access, disable or degrade service, or sabotage information systems are constantly evolving, and may be difficult to anticipate or detect for long periods of time. Any security breach, cyberattack, ransomware attack, data loss or system failure affecting FLYTE or its third-party service providers could result in the loss or unauthorized disclosure of sensitive data, regulatory investigations, litigation, reputational harm, business interruption, and substantial remediation and notification costs, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE relies on third-party Internet, mobile and other products and services to deliver its mobile and web applications, and any disruption of or interference with these third-party products and services could adversely affect FLYTE’s business.

 

FLYTE’s platform’s continuing and uninterrupted performance is critical to FLYTE’s success. That platform is dependent on a variety of third-party products and services, including cloud hosting providers and other third-party Internet, mobile and software services. FLYTE currently hosts its platform, including its mobile and web-based applications, with third-party hosting providers. Any interruption in, or failure of, these third-party products or services could result in FLYTE’s platform being unavailable, slow or unreliable, which could harm FLYTE’s reputation and FLYTE’s ability to attract and retain customers.

 

69

 

FLYTE relies on third parties maintaining open marketplaces to distribute FLYTE’s mobile and web applications, and any changes by such third parties could adversely affect FLYTE’s business.

 

FLYTE’s mobile applications rely on third parties maintaining open marketplaces, including the Apple App Store and the Google Play Store, for distribution of its app. If any of these third parties changes its terms of service, increases its fees, restricts the availability of FLYTE’s applications, removes FLYTE’s applications from its marketplace, or otherwise impairs the distribution of FLYTE’s applications, FLYTE’s ability to acquire and retain customers could be materially and adversely affected.

 

Because FLYTE’s software could be used to collect and store personal information, privacy concerns in the territories in which FLYTE operates could result in additional cost and liability to FLYTE or inhibit sales of FLYTE’s services.

 

The regulatory framework for privacy and data protection issues worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. In the United States, these regulations include rules and regulations promulgated under the authority of the Federal Trade Commission, the California Consumer Privacy Act (the “CCPA”) and the California Privacy Rights Act, and other state and federal laws relating to privacy and data security. Internationally, FLYTE may be subject to similar regulations, including the European Union’s General Data Protection Regulation (the “GDPR”) and the United Kingdom GDPR, as applicable. Compliance with these and other privacy and data security laws and regulations could be costly and could require significant changes to FLYTE’s business practices, products and services. Failure to comply with such laws and regulations could subject FLYTE to significant fines, penalties, reputational harm and litigation, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

Legal and Regulatory Risks Related to FLYTE’s Business

 

FLYTE is subject to significant governmental regulation, and changes in government regulations imposing additional requirements could have a material adverse effect on FLYTE’s business.

 

All interstate air carriers, including FLYTE, are subject to regulation by the U.S. Department of Transportation (the “DOT”), the Federal Aviation Administration (the “FAA”), the Transportation Security Administration (the “TSA”), U.S. Customs and Border Protection (“CBP”) and other federal, state and local agencies, both domestically and, to the extent FLYTE’s third-party aircraft operators conduct international flights, internationally. The laws and regulations enforced by these and other agencies impose substantial requirements on the operation of aircraft, including with respect to safety, maintenance, training, security, operational specifications, environmental matters, consumer protection and air traffic control.

 

Title 49, U.S. Code, Section 40102 and administrative interpretations thereof issued by the DOT or its predecessor agencies, as well as ongoing interpretive and enforcement actions taken by the DOT and the FAA in respect of charter brokers and on-demand operators, may affect the manner in which FLYTE conducts business. For example, the FAA has, in recent years, issued notices targeting certain air charter operators that the FAA believes are engaged in operations not consistent with applicable regulations. Although we believe FLYTE’s operations comply with applicable regulatory requirements, there can be no assurance that the DOT, FAA or other regulators will not assert positions that could affect FLYTE’s operations or impose additional costs or compliance burdens. Changes in laws and regulations applicable to FLYTE’s business, or new interpretations of existing laws or regulations, could have a material adverse effect on our business, financial condition and results of operations.

 

70

 

Revocation of permits, approvals, authorizations and licenses will adversely affect FLYTE’s business, results of operations and financial condition.

 

FLYTE’s business requires a variety of federal, state and local permits, approvals, authorizations and licenses. FLYTE’s business depends on the continued effectiveness of such permits, approvals, authorizations and licenses. Any suspension, revocation, modification or non-renewal of any of FLYTE’s material permits, approvals, authorizations or licenses, or any failure by FLYTE to obtain any necessary new or amended permits, approvals, authorizations or licenses, could have a material adverse effect on our business, results of operations and financial condition.

 

FLYTE is subject to various environmental and noise laws and regulations, which could have a material adverse effect on FLYTE’s business, results of operations and financial condition.

 

FLYTE is subject to increasingly stringent federal, state, local and foreign laws, regulations and ordinances relating to the protection of the environment, including those relating to emissions to the air, discharges to surface and subsurface waters, safe drinking water and the management, disposal and release of, and exposure to, hazardous substances, oils and waste materials. FLYTE is also subject to environmental laws and regulations that require FLYTE to investigate and remediate soil or groundwater contamination, regardless of fault. In addition, FLYTE is subject to noise laws and regulations that may restrict aircraft operations at certain airports or during certain hours.

 

Climate change-related regulatory developments may also restrict aviation activity. In December 2022, France became the first European nation to institute a ban on domestic commercial flights where train alternatives exist. Other European lawmakers, including in Spain, Germany and Scandinavia, have considered similar restrictions. If similar restrictions are adopted in the United States or other markets in which FLYTE operates, including with respect to private aviation, or if FLYTE’s third-party aircraft operators become subject to such restrictions, our business, results of operations and financial condition could be materially and adversely affected.

 

Environmental regulation and liabilities, including new or developing laws and regulations, or sustainability initiatives, could increase FLYTE’s costs of operations.

 

In recent years, governments, customers, suppliers, employees and other stakeholders have increasingly focused on environmental, social and governance matters, including the impact of aviation on climate change. New or developing laws and regulations relating to greenhouse gas emissions, sustainable aviation fuel mandates, carbon offset requirements or other environmental matters could materially increase FLYTE’s costs of operations or those of FLYTE’s third-party aircraft operators, which could have a material adverse effect on our business, financial condition and results of operations.

 

The issuance of operating restrictions applicable to one of the aircraft fleet types FLYTE operates, or on which FLYTE’s third-party aircraft operators rely, could have a material adverse effect on our business.

 

The issuance of FAA or manufacturer operating restrictions, airworthiness directives, mandatory service bulletins, or similar requirements that ground or otherwise restrict the use of this aircraft, or any other aircraft on which FLYTE or its third-party aircraft operators rely, could materially disrupt FLYTE’s operations and require FLYTE to incur additional costs to comply or to procure alternative capacity. Any such disruption could have a material adverse effect on our business, financial condition and results of operations.

 

FLYTE may become involved in litigation that may materially and adversely affect us.

 

From time to time, FLYTE may become involved in various legal proceedings relating to matters incidental to the ordinary course of its business, including, but not limited to, regulatory matters, customer disputes, employment matters, intellectual property claims, contractual disputes and personal injury claims relating to aviation operations. The outcome of any such legal proceedings is inherently uncertain, and any adverse outcome, settlement, judgment or regulatory action could have a material adverse effect on our business, financial condition and results of operations.

 

71

 

Risks Related to Existing and Potential Future Dilution from our Convertible Preferred Stock

 

Issued shares of our convertible preferred stock are convertible into a substantial number of shares of common stock that, upon conversion, will significantly dilute our existing common stockholders.

 

As of the date of this Form 10-Q, we have outstanding the following series of our convertible preferred stock, each with a stated value of $1,000 per share, that are convertible into shares of our common stock:

 

 

●

1,610.48 shares of our Series C-1 Convertible Preferred Stock (the “Series C-1 Preferred”), issued pursuant to the Securities Purchase Agreements that we entered into on February 6, 2026 and March 9, 2026 (the “Series C Purchase Agreements”);

 

●

2,031 shares of our Series C-2 Convertible Preferred Stock (the “Series C-2 Preferred”), issued on April 21, 2026 pursuant to the Series C Purchase Agreements;

  ● 2,740 shares of our Series C-3 Convertible Preferred Stock (the "Series C-3 Preferred"), issued on July 13, 2026 pursuant to the Series C Purchase Agreements;
  ● 6,821 shares of our Series C-4 Convertible Preferred Stock (the "Series C-4 Preferred"), issued on July 30, 2026 and August 14, 2026 pursuant to the Series C Purchase Agreement;
 

●

7,488 shares of our Series D Convertible Preferred Stock (the “Series D Preferred”), of which 5,250 shares were issued on April 20, 2026 to SEG Jets in partial consideration for our acquisition of an initial 19.98% interest in FLYTE and 5,778 shares were issued on April 20, 2026 to Creatd, Inc. (“Creatd”) in partial consideration for our acquisition of the remaining 80.02% interest in FLYTE and 100% of the membership interests of Ponderosa Air, LLC; and

 

●

9,489.488 shares of our Series J Convertible Preferred Stock (the “Series J Preferred”), issued on December 31, 2025 to David A. Jenkins, our Executive Chairman of the Board and Chief Executive Officer, and to FatBoy Capital, L.P., an entity controlled by Mr. Jenkins, in exchange for the termination of certain royalty rights.

 

The conversion price of each of the Series C-1 Preferred, Series C-2 Preferred, Series C-3 Preferred, Series C-4 Preferred and Series D Preferred is variable and is subject to downward adjustment based on the trading price of our common stock at specified dates following the effectiveness of the resale registration statement filed pursuant to the related registration rights agreements. In each case, the conversion price is subject to a floor of $0.35 per share, which we may waive at our sole discretion and which we elected to waive on August 10, 2026, and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3, Series C-4 and Series D to $0.23.  The conversion price of the Series J Preferred is fixed at $1.56 per share, subject to customary anti-dilution adjustments.

 

Assuming conversion at $0.23 (in the case of the Series C-1, Series C-2, Series C-3, Series C-4 and Series D Preferred) and at the applicable fixed conversion price (in the case of the Series J Preferred), our issued and outstanding shares of convertible preferred stock would convert into an aggregate of approximately 96,041,615 shares of our common stock, consisting of:

 

 

●

approximately 7,002,087 shares issuable upon conversion of the Series C-1 Preferred;

 

●

approximately 8,830,435 shares issuable upon conversion of the Series C-2 Preferred;

  ● approximately 11,913,044 shares issuable upon conversion of the Series C-3 Preferred;
  ● approximately 29,656,522 shares issuable upon conversion of the Series C-4 Preferred;
 

●

approximately 32,556,522 shares issuable upon conversion of the Series D Preferred; and

 

●

approximately 6,083,005 shares issuable upon conversion of the Series J Preferred.

 

As of August 10, 2026, we had 14,391,944 shares of our common stock outstanding. The aggregate number of shares of common stock issuable upon conversion of our issued and outstanding shares of convertible preferred stock as described above would represent approximately 6,673% of our common stock outstanding as of August 10, 2026, or, on a post-conversion basis, would result in the dilution of our existing common stockholders to less than approximately 13.0% of our post-conversion outstanding common stock. If we were to further lower the $0.23 conversion price with respect to any of the Series C-1 Preferred, the Series C-2 Preferred, the Series C-3 Preferred, the Series C-4 Preferred or the Series D Preferred, the number of shares of common stock issuable upon conversion of those securities could be substantially greater than the amounts above.

 

Conversion of the Series C-1 Preferred, the Series C-2 Preferred, the Series C-3 Preferred, the Series C-4 Preferred, the Series D Preferred and the Series J Preferred is also subject to customary beneficial ownership limitations applicable to each holder, which limit individual holders' as-converted ownership to specified thresholds (typically 4.99% or 9.99%) but do not limit the aggregate amount of common stock that may be issued upon conversion to all holders. Therefore, the beneficial ownership limitations do not constrain the aggregate dilution described above.

 

The market price of our common stock has been, and may continue to be, volatile. A sustained decline in our share price prior to the conversion of the Series C-1 Preferred, the Series C-2 Preferred, the Series C-3 Preferred, the Series C-4 Preferred or the Series D Preferred would significantly increase the number of shares issuable upon conversion of those securities, up to the limit imposed by the $0.35 floor, which we may waive in our sole discretion and which we elected to waive on August 10, 2026, and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3, Series C-4 and Series D to $0.23.  Any such conversion would dilute the voting power and economic interests of our existing common stockholders.

 

We may issue additional series of convertible preferred stock under the Series C Purchase Agreements that, upon issuance and conversion, could result in extraordinary additional dilution to our existing common stockholders.

 

In addition to the shares of convertible preferred stock currently outstanding, the Series C Purchase Agreements provide for additional issuances of our convertible preferred stock, as follows:

 

 

●

Series C-4 Preferred Stock. The investors in the Series C Purchase Agreements may elect in their sole discretion to purchase up to an aggregate of $70,179,000.00 of newly designated Series C-4 Convertible Preferred Stock (the “Series C-4 Preferred”), with a stated value of $1,000 per share, in one or more closings.

 

The conversion price of each of the Series C-4 Preferred is subject to adjustment in a manner substantially similar to the Series C-1 Preferred, the Series C-2 Preferred and the Series C-3 Preferred including a $0.35 floor that we may waive in our sole discretion and which we elected to waive on August 10, 2026, and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3, Series C-4 and Series D to $0.23. See Note 13 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information regarding the terms of the Series C-4 Preferred.

 

Assuming all the maximum amount of the Series C-4 Preferred are issued, and assuming conversion of each at the $0.023 conversion price, the Series C-4 Preferred would convert into an aggregate of approximately 305,126,087 shares of our common stock. Together with the shares of common stock that would be issued upon conversion of our currently outstanding Series C-1 Preferred, Series C-2 Preferred, Series C-3 Preferred, Series C-4 Preferred, Series D Preferred and Series J Preferred (as described in the preceding risk factor), the aggregate number of shares of common stock that could be issued upon conversion of all such securities at the relevant conversion prices would be approximately 401,167,702 shares.

 

As of August 10, 2026, we had 14,391,944 shares of common stock outstanding. The aggregate number of shares of common stock issuable upon conversion of all of our existing and potential future shares of convertible preferred stock described above would represent approximately 27,874% of our common stock outstanding as of August 10, 2026, or, on a post-conversion basis, would result in the dilution of our existing common stockholders to less than approximately 3.6% of our post-conversion outstanding common stock.

 

The actual number of shares of common stock that may be issued under the Series C Purchase Agreements could be higher than the amounts set forth above if we waive the $0.35 floor in our sole discretion, which we may do at any time and which we elected to waive on August 10, 2026, and reduced the conversion price of all outstanding shares of Series C-1, Series C-2, Series C-3, Series C-4 and Series D to $0.23. There can be no assurance that we will not further reduce the conversion price.

 

Whether and when these contingent issuances and conversions occur will depend on, among other things, the investors' decisions to exercise their respective rights, the satisfaction of remaining closing conditions, our ability and willingness to waive the floor or further reduce the conversion price, and the trading price of our common stock. There can be no assurance that any of these events will occur or will not occur. However, if the investors exercise the Series C-4 right in full and the conversion of all of our convertible preferred stock occurs at or near the floor, the resulting dilution to our existing common stockholders would be extraordinary, and would substantially eliminate the existing common stockholders' relative economic and voting interests in the Company. Moreover, the existence of these contingent issuance and conversion rights may itself adversely affect the trading price of our common stock, as market participants may anticipate the issuance and conversion of these securities and the resulting dilution.

 

We may not receive any proceeds from the Series C-4 right because exercise of that right is at the investors' option and is not within our control. As a result, we cannot rely on the Series C-4 right to fund our operations. 

 

72

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The information required by Item 701 of Regulation S-K with respect to unregistered sales of the Company's equity securities during the three months ended September 30, 2026 has been previously reported in the Company's Current Reports on Form 8-K filed with the SEC on July 15, 2026 and July 31, 2026. During the quarter ended September 30, 2026, we also issued an aggregate of 1,741,040 shares of common stock upon the conversion of 4,857 shares of Series C Convertible Preferred Stock and 4,219 shares of Series D Convertible Preferred Stock, in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

ITEM 5. OTHER INFORMATION

 

During the three months ended September 30, 2026, no director or officer, as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K. 

 

 

 

73

 

ITEM 6. EXHIBITS

 

Exhibit

     

Incorporated by Reference 

Number

 

Description

 

Form

 

File No. 

 

Exhibit 

 

Filing Date 

                     

3.1.1

 

Amended and Restated Certificate of Incorporation of the Registrant.

 

8-K

 

001-38677

 

3.1

 

10/1/2018

                     

3.1.2

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (effective 11/16/20)

 

8-K

 

001-38677

 

3.1

 

11/17/2020

                     

3.1.2A

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (effective 09/30/22)

 

8-K

 

001-38677

 

3.1

 

9/20/2022

                     

3.1.2B

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. (filed 08/01/23, effective 08/17/23)

 

8-K

 

001-38677

 

3.1

 

8/4/2023

                     

3.1.2C

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (filed 07/11/2024, effective 07/15/2024)

 

8-K

 

001-38677

 

3.1

 

7/12/2024

                     
3.1.2D   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 1/13/2025)   10-K   001-38677   3.1   3/31/2025
                     
3.1.2E   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 8/15/2025)   8-K   001-38677   3.1   8/15/2025
                     
3.1.2F   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 10/17/2025)   10-Q   001-38677   3.1.3E   11/13/2025
                     
3.1.2G   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 10/5/2026)   8-K   001-38677   3.1   10/2/2026
                     

3.1.3

 

Certificate of Designation of Series A Preferred Stock.

 

8-K

 

001-38677

 

3.2

 

1/13/2023

                     
3.1.3A   Certificate of Designation of Series B Preferred Stock.   8-K   001-38677   3.1  

5/13/2025

                     
3.1.3B   Certificate of Designation of Series C-1 Preferred Stock   10-K   001-38677   3.1.3B   3/31/2026
                     
3.1.3C   Certificate of Amendment of Certificate of Designations of Series C-1 Preferred Stock   10-K   001-38677   3.1.3C   3/31/2026
                     
3.1.3D   Certificate of Designation of Series C-2 Preferred Stock   8-K   001-38677   3.1   4/23/2026
                     
3.1.3E   Certificate of Designation of Series C-3 Preferred Stock   8-K   001-38677   3.1   7/15/2026
                     
3.1.3F   Certificate of Designation of Series C-4 Preferred Stock   8-K   001-38677   3.1   7/31/2026
                     
3.1.3G   Certificate of Designation of Series D Preferred Stock   8-K   001-38677   3.2   04/23/2026
                     
3.1.3H   Certificate of Designation of Series J Preferred Stock   8-K   001-38677   3.1   2/12/2026
                     
3.1.3I   Certificate of Correction of Certificate of Designation of Series J Preferred Stock   8-K   001-38677   3.2   2/12/2026
                     
3.1.3J   Certificate of Designation of Series X Convertible Preferred Stock.   8-K   001-38677   3.1   1/13/2023
                     

3.2.1

 

Amended and Restated Bylaws of the Registrant.

 

8-K

 

001-38677

 

3.2

 

10/1/2018

                     

3.2.2

 

Amendment to Amended and Restated Bylaws of the Registrant.

 

8-K

 

001-38677

 

3.1

 

8/17/2022

                     
10.1   Securities Purchase Agreement, dated February 6, 2026, by and among the Company and the investor signatory thereto  

8-K

 

001-38677

 

10.1

 

2/6/2026

                     
10.2   Securities Purchase Agreement, dated February 6, 2026 by and among the Company and SEG Jets LLC   8-K   001-38677   10.2   2/6/2026
                     
10.3   Registration Rights Agreement, dated February 6, 2026 by and among the Company and the investor signatory thereto   8-K   001-38677   10.3   2/6/2026
                     
10.4   Series J Exchange Agreement dated February 12, 2026 between the Company and David A. Jenkins   8-K   001-38677   10.1   2/12/2026
                     
10.5   Series J Exchange Agreement dated February 12, 2026 between the Company and FatBoy Capital, L.P.   8-K   001-38677   10.2   2/12/2026
                     
10.6   Securities Purchase Agreement, dated March 9, 2026, by and among the Company and the investors signatory thereto   8-K   001-38677   10.1   3/9/2026

 

74

 

10.7   Stock Purchase Agreement, dated March 9, 2026, by and among the Company and the investors signatory thereto   8-K   001-38677   10.1   3/9/2026
                     
10.8   Registration Rights Agreement, dated March 9, 2026, by and among the investors signatory thereto   10-K   001-38677   10.14.5   3/31/2026
                     
10.9   Secured Promissory Note dated February 27, 2025 by and between Creatd, Inc. and Marc Sellouk   10-Q   001-38677   10.9   5/18/2026
                     
10.10   Exclusive Aircraft Dry Lease Agreement dated September 9, 2025 by and between SEG Jets, LLC and Ponderosa Air, LLC   10-Q   001-38677   10.10   5/18/2026
                     
10.11   Exclusive Aircraft Dry Lease Agreement dated February 11, 2026 by and between SEG Jets, LLC and Ponderosa Air, LLC   10-Q   001-38677   10.11   5/18/2026
                     
10.12   Exclusive Aircraft Dry Lease Agreement dated March 16, 2026 by and between SEG Jets, LLC and Ponderosa Air, LLC   10-Q   001-38677   10.12   5/18/2026
                     
10.13   Form of Unsecured 10% Discount Convertible Note by and among Flewber Global, Inc. and the holders thereto   10-Q   001-38677   10.13   5/18/2026
   

 

               
10.14   Form of Unsecured Convertible Note by and among Flewber Global, Inc. and the holders thereto   10-Q   001-38677   10.14   5/18/2026
                     
10.15   Form of Unsecured Subordinated Promissory Note by and among Flewber Global, Inc. and the holders thereto   10-Q   001-38677   10.15   5/18/2026
                     
10.16   Securities Purchase Agreement, dated as of June 7, 2026, by and between Volato Group, Inc. and Catheter Precision, Inc.   8-K   001-38677   10.1   6/8/2026
                     
10.17   Registration Rights Agreement, dated as of June 7, 2026, by and between Volato Group, Inc. and Catheter Precision, Inc.   8-K   001-38677   10.2   6/8/2026

 

31.1*

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

31.2*

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

32.1*@

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

32.2*@

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS*

 

Inline XBRL Instance Document

     

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

     

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

     

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

     

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

     

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

     

104*

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*

Filed herewith.

   

@

The information in this exhibit is furnished and deemed not filed with the Securities and Exchange Commission for purposes of section 18 of the Exchange Act of 1934, as amended (Exchange Act), and is not to be incorporated by reference into any filing of Flyte Aviation, Inc. under the Securities Act of 1933, as amended (Securities Act), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

75

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Flyte Aviation, Inc.

 

(Registrant)

 
       

Date: November 16, 2026

By:

/s/ David A. Jenkins

 
   

David A. Jenkins

Executive Chairman of the Board and

Chief Executive Officer

(Principal Executive Officer)

 
       

Date: November 16, 2026

By:

/s/ Philip Anderson

 
   

Philip Anderson

 
   

Chief Financial Officer

 
   

(Principal Financial and Accounting Officer)

 

 

76

Keep reading